NCTId;BriefTitle;LeadSponsorName;CollaboratorName;OverallStatus;StudyType;HasResults;StudyFirstPostDate;StartDate;CompletionDate;pmid;type;title;authors;doi;publication_types;is_oa;published_date
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;ANRS, Emerging Infectious Diseases;Institut de Recherche pour le Developpement | UNITAID;COMPLETED;INTERVENTIONAL;False;2016-05-19;2016-07;2021-07;37851566;PUBMED;Improvements in Patient-Reported Outcomes Following Initiation of Dolutegravir-Based or Low-Dose Efavirenz-Based First-Line Antiretroviral Therapy: A Four-Year Longitudinal Analysis in Cameroon (NAMSAL ANRS 12313 Trial).;"Bousmah MA; Protopopescu C; Mpoudi-Etame M; Omgba Bassega P; Maradan G; Olinga J; Varloteaux M; Tovar-Sanchez T; Delaporte É; Kouanfack C; Boyer S; NAMSAL ANRS 12313 Study Group";10.1097/QAI.0000000000003273;['Randomized Controlled Trial', 'Journal Article'];False;2023-11-01
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;ANRS, Emerging Infectious Diseases;Institut de Recherche pour le Developpement | UNITAID;COMPLETED;INTERVENTIONAL;False;2016-05-19;2016-07;2021-07;33355914;DERIVED;Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial).;"Bousmah MA; Nishimwe ML; Tovar-Sanchez T; Lantche Wandji M; Mpoudi-Etame M; Maradan G; Omgba Bassega P; Varloteaux M; Montoyo A; Kouanfack C; Delaporte E; Boyer S; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group";10.1007/s40273-020-00987-3;['Journal Article'];True;2020-12-23
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;ANRS, Emerging Infectious Diseases;Institut de Recherche pour le Developpement | UNITAID;COMPLETED;INTERVENTIONAL;False;2016-05-19;2016-07;2021-07;33010241;DERIVED;Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.;"Calmy A; Tovar Sanchez T; Kouanfack C; Mpoudi-Etame M; Leroy S; Perrineau S; Lantche Wandji M; Tetsa Tata D; Omgba Bassega P; Abong Bwenda T; Varloteaux M; Tongo M; Mpoudi-Ngolé E; Montoyo A; Mercier N; LeMoing V; Peeters M; Reynes J; Delaporte E; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group";10.1016/S2352-3018(20)30238-1;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];False;2020-10-01
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;ANRS, Emerging Infectious Diseases;Institut de Recherche pour le Developpement | UNITAID;COMPLETED;INTERVENTIONAL;False;2016-05-19;2016-07;2021-07;38156046;PUBMED;Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study.;"Mpoudi-Etame M; Tovar Sanchez T; Bousmah MA; Omgba Bassega P; Olinga J; Mimbe E; Foalem M; Chiep C; Edimo S; Varloteaux M; Pelloquin R; Lamare N; Boyer S; Peeters M; Reynes J; Calmy A; Hill A; Delaporte E; Kouanfack C; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-income countries (NAMSAL-ANRS-12313) study group";10.1093/ofid/ofad582;['Journal Article'];True;2023-11-20
NCT02777229;Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings;ANRS, Emerging Infectious Diseases;Institut de Recherche pour le Developpement | UNITAID;COMPLETED;INTERVENTIONAL;False;2016-05-19;2016-07;2021-07;31339676;DERIVED;Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.;"NAMSAL ANRS 12313 Study Group; Kouanfack C; Mpoudi-Etame M; Omgba Bassega P; Eymard-Duvernay S; Leroy S; Boyer S; Peeters M; Calmy A; Delaporte E";10.1056/NEJMoa1904340;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2019-08-29
NCT01882062;Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2013-06-20;2013-05;2013-07;25568297;RESULT;Triheptanoin improves brain energy metabolism in patients with Huntington disease.;"Adanyeguh IM; Rinaldi D; Henry PG; Caillet S; Valabregue R; Durr A; Mochel F";10.1212/WNL.0000000000001214;['Clinical Trial', 'Journal Article'];True;2015-02-03
NCT03671291;Missed Opportunities to Pre-exposure Prophylaxis for HIV Infection on Person Newly Diagnosed With HIV;French National Agency for Research on AIDS and Viral Hepatitis;University Hospital, Marseille | University Hospital, Grenoble | Centre Hospitalier Universitaire de Nice | University Hospital, Montpellier | Hospital Purpan | University Hospital, Bordeaux | Hôpital de la Croix-Rousse | Centre Hospitalier Universitaire Dijon | University Hospital of Saint-Etienne | University Hospital, Clermont-Ferrand | Centre Hospitalier Universitaire de Besancon | Tourcoing Hospital | University Hospital, Strasbourg | Nantes University Hospital | Centre Hospitalier Régional d'Orléans | Rennes University Hospital | Saint Antoine University Hospital | Tenon Hospital, Paris | Saint-Louis Hospital, Paris, France | Hôpital Necker-Enfants Malades | Bicetre Hospital | Pitié-Salpêtrière Hospital | Bichat Hospital | University Hospital Center of Martinique;COMPLETED;INTERVENTIONAL;False;2018-09-14;2019-04-03;2021-10-03;;;;;;;;
NCT05349162;Epicardial vs. Transvenous ICDs in Children;Paris Cardiovascular Research Center (Inserm U970);Hôpital Necker-Enfants Malades;COMPLETED;OBSERVATIONAL;False;2022-04-27;2003-01-01;2022-04-01;36735263;PUBMED;Epicardial vs. transvenous implantable cardioverter defibrillators in children.;"Le Bos PA; Pontailler M; Maltret A; Kraiche D; Gaudin R; Barbanti C; Marijon E; Raisky O; Bonnet D; Waldmann V";10.1093/europace/euad015;['Clinical Trial', 'Journal Article'];True;2023-02-03
NCT01703962;Non Invasive IDentification of Gliomas With IDH1 Mutation;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-10-11;2012-03-14;2014-03-20;37668523;PUBMED;Neurochemical Differences between 1p/19q Codeleted and Noncodeleted IDH-mutant Gliomas by in Vivo MR Spectroscopy.;"Branzoli F; Liserre R; Deelchand DK; Poliani PL; Bielle F; Nichelli L; Sanson M; Lehéricy S; Marjańska M";10.1148/radiol.223255;['Journal Article'];False;2023-09-01
NCT01508494;Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-01-12;2011-06-29;2016-06-22;;;;;;;;
NCT02542891;European Comparative Effectiveness Research on Internet-based Depression Treatment;Institut National de la Santé Et de la Recherche Médicale, France;European Commission | Fondation FondaMental | Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2015-09-07;2015-09;2018-09-15;27488181;DERIVED;European COMPARative Effectiveness research on blended Depression treatment versus treatment-as-usual (E-COMPARED): study protocol for a randomized controlled, non-inferiority trial in eight European countries.;"Kleiboer A; Smit J; Bosmans J; Ruwaard J; Andersson G; Topooco N; Berger T; Krieger T; Botella C; Baños R; Chevreul K; Araya R; Cerga-Pashoja A; Cieślak R; Rogala A; Vis C; Draisma S; van Schaik A; Kemmeren L; Ebert D; Berking M; Funk B; Cuijpers P; Riper H";10.1186/s13063-016-1511-1;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2016-08-03
NCT02542891;European Comparative Effectiveness Research on Internet-based Depression Treatment;Institut National de la Santé Et de la Recherche Médicale, France;European Commission | Fondation FondaMental | Assistance Publique - Hôpitaux de Paris;COMPLETED;INTERVENTIONAL;False;2015-09-07;2015-09;2018-09-15;34874888;DERIVED;Examining the Theoretical Framework of Behavioral Activation for Major Depressive Disorder: Smartphone-Based Ecological Momentary Assessment Study.;"van Genugten CR; Schuurmans J; Hoogendoorn AW; Araya R; Andersson G; Baños R; Botella C; Cerga Pashoja A; Cieslak R; Ebert DD; García-Palacios A; Hazo JB; Herrero R; Holtzmann J; Kemmeren L; Kleiboer A; Krieger T; Smoktunowicz E; Titzler I; Topooco N; Urech A; Smit JH; Riper H";10.2196/32007;['Journal Article'];True;2021-12-06
NCT03298360;A Chronological Study of the Formation of HIV Cellular Reservoirs Through the Expression of Surface Markers on CD4 + T Lymphocytes, Including CD32a;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-10-02;2018-06-28;2020-06-25;;;;;;;;
NCT01771562;Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2013-01-18;2013-04;2016-04;27881690;DERIVED;Acceptability of Outpatient Ready-To-Use Food-Based Protocols in HIV-Infected Senegalese Children and Adolescents Within the MAGGSEN Cohort Study.;"Cames C; Varloteaux M; Have NN; Diom AB; Msellati P; Mbaye N; Mbodj H; Sy Signate H; Diack A; ANRS 12279 MAGGSEN Cohort Study Group";10.1177/0379572116679053;['Journal Article'];True;2016-11-23
NCT01771562;Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2013-01-18;2013-04;2016-04;30081838;DERIVED;Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study.;"Cames C; Pascal L; Ba A; Mbodj H; Ouattara B; Diallo NF; Msellati P; Mbaye N; Sy Signate H; Blanche S; Diack A; MAGGSEN Cohort Study Group";10.1186/s12879-018-3282-7;['Journal Article'];True;2018-08-06
NCT01453192;Renal Transplantation and Raltegravir in HIV-Infected Patients;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2011-10-17;2011-12;2015-11;30688008;PUBMED;Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial.;"Matignon M; Lelièvre JD; Lahiani A; Abbassi K; Desvaux D; Diallo A; Peraldi MN; Taburet AM; Saillard J; Delaugerre C; Costagliola D; Assoumou L; Grimbert P; ANRS 153 TREVE study group";10.1111/hiv.12700;['Journal Article', 'Multicenter Study'];True;2019-01-27
NCT01490489;EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-13;2011-07-11;2015-03-13;19602057;RESULT;Role of EG-VEGF in human placentation: Physiological and pathological implications.;"Hoffmann P; Saoudi Y; Benharouga M; Graham CH; Schaal JP; Mazouni C; Feige JJ; Alfaidy N";10.1111/j.1582-4934.2008.00554.x;['Journal Article'];True;2008-10-16
NCT01490489;EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-13;2011-07-11;2015-03-13;16384869;RESULT;Expression and oxygen regulation of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 and its receptors in human placenta during early pregnancy.;"Hoffmann P; Feige JJ; Alfaidy N";10.1210/en.2005-0912;['Journal Article'];False;2006-04-01
NCT01490489;EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-13;2011-07-11;2015-03-13;17531315;RESULT;Placental expression of EG-VEGF and its receptors PKR1 (prokineticin receptor-1) and PKR2 throughout mouse gestation.;"Hoffmann P; Feige JJ; Alfaidy N";10.1016/j.placenta.2007.03.008;['Journal Article'];False;2007-10-01
NCT01033760;Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM);ANRS, Emerging Infectious Diseases;Gilead Sciences | Merck Sharp & Dohme LLC | Pfizer | Janssen-Cilag Ltd.;COMPLETED;INTERVENTIONAL;False;2009-12-16;2010-04;2013-12;25701561;DERIVED;Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.;"Chéret A; Nembot G; Mélard A; Lascoux C; Slama L; Miailhes P; Yeni P; Abel S; Avettand-Fenoel V; Venet A; Chaix ML; Molina JM; Katlama C; Goujard C; Tamalet C; Raffi F; Lafeuillade A; Reynes J; Ravaux I; Hoën B; Delfraissy JF; Meyer L; Rouzioux C; OPTIPRIM ANRS Study Group";10.1016/S1473-3099(15)70021-6;['Journal Article', 'Randomized Controlled Trial'];False;2015-04-01
NCT01033760;Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM);ANRS, Emerging Infectious Diseases;Gilead Sciences | Merck Sharp & Dohme LLC | Pfizer | Janssen-Cilag Ltd.;COMPLETED;INTERVENTIONAL;False;2009-12-16;2010-04;2013-12;28708873;DERIVED;Impact of early cART on HIV blood and semen compartments at the time of primary infection.;"Chéret A; Durier C; Mélard A; Ploquin M; Heitzmann J; Lécuroux C; Avettand-Fenoël V; David L; Pialoux G; Chennebault JM; Müller-Trutwin M; Goujard C; Rouzioux C; Meyer L; ANRS OPTIPRIM study group";10.1371/journal.pone.0180191;['Journal Article', 'Randomized Controlled Trial'];True;2017-07-14
NCT01335529;Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin;ANRS, Emerging Infectious Diseases;Rennes University Hospital | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2011-04-14;2011-05;2014-05;27077673;DERIVED;Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.;"Poizot-Martin I; Bellissant E; Garraffo R; Colson P; Piroth L; Solas C; Renault A; Bourlière M; Halfon P; Ghosn J; Alric L; Naqvi A; Carrieri P; Molina JM; ANRS HC27 BOCEPREVIH Study Group";10.1080/15284336.2015.1135553;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2016-02-11
NCT03047967;Effects of Prenatal Tobacco Smoke Exposure on Lung Function and Respiratory Epithelium Functionality in Newborns;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2017-02-09;2017-11-10;2019-02-09;;;;;;;;
NCT00323804;Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC | Rennes University Hospital;COMPLETED;INTERVENTIONAL;False;2006-05-10;2006-05;2013-03;;;;;;;;
NCT02267304;Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Morphine and Naloxone on Motivation (MBBAnalgesic);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-10-17;2013-10-30;2016-08-30;;;;;;;;
NCT03109067;Genetic and Metabolism of Post-prandial HDL Particles;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2017-04-12;2011-09-21;2015-11-21;;;;;;;;
NCT01552044;Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-03-13;2012-01;2013-02;;;;;;;;
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;28434406;DERIVED;Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.;"Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V; MONOD Study Group";10.1186/s12916-017-0842-4;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2017-04-24
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;28483965;DERIVED;Pharmacokinetics of Efavirenz at a High Dose of 25 Milligrams per Kilogram per Day in Children 2 to 3 Years Old.;"Pressiat C; Amorissani-Folquet M; Yonaba C; Treluyer JM; Dahourou DL; Eboua F; Blanche S; Mea-Assande V; Bouazza N; Foissac F; Malateste K; Ouedraogo S; Lui G; Leroy V; Hirt D";10.1128/AAC.00297-17;['Journal Article'];True;2017-07-01
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;28453240;DERIVED;Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.;"Amani-Bosse C; Dahourou DL; Malateste K; Amorissani-Folquet M; Coulibaly M; Dattez S; Emieme A; Barry M; Rouzioux C; N'gbeche S; Yonaba C; Timité-Konan M; Mea V; Ouédraogo S; Blanche S; Meda N; Seguin-Devaux C; Leroy V";10.7448/IAS.20.01.21362;['Journal Article'];True;2017-01-01
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;28800382;DERIVED;Suboptimal cotrimoxazole prophylactic concentrations in HIV-infected children according to the WHO guidelines.;"Pressiat C; Mea-Assande V; Yonaba C; Treluyer JM; Dahourou DL; Amorissani-Folquet M; Blanche S; Eboua F; Ye D; Lui G; Malateste K; Zheng Y; Leroy V; Hirt D; MONOD Study Group";10.1111/bcp.13397;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2017-09-20
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;27015798;DERIVED;Missed opportunities of inclusion in a cohort of HIV-infected children to initiate antiretroviral treatment before the age of two in West Africa, 2011 to 2013.;"Dahourou DL; Amorissani-Folquet M; Coulibaly M; Avit-Edi D; Meda N; Timite-Konan M; Arendt V; Ye D; Amani-Bosse C; Salamon R; Lepage P; Leroy V; Monod Anrs 12206 Study Group";10.7448/IAS.19.1.20601;['Journal Article'];True;2016-01-01
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;34723858;DERIVED;High nevirapine levels in breast milk and consequences in HIV-infected child when initiated on antiretroviral therapy.;"Pressiat C; Toni TD; Treluyer JM; Yonaba C; Dahourou DL; Malateste K; Seguin-Devaux C; Leroy V; Hirt D; MONOD ANRS Study Group";10.1097/QAD.0000000000003043;['Letter'];False;2021-11-15
NCT01127204;Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age;ANRS, Emerging Infectious Diseases;European and Developing Countries Clinical Trials Partnership (EDCTP) | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | Ministry of Health, Rwanda | Institut National de la Santé Et de la Recherche Médicale, France | University of Bordeaux | Institut de Sante Publique, d'Epidémiologie et de Développement | Université Montpellier | University of Paris 5 - Rene Descartes | Queen Fabiola Children's University Hospital;COMPLETED;INTERVENTIONAL;False;2010-05-20;2011-06;2015-04;31334298;DERIVED;Cost-Effectiveness of Preemptive Switching to Efavirenz-Based Antiretroviral Therapy for Children With Human Immunodeficiency Virus.;"Desmonde S; Frank SC; Coovadia A; Dahourou DL; Hou T; Abrams EJ; Amorissani-Folquet M; Walensky RP; Strehlau R; Penazzato M; Freedberg KA; Kuhn L; Leroy V; Ciaranello AL";10.1093/ofid/ofz276;['Journal Article'];True;2019-06-11
NCT03642704;HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-08-22;2017-02-22;2019-09-17;;;;;;;;
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;15897497;BACKGROUND;Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease?;"Czernecki V; Pillon B; Houeto JL; Welter ML; Mesnage V; Agid Y; Dubois B";10.1136/jnnp.2003.033258;['Journal Article'];True;2005-06-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;19713543;BACKGROUND;A longitudinal view of apathy and its impact after stroke.;"Mayo NE; Fellows LK; Scott SC; Cameron J; Wood-Dauphinee S";10.1161/STROKEAHA.109.554410;['Journal Article'];False;2009-10-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;19933975;BACKGROUND;Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study.;"Le Jeune F; Drapier D; Bourguignon A; Péron J; Mesbah H; Drapier S; Sauleau P; Haegelen C; Travers D; Garin E; Malbert CH; Millet B; Vérin M";10.1212/WNL.0b013e3181c34b34;['Clinical Trial', 'Journal Article'];False;2009-11-24
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;1821241;BACKGROUND;Apathy: a neuropsychiatric syndrome.;Marin RS;10.1176/jnp.3.3.243;['Journal Article', 'Review'];False;1991-08-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;10436334;BACKGROUND;The clinical picture of frontotemporal dementia: diagnosis and follow-up.;"Pasquier F; Lebert F; Lavenu I; Guillaume B";10.1159/000051206;['Journal Article'];False;1999-01-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;19533496;BACKGROUND;Apathy after acquired brain impairment: a systematic review of non-pharmacological interventions.;"Lane-Brown AT; Tate RL";10.1080/09602010902949207;['Journal Article', 'Review'];False;2009-08-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;17131230;BACKGROUND;Apathy and the basal ganglia.;"Levy R; Czernecki V";10.1007/s00415-006-7012-5;['Journal Article', 'Review'];False;2006-12-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;10941190;BACKGROUND;Negative symptoms: the 'pathology' of motivation and goal-directed behaviour.;"Brown RG; Pluck G";10.1016/s0166-2236(00)01626-x;['Journal Article', 'Review'];False;2000-09-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;10678322;BACKGROUND;Group differences in the relationship between apathy and depression.;"Marin RS; Firinciogullari S; Biedrzycki RC";10.1097/00005053-199404000-00008;['Journal Article'];False;1994-04-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;18307266;BACKGROUND;The Lille Apathy Rating Scale: validation of a caregiver-based version.;"Dujardin K; Sockeel P; Delliaux M; Destée A; Defebvre L";10.1002/mds.21968;['Journal Article'];False;2008-04-24
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;21895376;BACKGROUND;The SEA (Social cognition and Emotional Assessment): a clinical neuropsychological tool for early diagnosis of frontal variant of frontotemporal lobar degeneration.;"Funkiewiez A; Bertoux M; de Souza LC; Lévy R; Dubois B";10.1037/a0025318;['Journal Article'];False;2012-01-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;16421064;BACKGROUND;Reduced daytime activity in patients with acquired brain damage and apathy: a study with ambulatory actigraphy.;"Müller U; Czymmek J; Thöne-Otto A; Von Cramon DY";10.1080/02699050500443467;['Journal Article'];False;2006-01-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;17027767;BACKGROUND;Negative symptoms: A review of schizophrenia, melancholic depression and Parkinson's disease.;"Winograd-Gurvich C; Fitzgerald PB; Georgiou-Karistianis N; Bradshaw JL; White OB";10.1016/j.brainresbull.2006.06.007;['Journal Article', 'Review'];False;2006-10-01
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;12461757;BACKGROUND;The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment.;"Robert PH; Clairet S; Benoit M; Koutaich J; Bertogliati C; Tible O; Caci H; Borg M; Brocker P; Bedoucha P";10.1002/gps.755;['Journal Article'];False;2002-10-23
NCT02496312;Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2015-07-10;2015-10-02;16207933;BACKGROUND;Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits.;"Levy R; Dubois B";10.1093/cercor/bhj043;['Journal Article', 'Review'];True;2005-10-05
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;36601747;PUBMED;Hepatitis A and B vaccine uptake and immunisation among men who have sex with men seeking PrEP: a substudy of the ANRS IPERGAY trial.;"Le Turnier P; Charreau I; Gabassi A; Carette D; Cotte L; Pialoux G; Tremblay C; Spire B; Chaix ML; Meyer L; Capitant C; Delaugerre C; Raffi F; Molina JM; ANRS IPERGAY study group";10.1136/sextrans-2022-055634;['Clinical Trial', 'Letter'];True;2022-12-08
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;26624850;DERIVED;On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.;"Molina JM; Capitant C; Spire B; Pialoux G; Cotte L; Charreau I; Tremblay C; Le Gall JM; Cua E; Pasquet A; Raffi F; Pintado C; Chidiac C; Chas J; Charbonneau P; Delaugerre C; Suzan-Monti M; Loze B; Fonsart J; Peytavin G; Cheret A; Timsit J; Girard G; Lorente N; Préau M; Rooney JF; Wainberg MA; Thompson D; Rozenbaum W; Doré V; Marchand L; Simon MC; Etien N; Aboulker JP; Meyer L; Delfraissy JF; ANRS IPERGAY Study Group";10.1056/NEJMoa1506273;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2015-12-03
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;28747274;DERIVED;Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.;"Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L; ANRS IPERGAY Study Group";10.1016/S2352-3018(17)30089-9;['Journal Article', 'Multicenter Study'];True;2017-09-01
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;29229440;DERIVED;Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.;"Molina JM; Charreau I; Chidiac C; Pialoux G; Cua E; Delaugerre C; Capitant C; Rojas-Castro D; Fonsart J; Bercot B; Bébéar C; Cotte L; Robineau O; Raffi F; Charbonneau P; Aslan A; Chas J; Niedbalski L; Spire B; Sagaon-Teyssier L; Carette D; Mestre SL; Doré V; Meyer L; ANRS IPERGAY Study Group";10.1016/S1473-3099(17)30725-9;['Journal Article', 'Randomized Controlled Trial'];True;2018-03-01
NCT01473472;On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-11-17;2012-01;2016-12-15;31784343;DERIVED;On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.;"Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM; ANRS IPERGAY study group";10.1016/S2352-3018(19)30341-8;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2020-02-01
NCT02073604;Role of the SMA During Unimanual and Bimanual Movements Preparation: the Mirror Movements Paradigm;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-02-27;2014-03;2016-02;;;;;;;;
NCT04849767;National Survey About Trajectory and Life Conditions of HIV Trans People in France;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;OBSERVATIONAL;False;2021-04-19;2020-10-01;2023-12-31;34916316;DERIVED;Living conditions, HIV and gender affirmation care pathways of transgender people living with HIV in France: a nationwide, comprehensive, cross-sectional, community-based research protocol (ANRS Trans&HIV).;"Mora M; Rincon G; Bourrelly M; Maradan G; Freire Maresca A; Michard F; Rouveix E; Pannetier J; Leriche D; Alain T; Yazdanpanah Y; Michels D; Spire B";10.1136/bmjopen-2021-052691;['Journal Article'];True;2021-12-01
NCT01525472;Accelerated Aging of the Cells of Visceral Adipose Tissue in Morbid Obese Subjects;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-02-03;2012-02-13;2015-10-20;;;;;;;;
NCT04484740;Penetration of the Innovative Antibiotic Gepotidacin Into Prostate and Tonsillar Tissue;Institut National de la Santé Et de la Recherche Médicale, France;Medical University of Vienna;COMPLETED;INTERVENTIONAL;False;2020-07-24;2021-01-29;2023-05-27;;;;;;;;
NCT02384967;Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2015-03-10;2015-03;2016-10;29905808;DERIVED;Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.;"Lê MP; Chaix ML; Chevret S; Bertrand J; Raffi F; Gallien S; El Abbassi EMB; Katlama C; Delobel P; Yazdanpanah Y; Saillard J; Molina JM; Peytavin G; ANRS 165 DARULIGHT Study Group";10.1093/jac/dky193;['Journal Article', 'Multicenter Study'];True;2018-06-13
NCT03335995;Stroke Prognosis in Intensive CarE;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2017-11-08;2017-10-18;2020-11-18;37497675;PUBMED;One-Year Outcomes in Patients With Acute Stroke Requiring Mechanical Ventilation.;"Sonneville R; Mazighi M; Collet M; Gayat E; Degos V; Duranteau J; Grégoire C; Sharshar T; Naim G; Cortier D; Jost PH; Foucrier A; Bagate F; de Montmollin E; Papin G; Magalhaes E; Guidet B; Ben Hadj Salem O; Benghanem S; le Guennec L; Delpierre E; Legriel S; Megarbane B; Toumert K; Tran M; Geri G; Monchi M; Bodiguel E; Mariotte E; Demoule A; Zarka J; Diehl JL; Roux D; Barré E; Tanaka S; Osman D; Pasquier P; Lamara F; Crassard I; Boursin P; Ruckly S; Staiquly Q; Timsit JF; Woimant F; SPICE Investigators";10.1161/STROKEAHA.123.042910;['Multicenter Study', 'Journal Article'];True;2023-09-01
NCT03335995;Stroke Prognosis in Intensive CarE;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2017-11-08;2017-10-18;2020-11-18;32026446;DERIVED;Outcomes of Acute Stroke Patients Requiring Mechanical Ventilation: Study Protocol for the SPICE Multicenter Prospective Observational Study.;"Sonneville R; Mazighi M; Bresson D; Crassard I; Crozier S; de Montmollin E; Degos V; Faugeras F; Gayat E; Josse L; Lamy C; Magalhaes E; Maldjian A; Ruckly S; Servan J; Vassel P; Vigué B; Timsit JF; Woimant F; SPICE investigators";10.1007/s12028-019-00907-0;['Journal Article'];False;2020-02-05
NCT01647295;Social Interactions: Ocular Explorations and Pupillometry in Autism;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-07-23;2013-02-25;2019-06-18;;;;;;;;
NCT01226446;Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2010-10-22;2010-11;2013-01;25987791;DERIVED;Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.;"Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P";10.3748/wjg.v21.i18.5647;['Clinical Trial', 'Journal Article', 'Multicenter Study'];True;2015-01-01
NCT04780191;Investigation of Treatment Using the MyoRegulator® Device in Patients With Spasticity in the Lower Limb Due to Stroke;Institut National de la Santé Et de la Recherche Médicale, France;PathMaker Neurosystems Inc.;COMPLETED;INTERVENTIONAL;False;2021-03-03;2018-07-19;2021-01-19;32232101;BACKGROUND;Non-invasive treatment of patients with upper extremity spasticity following stroke using paired trans-spinal and peripheral direct current stimulation.;"Paget-Blanc A; Chang JL; Saul M; Lin R; Ahmed Z; Volpe BT";10.1186/s42234-019-0028-9;['Journal Article'];True;2019-07-23
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;ANRS, Emerging Infectious Diseases;NEAT - European AIDS Treatment Network;COMPLETED;INTERVENTIONAL;False;2010-02-10;2010-08;2013-10;30365452;DERIVED;Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial.;"Ammassari A; Stöhr W; Antinori A; Molina JM; Schwimmer C; Domingo P; Thalme A; Di Pietro M; Wallet C; Pozniak A; Richert L; Raffi F; NEAT001/ANRS143 Trial Study Group";10.1097/QAI.0000000000001834;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2018-12-01
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;ANRS, Emerging Infectious Diseases;NEAT - European AIDS Treatment Network;COMPLETED;INTERVENTIONAL;False;2010-02-10;2010-08;2013-10;25103176;DERIVED;Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.;"Raffi F; Babiker AG; Richert L; Molina JM; George EC; Antinori A; Arribas JR; Grarup J; Hudson F; Schwimmer C; Saillard J; Wallet C; Jansson PO; Allavena C; Van Leeuwen R; Delfraissy JF; Vella S; Chêne G; Pozniak A; NEAT001/ANRS143 Study Group";10.1016/S0140-6736(14)61170-3;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];False;2014-11-01
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;ANRS, Emerging Infectious Diseases;NEAT - European AIDS Treatment Network;COMPLETED;INTERVENTIONAL;False;2010-02-10;2010-08;2013-10;33794182;DERIVED;Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial.;"Esteban-Cantos A; Rodríguez-Centeno J; Barruz P; Alejos B; Saiz-Medrano G; Nevado J; Martin A; Gayá F; De Miguel R; Bernardino JI; Montejano R; Mena-Garay B; Cadiñanos J; Florence E; Mulcahy F; Banhegyi D; Antinori A; Pozniak A; Wallet C; Raffi F; Rodés B; Arribas JR; NEAT001/ANRS143 Study Group";10.1016/S2352-3018(21)00006-0;['Journal Article'];False;2021-04-01
NCT01066962;Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects;ANRS, Emerging Infectious Diseases;NEAT - European AIDS Treatment Network;COMPLETED;INTERVENTIONAL;False;2010-02-10;2010-08;2013-10;26520926;DERIVED;Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.;"Bernardino JI; Mocroft A; Mallon PW; Wallet C; Gerstoft J; Russell C; Reiss P; Katlama C; De Wit S; Richert L; Babiker A; Buño A; Castagna A; Girard PM; Chene G; Raffi F; Arribas JR; NEAT001/ANRS143 Study Group";10.1016/S2352-3018(15)00181-2;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];False;2015-11-01
NCT02486731;Hormonal Sensitivity in Patients With Noonan and LEOPARD Syndromes;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2015-07-01;2015-12-16;2018-12;;;;;;;;
NCT05199831;Situational Analysis of HIV-related Disability in the Context of Ivory Coast;Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire;Institute of Research for Development, France | Institut de Sante Publique, d'Epidemiologie et de Developpement | University of Toronto | Université de Lille;COMPLETED;OBSERVATIONAL;False;2022-01-20;2021-02-05;2022-08-10;;;;;;;;
NCT02107365;Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO);ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb;COMPLETED;INTERVENTIONAL;False;2014-04-08;2013-11;2015-04;;;;;;;;
NCT03150290;Brown Adipose Tissue in ALS;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2017-05-12;2017-10-26;2019-04-01;;;;;;;;
NCT01605890;Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients;ANRS, Emerging Infectious Diseases;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;True;2012-05-25;2012-07;2015-12;29590335;DERIVED;First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).;"Matheron S; Descamps D; Gallien S; Besseghir A; Sellier P; Blum L; Mortier E; Charpentier C; Tubiana R; Damond F; Peytavin G; Ponscarme D; Collin F; Brun-Vezinet F; Chene G; France REcherche Nord&Sud Sida-Hiv Hépatites (ANRS) 159 HIV-2 Trial Study Group";10.1093/cid/ciy245;['Journal Article', 'Multicenter Study'];True;2018-03-24
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;15037514;RESULT;Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat.;"Ahmad S; Fowler LJ; Whitton PS";10.1038/sj.bjp.0705737;['Journal Article'];True;2004-05-01
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;15249613;RESULT;PET evidence for a role of the basal ganglia in patients with ring chromosome 20 epilepsy.;"Biraben A; Semah F; Ribeiro MJ; Douaud G; Remy P; Depaulis A";10.1212/01.wnl.0000132840.40838.13;['Journal Article'];False;2004-07-13
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;15777732;RESULT;Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids.;"Ahmad S; Fowler LJ; Whitton PS";10.1016/j.eplepsyres.2005.02.002;['Journal Article'];False;2005-02-01
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;2271377;RESULT;Apomorphine-induced blinking and yawning in healthy volunteers.;"Blin O; Masson G; Azulay JP; Fondarai J; Serratrice G";10.1111/j.1365-2125.1990.tb03848.x;['Clinical Trial', 'Journal Article', 'Randomized Controlled Trial'];True;1990-11-01
NCT01432821;Blinking and Yawning in Epilepsy: The Role of Dopamine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-09-13;2011-09;2014-12;12914551;RESULT;Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects.;"Aymard G; Berlin I; de Brettes B; Diquet B";10.1046/j.1472-8206.2003.00152.x;['Clinical Trial', 'Journal Article', 'Randomized Controlled Trial'];False;2003-07-07
NCT02071784;Imaging Study of Neurovascular Coupling in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2014-02-26;2014-07-08;2016-10-24;;;;;;;;
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;23766338;BACKGROUND;Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial.;"Tubiana R; Mandelbrot L; Le Chenadec J; Delmas S; Rouzioux C; Hirt D; Treluyer JM; Ekoukou D; Bui E; Chaix ML; Blanche S; Warszawski J; ANRS 135 PRIMEVA (Protease Inhibitor Monotherapy Evaluation) Study Group";10.1093/cid/cit390;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2013-06-12
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;26709605;BACKGROUND;Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.;"Arribas JR; Girard PM; Paton N; Winston A; Marcelin AG; Elbirt D; Hill A; Hadacek MB";10.1111/hiv.12348;['Journal Article', 'Meta-Analysis'];True;2015-12-28
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;22848481;BACKGROUND;Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks.;"Lambert-Niclot S; Flandre P; Valantin MA; Soulie C; Fourati S; Wirden M; Sayon S; Pakianather S; Bocket L; Masquelier B; Dos Santos G; Katlama C; Calvez V; Marcelin AG";10.1371/journal.pone.0041390;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2012-07-25
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;26197844;BACKGROUND;No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception.;"Mandelbrot L; Tubiana R; Le Chenadec J; Dollfus C; Faye A; Pannier E; Matheron S; Khuong MA; Garrait V; Reliquet V; Devidas A; Berrebi A; Allisy C; Elleau C; Arvieux C; Rouzioux C; Warszawski J; Blanche S; ANRS-EPF Study Group";10.1093/cid/civ578;['Journal Article', 'Multicenter Study'];True;2015-07-21
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;26854809;BACKGROUND;Risk of cancer in children exposed to didanosine in utero.;"Hleyhel M; Goujon S; Delteil C; Vasiljevic A; Luzi S; Stephan JL; Reliquet V; Jannier S; Tubiana R; Dollfus C; Faye A; Mandelbrot L; Clavel J; Warszawski J; Blanche S; ANRS French Perinatal Cohort Study Group";10.1097/QAD.0000000000001051;['Journal Article', 'Multicenter Study'];False;2016-05-15
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;22160145;BACKGROUND;Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.;"Valantin MA; Lambert-Niclot S; Flandre P; Morand-Joubert L; Cabiè A; Meynard JL; Ponscarme D; Ajana F; Slama L; Curjol A; Cuzin L; Schneider L; Taburet AM; Marcelin AG; Katlama C; MONOI ANRS 136 Study Group";10.1093/jac/dkr504;['Journal Article', 'Randomized Controlled Trial'];True;2011-12-07
NCT02738502;Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-04-14;2016-07-06;2020-07-16;23559464;BACKGROUND;Genotoxic signature in cord blood cells of newborns exposed in utero to a Zidovudine-based antiretroviral combination.;"André-Schmutz I; Dal-Cortivo L; Six E; Kaltenbach S; Cocchiarella F; Le Chenadec J; Cagnard N; Cordier AG; Benachi A; Mandelbrot L; Azria E; Bouallag N; Luce S; Ternaux B; Reimann C; Revy P; Radford-Weiss I; Leschi C; Recchia A; Mavilio F; Cavazzana M; Blanche S";10.1093/infdis/jit149;['Journal Article'];True;2013-04-04
NCT03652090;Primary Nasal Cell Culture as a Tool for Personalized Therapy in Cystic Fibrosis;Institut National de la Santé Et de la Recherche Médicale, France;ABCF2;COMPLETED;OBSERVATIONAL;False;2018-08-29;2010-09-01;2016-03-03;;;;;;;;
NCT02126384;Identifocation the B Cell Subsets Responsible for Anti-pneumococcal Response;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-04-30;2014-11-18;2016-04-05;;;;;;;;
NCT02992184;PoC-HCV Genedrive Viral Detection Assay Validation Study;ANRS, Emerging Infectious Diseases;EPISTEM;COMPLETED;OBSERVATIONAL;False;2016-12-14;2016-09;2016-12;29615488;DERIVED;Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus.;"Llibre A; Shimakawa Y; Mottez E; Ainsworth S; Buivan TP; Firth R; Harrison E; Rosenberg AR; Meritet JF; Fontanet A; Castan P; Madejón A; Laverick M; Glass A; Viana R; Pol S; McClure CP; Irving WL; Miele G; Albert ML; Duffy D";10.1136/gutjnl-2017-315783;['Clinical Trial', 'Journal Article'];True;2018-04-03
NCT04824638;BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2021-04-01;2021-03-08;2023-12-02;;;;;;;;
NCT02212379;Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC | Janssen-Cilag Ltd.;COMPLETED;INTERVENTIONAL;True;2014-08-08;2015-01;2018-04;31269208;PUBMED;Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.;"Katlama C; Assoumou L; Valantin MA; Soulié C; Martinez E; Béniguel L; Bouchaud O; Raffi F; Molina JM; Fellahi S; Peytavin G; Marcelin AG; Kolta S; Capeau J; Gibowski S; Cardon F; Reynes J; Costagliola D; members of the ANRS 163 ETRAL study";10.1093/jac/dkz224;['Journal Article', 'Multicenter Study'];True;2019-07-03
NCT02113943;Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Citalopram on Motivation;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-04-15;2014-04;2014-06;;;;;;;;
NCT01426243;The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2011-08-31;2011-07;2017-12;30096071;DERIVED;Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients.;"Colin de Verdiere N; Durier C; Samri A; Meiffredy V; Launay O; Matheron S; Mercier-Delarue S; Even S; Aboulker JP; Molina JM; Autran B; Simon F; ANRS EP46 NOVAA Group";10.1097/QAD.0000000000001963;['Journal Article'];False;2018-10-23
NCT01426243;The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2011-08-31;2011-07;2017-12;26314624;PUBMED;Molecular characterization of the 17D-204 yellow fever vaccine.;"Salmona M; Gazaignes S; Mercier-Delarue S; Garnier F; Korimbocus J; Colin de Verdière N; LeGoff J; Roques P; Simon F";10.1016/j.vaccine.2015.08.055;['Journal Article'];False;2015-10-01
NCT03519503;Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2018-05-09;2017-02-27;2018-02-15;22814853;BACKGROUND;HIV-1 reservoirs in breast milk and challenges to elimination of breast-feeding transmission of HIV-1.;"Van de Perre P; Rubbo PA; Viljoen J; Nagot N; Tylleskär T; Lepage P; Vendrell JP; Tuaillon E";10.1126/scitranslmed.3003327;['Journal Article', 'Review'];False;2012-07-18
NCT03519503;Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2018-05-09;2017-02-27;2018-02-15;26603917;BACKGROUND;Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.;"Nagot N; Kankasa C; Tumwine JK; Meda N; Hofmeyr GJ; Vallo R; Mwiya M; Kwagala M; Traore H; Sunday A; Singata M; Siuluta C; Some E; Rutagwera D; Neboua D; Ndeezi G; Jackson D; Maréchal V; Neveu D; Engebretsen IMS; Lombard C; Blanche S; Sommerfelt H; Rekacewicz C; Tylleskär T; Van de Perre P; ANRS 12174 Trial Group";10.1016/S0140-6736(15)00984-8;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];False;2016-02-01
NCT03519503;Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2018-05-09;2017-02-27;2018-02-15;21602695;BACKGROUND;Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children.;"Heidari S; Mofenson L; Cotton MF; Marlink R; Cahn P; Katabira E";10.1097/QAI.0b013e318221c56a;['Journal Article', 'Review'];True;2011-08-01
NCT02314208;Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-11;2015-01;2018-01-01;;;;;;;;
NCT01348308;Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients;ANRS, Emerging Infectious Diseases;Pfizer;COMPLETED;INTERVENTIONAL;False;2011-05-05;2011-09;2016-03;32040959;DERIVED;Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial.;"Lévy Y; Lelièvre JD; Assoumou L; Aznar E; Pulido F; Tambussi G; Crespo M; Meybeck A; Molina JM; Delaugerre C; Izopet J; Peytavin G; Cardon F; Diallo A; Lancar R; Béniguel L; Costagliola D";10.7326/M19-2133;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];False;2020-02-11
NCT01942655;IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV Infection;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2013-09-16;2014-06-01;2018-03-01;;;;;;;;
NCT01332955;Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen;ANRS, Emerging Infectious Diseases;Janssen-Cilag Ltd.;COMPLETED;INTERVENTIONAL;False;2011-04-11;2011-04;2013-09;25139963;DERIVED;Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.;"Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group";10.1093/cid/ciu659;['Journal Article'];True;2014-08-18
NCT04945655;Impact of a School- and Primary Care-based Multicomponent Intervention on HPV Vaccination Acceptability;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2021-06-30;2021-11-15;2023-04-30;35332045;DERIVED;Impact of a school-based and primary care-based multicomponent intervention on HPV vaccination coverage among French adolescents: a cluster randomised controlled trial protocol (the PrevHPV study).;"Bocquier A; Michel M; Giraudeau B; Bonnay S; Gagneux-Brunon A; Gauchet A; Gilberg S; Le Duc-Banaszuk AS; Mueller JE; Chevreul K; Thilly N; PrevHPV Study group";10.1136/bmjopen-2021-057943;['Journal Article'];True;2022-03-01
NCT01696708;Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-10-01;2012-12-06;2015-11;25568297;DERIVED;Triheptanoin improves brain energy metabolism in patients with Huntington disease.;"Adanyeguh IM; Rinaldi D; Henry PG; Caillet S; Valabregue R; Durr A; Mochel F";10.1212/WNL.0000000000001214;['Clinical Trial', 'Journal Article'];True;2015-02-03
NCT02323308;Isolated Anti-HBc Serological Profile in HIV Infected Patients: Immunological, Virological Characteristics and Response to Hepatitis B Vaccination;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2014-12-23;2010-12;2014-06;;;;;;;;
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;23880306;DERIVED;Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial.;"Iwuji CC; Orne-Gliemann J; Tanser F; Boyer S; Lessells RJ; Lert F; Imrie J; Bärnighausen T; Rekacewicz C; Bazin B; Newell ML; Dabis F; ANRS 12249 TasP Study Group";10.1186/1745-6215-14-230;['Journal Article', 'Randomized Controlled Trial'];True;2013-01-01
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;32970730;DERIVED;Test but not treat: Community members' experiences with barriers and facilitators to universal antiretroviral therapy uptake in rural KwaZulu-Natal, South Africa.;"Iwuji C; Chimukuche RS; Zuma T; Plazy M; Larmarange J; Orne-Gliemann J; Siedner M; Shahmanesh M; Seeley J";10.1371/journal.pone.0239513;['Journal Article'];True;2020-09-24
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;28329393;DERIVED;Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.;"Collier D; Iwuji C; Derache A; de Oliveira T; Okesola N; Calmy A; Dabis F; Pillay D; Gupta RK; French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Prevention (TasP) Study Group";10.1093/cid/cix015;['Journal Article'];True;2017-03-13
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;30412926;DERIVED;"""If you are here at the clinic, you do not know how many people need help in the community"": Perspectives of home-based HIV services from health care workers in rural KwaZulu-Natal, South Africa in the era of universal test-and-treat.";"Perriat D; Plazy M; Gumede D; Boyer S; Pillay D; Dabis F; Seeley J; Orne-Gliemann J; ANRS 12249 TasP Study Group";10.1371/journal.pone.0202473;['Clinical Trial', 'Journal Article'];True;2018-11-09
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;30321314;DERIVED;Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial.;"Derache A; Iwuji CC; Baisley K; Danaviah S; Marcelin AG; Calvez V; de Oliveira T; Dabis F; Porter K; Pillay D";10.1093/cid/ciy881;['Journal Article'];True;2018-10-15
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;31637821;DERIVED;Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa.;"Larmarange J; Diallo MH; McGrath N; Iwuji C; Plazy M; Thiébaut R; Tanser F; Bärnighausen T; Orne-Gliemann J; Pillay D; Dabis F; ANRS 12249 TasP Study Group";10.1002/jia2.25402;['Journal Article'];True;2019-10-01
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;29890048;DERIVED;Universal test and treat is not associated with sub-optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial.;"Iwuji C; McGrath N; Calmy A; Dabis F; Pillay D; Newell ML; Baisley K; Porter K";10.1002/jia2.25112;['Journal Article', 'Randomized Controlled Trial'];True;2018-06-01
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;27504637;DERIVED;Uptake of Home-Based HIV Testing, Linkage to Care, and Community Attitudes about ART in Rural KwaZulu-Natal, South Africa: Descriptive Results from the First Phase of the ANRS 12249 TasP Cluster-Randomised Trial.;"Iwuji CC; Orne-Gliemann J; Larmarange J; Okesola N; Tanser F; Thiebaut R; Rekacewicz C; Newell ML; Dabis F; ANRS 12249 TasP trial group";10.1371/journal.pmed.1002107;['Journal Article', 'Randomized Controlled Trial'];True;2016-08-09
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;30027600;DERIVED;The impact of population dynamics on the population HIV care cascade: results from the ANRS 12249 Treatment as Prevention trial in rural KwaZulu-Natal (South Africa).;"Larmarange J; Diallo MH; McGrath N; Iwuji C; Plazy M; Thiébaut R; Tanser F; Bärnighausen T; Pillay D; Dabis F; Orne-Gliemann J; ANRS 12249 TasP Study Group";10.1002/jia2.25128;['Journal Article', 'Randomized Controlled Trial'];True;2018-07-01
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;25880823;DERIVED;Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal.;"Orne-Gliemann J; Larmarange J; Boyer S; Iwuji C; McGrath N; Bärnighausen T; Zuma T; Dray-Spira R; Spire B; Rochat T; Lert F; Imrie J; ANRS 12249 TasP Group";10.1186/s12889-015-1344-y;['Journal Article'];True;2015-03-01
NCT01509508;Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence;ANRS, Emerging Infectious Diseases;Africa Centre For Health and Population Studies | University of KwaZulu;COMPLETED;INTERVENTIONAL;False;2012-01-13;2012-03;2016-06;29199100;DERIVED;Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial.;"Iwuji CC; Orne-Gliemann J; Larmarange J; Balestre E; Thiebaut R; Tanser F; Okesola N; Makowa T; Dreyer J; Herbst K; McGrath N; Bärnighausen T; Boyer S; De Oliveira T; Rekacewicz C; Bazin B; Newell ML; Pillay D; Dabis F; ANRS 12249 TasP Study Group";10.1016/S2352-3018(17)30205-9;['Journal Article', 'Randomized Controlled Trial'];True;2018-03-01
NCT02469350;Serious Game for Parkinson's Disease Patients;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-06-11;2015-06;2017-10-04;29636105;DERIVED;The feasibility and positive effects of a customised videogame rehabilitation programme for freezing of gait and falls in Parkinson's disease patients: a pilot study.;"Nuic D; Vinti M; Karachi C; Foulon P; Van Hamme A; Welter ML";10.1186/s12984-018-0375-x;['Clinical Trial', 'Journal Article'];True;2018-04-10
NCT02488395;Superior Colliculus Activity in Parkinson Disease: a Potential Marker?;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2015-07-02;2015-10-07;2018-01-19;23916713;RESULT;Enhanced visual responses in the superior colliculus and subthalamic nucleus in an animal model of Parkinson's disease.;"Rolland M; Carcenac C; Overton PG; Savasta M; Coizet V";10.1016/j.neuroscience.2013.07.047;['Journal Article'];False;2013-11-01
NCT02488395;Superior Colliculus Activity in Parkinson Disease: a Potential Marker?;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2015-07-02;2015-10-07;2018-01-19;22639796;RESULT;Linking visual response properties in the superior colliculus to saccade behavior.;"Marino RA; Levy R; Boehnke S; White BJ; Itti L; Munoz DP";10.1111/j.1460-9568.2012.08079.x;['Journal Article'];True;2012-05-28
NCT02488395;Superior Colliculus Activity in Parkinson Disease: a Potential Marker?;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2015-07-02;2015-10-07;2018-01-19;6774653;RESULT;Visual-motor function of the primate superior colliculus.;"Wurtz RH; Albano JE";10.1146/annurev.ne.03.030180.001201;['Journal Article', 'Review'];False;1980-03-01
NCT00946595;Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients;French National Agency for Research on AIDS and Viral Hepatitis;Abbott | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2009-07-27;2009-11;2014-01;29767684;DERIVED;Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies.;"Lambert-Niclot S; Grude M; Meynard JL; Marcelin AG; Valantin MA; Flandre P; Izopet J; Moinot L; Bouteloup V; Calvez V; Katlama C; Girard PM; Morand-Joubert L";10.1093/cid/ciy382;['Journal Article', 'Randomized Controlled Trial'];True;2018-05-15
NCT00946595;Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients;French National Agency for Research on AIDS and Viral Hepatitis;Abbott | Gilead Sciences;COMPLETED;INTERVENTIONAL;False;2009-07-27;2009-11;2014-01;30968368;DERIVED;Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM).;"Garay OU; Nishimwe ML; Bousmah MA; Janah A; Girard PM; Chêne G; Moinot L; Sagaon-Teyssier L; Meynard JL; Spire B; Boyer S";10.1007/s41669-019-0130-7;['Journal Article'];True;2019-04-09
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;29369084;RESULT;DIRECTIONAL VARIABILITY OF FUNDUS REFLECTANCE IN ACUTE MACULAR NEURORETINOPATHY: EVIDENCE FOR A CONTRIBUTION OF THE STILES-CRAWFORD EFFECT.;"Bottin C; Grieve K; Rossant F; Pedinielli A; Mrejen S; Paques M";10.1097/ICB.0000000000000701;['Journal Article'];False;2018-01-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;28900746;RESULT;Electrophysiological features and multimodal imaging in ritonavir-related maculopathy.;"Faure C; Paques M; Audo I";10.1007/s10633-017-9612-z;['Journal Article'];False;2017-09-12
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;24406779;RESULT;Morphometric analysis of small arteries in the human retina using adaptive optics imaging: relationship with blood pressure and focal vascular changes.;"Koch E; Rosenbaum D; Brolly A; Sahel JA; Chaumet-Riffaud P; Girerd X; Rossant F; Paques M";10.1097/HJH.0000000000000095;['Clinical Trial', 'Journal Article'];True;2014-04-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;25077537;RESULT;High-resolution imaging of gunn's dots.;"Paques M; Miloudi C; Kulcsar C; Leseigneur A; Chaumette C; Koch E";10.1097/IAE.0000000000000269;['Journal Article'];False;2015-01-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;24576889;RESULT;Retinal vasculitis imaging by adaptive optics.;"Errera MH; Coisy S; Fardeau C; Sahel JA; Kallel S; Westcott M; Bodaghi B; Paques M";10.1016/j.ophtha.2013.12.036;['Journal Article'];False;2014-06-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;31972545;RESULT;IGF-1 is an independent predictor of retinal arterioles remodeling in subjects with uncontrolled acromegaly.;"Gallo A; Chaigneau E; Jublanc C; Rosenbaum D; Mattina A; Paques M; Rossant F; Girerd X; Leban M; Bruckert E";10.1530/EJE-19-0390;['Journal Article'];False;2020-03-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;23620431;RESULT;Adaptive optics imaging of geographic atrophy.;"Gocho K; Sarda V; Falah S; Sahel JA; Sennlaub F; Benchaboune M; Ullern M; Paques M";10.1167/iovs.12-10672;['Journal Article'];False;2013-04-25
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;31568064;RESULT;IN VIVO OBSERVATION OF RETINAL VASCULAR DEPOSITS USING ADAPTIVE OPTICS IMAGING IN FABRY DISEASE.;"Sodi A; Germain DP; Bacherini D; Finocchio L; Pacini B; Marziali E; Lenzetti C; Tanini I; Koraichi F; Coriat C; Nencini P; Olivotto I; Virgili G; Rizzo S; Paques M";10.1097/IAE.0000000000002648;['Journal Article', 'Multicenter Study'];True;2020-08-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;24337723;RESULT;Functional and high resolution retinal imaging assessment in a case of ocular siderosis.;"Faure C; Gocho K; Le Mer Y; Sahel JA; Paques M; Audo I";10.1007/s10633-013-9421-y;['Journal Article'];False;2013-12-13
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;25284764;RESULT;Meaning of visualizing retinal cone mosaic on adaptive optics images.;"Jacob J; Paques M; Krivosic V; Dupas B; Couturier A; Kulcsar C; Tadayoni R; Massin P; Gaudric A";10.1016/j.ajo.2014.09.043;['Journal Article'];False;2015-01-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;30010022;RESULT;Adaptive optics ophthalmoscopy: Application to age-related macular degeneration and vascular diseases.;"Paques M; Meimon S; Rossant F; Rosenbaum D; Mrejen S; Sennlaub F; Grieve K";10.1016/j.preteyeres.2018.07.001;['Journal Article', 'Review'];True;2018-09-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;31573376;RESULT;High-Resolution Imaging of Retinal Vasculitis by Flood Illumination Adaptive Optics Ophthalmoscopy: A Follow-up Study.;"Errera MH; Laguarrigue M; Rossant F; Koch E; Chaumette C; Fardeau C; Westcott M; Sahel JA; Bodaghi B; Benesty J; Paques M";10.1080/09273948.2019.1646773;['Journal Article'];False;2019-10-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;27065002;RESULT;Effects of age, blood pressure and antihypertensive treatments on retinal arterioles remodeling assessed by adaptive optics.;"Rosenbaum D; Mattina A; Koch E; Rossant F; Gallo A; Kachenoura N; Paques M; Redheuil A; Girerd X";10.1097/HJH.0000000000000894;['Journal Article'];False;2016-06-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;31922497;RESULT;ATTENUATION OUTER RETINAL BANDS ON OPTICAL COHERENCE TOMOGRAPHY FOLLOWING MACULAR EDEMA: A Possible Manifestation of Photoreceptor Misalignment.;"Paques M; Rossant F; Finocchio L; Grieve K; Sahel JA; Pedinielli A; Mrejen S";10.1097/IAE.0000000000002738;['Journal Article'];True;2020-01-07
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;26523388;RESULT;The Negative Cone Mosaic: A New Manifestation of the Optical Stiles-Crawford Effect in Normal Eyes.;"Miloudi C; Rossant F; Bloch I; Chaumette C; Leseigneur A; Sahel JA; Meimon S; Mrejen S; Paques M";10.1167/iovs.15-17022;['Clinical Trial', 'Journal Article'];True;2015-11-02
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;25997175;RESULT;Venous Nicking Without Arteriovenous Contact: The Role of the Arteriolar Microenvironment in Arteriovenous Nickings.;"Paques M; Brolly A; Benesty J; Lermé N; Koch E; Rossant F; Bloch I; Girmens JF";10.1001/jamaophthalmol.2015.1132;['Journal Article'];True;2015-08-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;27009576;RESULT;Relationships between retinal arteriole anatomy and aortic geometry and function and peripheral resistance in hypertensives.;"Rosenbaum D; Kachenoura N; Koch E; Paques M; Cluzel P; Redheuil A; Girerd X";10.1038/hr.2016.26;['Journal Article'];True;2016-03-24
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;26418443;DERIVED;CONE DENSITY LOSS ON ADAPTIVE OPTICS IN EARLY MACULAR TELANGIECTASIA TYPE 2.;"Jacob J; Krivosic V; Paques M; Tadayoni R; Gaudric A";10.1097/IAE.0000000000000737;['Journal Article'];False;2016-03-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;30947025;RESULT;Vision loss after chemotherapy: an irinotecan-induced retinopathy.;"Boilève A; Jozwiak M; Malka D; Boige V; Le Roy F; Paques M; Ducreux M";10.1016/j.ejca.2019.02.015;['Letter'];False;2019-05-01
NCT01546181;Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-03-07;2010-10;2017-06-15;26344727;RESULT;Functional and high-resolution retinal imaging monitoring photoreceptor damage in acute macular neuroretinopathy.;"Audo I; Gocho K; Rossant F; Mohand-Saïd S; Loquin K; Bloch I; Sahel JA; Paques M";10.1007/s00417-015-3136-6;['Journal Article'];False;2015-09-07
NCT03870438;Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention;ANRS, Emerging Infectious Diseases;University Teaching Hospital, Lusaka, Zambia | Centre Muraz | Institut National de la Santé Et de la Recherche Médicale, France | University of Bergen;COMPLETED;INTERVENTIONAL;False;2019-03-12;2019-12-14;2022-10-31;33872801;BACKGROUND;Design and challenges of a large HIV prevention clinical study on mother-to-child transmission: ANRS 12397 PROMISE-EPI study in Zambia and Burkina Faso.;"Mennecier A; Kankasa C; Fao P; Moles JP; Eymard-Duvernay S; Mwiya M; Kania D; Chunda-Liyoka C; Sakana L; Rutagwera D; Tassembedo S; Wilfred-Tonga MM; Mosqueira B; Tylleskär T; Nagot N; Van de Perre P; ANRS 12397 Study group";10.1016/j.cct.2021.106402;['Journal Article'];True;2021-06-01
NCT03870438;Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention;ANRS, Emerging Infectious Diseases;University Teaching Hospital, Lusaka, Zambia | Centre Muraz | Institut National de la Santé Et de la Recherche Médicale, France | University of Bergen;COMPLETED;INTERVENTIONAL;False;2019-03-12;2019-12-14;2022-10-31;38484756;PUBMED;Optimised prevention of postnatal HIV transmission in Zambia and Burkina Faso (PROMISE-EPI): a phase 3, open-label, randomised controlled trial.;"Kankasa C; Mennecier A; Sakana BLD; Molès JP; Mwiya M; Chunda-Liyoka C; D'Ottavi M; Tassembedo S; Wilfred-Tonga MM; Fao P; Rutagwera D; Matoka B; Kania D; Taofiki OA; Tylleskär T; Van de Perre P; Nagot N; PROMISE-EPI Trial Group";10.1016/S0140-6736(23)02464-9;['Randomized Controlled Trial', 'Journal Article'];False;2024-04-01
NCT03870438;Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention;ANRS, Emerging Infectious Diseases;University Teaching Hospital, Lusaka, Zambia | Centre Muraz | Institut National de la Santé Et de la Recherche Médicale, France | University of Bergen;COMPLETED;INTERVENTIONAL;False;2019-03-12;2019-12-14;2022-10-31;26603917;BACKGROUND;Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.;"Nagot N; Kankasa C; Tumwine JK; Meda N; Hofmeyr GJ; Vallo R; Mwiya M; Kwagala M; Traore H; Sunday A; Singata M; Siuluta C; Some E; Rutagwera D; Neboua D; Ndeezi G; Jackson D; Maréchal V; Neveu D; Engebretsen IMS; Lombard C; Blanche S; Sommerfelt H; Rekacewicz C; Tylleskär T; Van de Perre P; ANRS 12174 Trial Group";10.1016/S0140-6736(15)00984-8;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];False;2016-02-01
NCT01555450;Study of Patient Navigation to Reduce Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;National Cancer Institute, France;COMPLETED;INTERVENTIONAL;False;2012-03-15;2011-03;2013-11;29909873;DERIVED;Cost-Effectiveness Analysis of a Navigation Program for Colorectal Cancer Screening to Reduce Social Health Inequalities: A French Cluster Randomized Controlled Trial.;"De Mil R; Guillaume E; Guittet L; Dejardin O; Bouvier V; Pornet C; Christophe V; Notari A; Delattre-Massy H; De Seze C; Peng J; Launoy G; Berchi C";10.1016/j.jval.2017.09.020;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2018-06-01
NCT01555450;Study of Patient Navigation to Reduce Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;National Cancer Institute, France;COMPLETED;INTERVENTIONAL;False;2012-03-15;2011-03;2013-11;21256688;BACKGROUND;[Social inequalities in health from observational studies to intervention: can the patient navigator reduce social inequalities in cancer patients?].;"Dejardin O; Berchi C; Mignon A; Pornet C; Guillaume E; Guittet L; Bouvier V; Sailly M; Salinas A; Christophe V; Launoy G";10.1016/j.respe.2010.10.008;['Journal Article', 'Review'];True;2011-02-01
NCT01555450;Study of Patient Navigation to Reduce Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;National Cancer Institute, France;COMPLETED;INTERVENTIONAL;False;2012-03-15;2011-03;2013-11;28823681;DERIVED;Patient navigation to reduce social inequalities in colorectal cancer screening participation: A cluster randomized controlled trial.;"Guillaume E; Dejardin O; Bouvier V; De Mil R; Berchi C; Pornet C; Christophe V; Notari A; Delattre Massy H; De Seze C; Peng J; Guittet L; Launoy G";10.1016/j.ypmed.2017.08.012;['Journal Article', 'Randomized Controlled Trial'];False;2017-10-01
NCT01514890;French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2012-01-23;2011-02;2014-03;25556540;DERIVED;Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.;"Sultanik P; Mallet V; Lagaye S; Casrouge A; Dorival C; Barthe Y; Fontaine H; Hézode C; Mottez E; Bronowicki JP; Carrat F; Theodorou I; Abel L; Gayat E; Fontanet A; Pol S; Albert ML; ANRS CO20-CUPIC";10.1111/liv.12759;['Clinical Trial', 'Journal Article', 'Multicenter Study'];False;2015-01-23
NCT01514890;French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2012-01-23;2011-02;2014-03;24704719;DERIVED;Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.;"Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP; CUPIC Study Group";10.1053/j.gastro.2014.03.051;['Journal Article', 'Multicenter Study'];True;2014-07-01
NCT01514890;French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2012-01-23;2011-02;2014-03;23669289;DERIVED;Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.;"Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP; CUPIC Study Group";10.1016/j.jhep.2013.04.035;['Clinical Trial', 'Journal Article', 'Multicenter Study'];False;2013-09-01
NCT04133012;Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone;ANRS, Emerging Infectious Diseases;ViiV Healthcare;COMPLETED;INTERVENTIONAL;False;2019-10-21;2020-02-10;2023-06-09;;;;;;;;
NCT00658346;Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2008-04-15;2010-06;2016-09;31063537;DERIVED;Comparative Immunovirological and Clinical Responses to Antiretroviral Therapy Between HIV-1 Group O and HIV-1 Group M Infected Patients.;"Kouanfack C; Unal G; Schaeffer L; Kfutwah A; Aghokeng A; Mougnutou R; Tchemgui-Noumsi N; Alessandri-Gradt E; Delaporte E; Simon F; Vray M; Plantier JC; ANRS 12168 DynaMO Study";10.1093/cid/ciz371;['Journal Article'];True;2019-05-07
NCT02073630;Contribution of the Cerebellum In Sensory-motor Adaptation Via Gamma Oscillations: the Case of Dystonia;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-02-27;2014-02;2016-08;;;;;;;;
NCT03446430;Validation of Laser Doppler Vibrometer (LDV) for Measurement of Arterial Stiffness in Hypertensive Patients;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2018-02-26;2018-06-21;2018-12-04;;;;;;;;
NCT01693848;"""Cancersensor"" Metastasis Resection";Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-09-26;2012-09;2014-11;;;;;;;;
NCT05040048;Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease;Institut National de la Santé Et de la Recherche Médicale, France;Innovative Medicines Initiative | Institut d'Investigacions Biomèdiques August Pi i Sunyer | ICM Co. Ltd. | University Hospital, Bonn | Karolinska Institutet;COMPLETED;OBSERVATIONAL;False;2021-09-10;2015-09-04;2018-02;;;;;;;;
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;31945015;DERIVED;Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans.;"Lin A; Apostolovic D; Jahnmatz M; Liang F; Ols S; Tecleab T; Wu C; van Hage M; Solovay K; Rubin K; Locht C; Thorstensson R; Thalen M; Loré K";10.1172/JCI135020;['Journal Article', 'Randomized Controlled Trial'];True;2020-03-23
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;18762220;BACKGROUND;Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.;"Feunou PF; Ismaili J; Debrie AS; Huot L; Hot D; Raze D; Lemoine Y; Locht C";10.1016/j.vaccine.2008.08.018;['Journal Article'];False;2008-10-01
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;21147936;BACKGROUND;A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model.;"Skerry CM; Mahon BP";10.1128/CVI.00371-10;['Journal Article'];True;2011-02-01
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;20107007;BACKGROUND;Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice.;"Mielcarek N; Debrie AS; Mahieux S; Locht C";10.1128/CVI.00322-09;['Journal Article'];True;2010-03-01
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;24793938;BACKGROUND;B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial.;"Jahnmatz M; Amu S; Ljungman M; Wehlin L; Chiodi F; Mielcarek N; Locht C; Thorstensson R";10.1016/j.vaccine.2014.04.048;['Journal Article', 'Randomized Controlled Trial'];True;2014-06-01
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;20419113;BACKGROUND;T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis.;"Feunou PF; Bertout J; Locht C";10.1371/journal.pone.0010178;['Journal Article'];True;2010-04-15
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;20708998;BACKGROUND;Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.;"Feunou PF; Kammoun H; Debrie AS; Mielcarek N; Locht C";10.1016/j.vaccine.2010.08.017;['Journal Article'];False;2010-10-01
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;24950361;BACKGROUND;Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice.;"Feunou PF; Kammoun H; Debrie AS; Locht C";10.1016/j.vaccine.2014.06.019;['Journal Article'];False;2014-07-01
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;21430219;BACKGROUND;Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response.;"Fedele G; Bianco M; Debrie AS; Locht C; Ausiello CM";10.4049/jimmunol.1003765;['Journal Article'];True;2011-05-01
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;22814407;BACKGROUND;Dual mechanism of protection by live attenuated Bordetella pertussis BPZE1 against Bordetella bronchiseptica in mice.;"Kammoun H; Feunou PF; Foligne B; Debrie AS; Raze D; Mielcarek N; Locht C";10.1016/j.vaccine.2012.07.005;['Journal Article'];False;2012-08-01
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;24421886;BACKGROUND;"A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers.";"Thorstensson R; Trollfors B; Al-Tawil N; Jahnmatz M; Bergström J; Ljungman M; Törner A; Wehlin L; Van Broekhoven A; Bosman F; Debrie AS; Mielcarek N; Locht C";10.1371/journal.pone.0083449;['Journal Article', 'Randomized Controlled Trial'];True;2014-01-08
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;19625486;BACKGROUND;A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice.;"Skerry CM; Cassidy JP; English K; Feunou-Feunou P; Locht C; Mahon BP";10.1128/CVI.00082-09;['Journal Article'];True;2009-09-01
NCT02453048;Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;True;2015-05-25;2015-09;2017-12;32687804;DERIVED;Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study.;"Jahnmatz M; Richert L; Al-Tawil N; Storsaeter J; Colin C; Bauduin C; Thalen M; Solovay K; Rubin K; Mielcarek N; Thorstensson R; Locht C; BPZE1 study team";10.1016/S1473-3099(20)30274-7;['Journal Article', 'Randomized Controlled Trial'];True;2020-11-01
NCT01207986;Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2010-09-23;2011-02;2014-08;;;;;;;;
NCT01620957;Longitudinal Study of the Default-mode Network Connectivity in Brain Injured Patients Recovering From Coma;Institut National de la Santé Et de la Recherche Médicale, France;University Hospital, Toulouse | Association des Traumatisés du Crane et de la Face, Paris, France;COMPLETED;OBSERVATIONAL;False;2012-06-15;2012-07-10;2017-07;;;;;;;;
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;31994250;DERIVED;Association of maternal HIV-1 severity with dental caries: an observational study of uninfected 5- to 7-yr-old children of HIV-1-infected mothers without severe immune suppression.;"Birungi N; Fadnes LT; Engebretsen IMS; Lie SA; Tumwine JK; Åstrøm AN; ANRS 12174 and 12341 study groups";10.1111/eos.12669;['Journal Article'];True;2020-01-29
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;26603917;DERIVED;Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.;"Nagot N; Kankasa C; Tumwine JK; Meda N; Hofmeyr GJ; Vallo R; Mwiya M; Kwagala M; Traore H; Sunday A; Singata M; Siuluta C; Some E; Rutagwera D; Neboua D; Ndeezi G; Jackson D; Maréchal V; Neveu D; Engebretsen IMS; Lombard C; Blanche S; Sommerfelt H; Rekacewicz C; Tylleskär T; Van de Perre P; ANRS 12174 Trial Group";10.1016/S0140-6736(15)00984-8;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];False;2016-02-01
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;32067040;DERIVED;Clinical and Biological Factors Associated With Early Epstein-Barr Virus Infection in Human Immunodeficiency Virus-Exposed Uninfected Infants in Eastern Uganda.;"Montoya-Ferrer A; Sanosyan A; Fayd'herbe de Maudave A; Pisoni A; Bollore K; Molès JP; Peries M; Tylleskar T; Tumwine JK; Ndeezi G; Gorgolas M; Nagot N; van de Perre P; Tuaillon E";10.1093/cid/ciaa161;['Journal Article'];True;2020-02-18
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;34425825;PUBMED;The prevalence and socio-behavioural and clinical covariates of oral health related quality of life in Ugandan mothers with and without HIV-1.;"Birungi N; Fadnes LT; Engebretsen IMS; Tumwine JK; Åstrøm AN; ANRS 12174 and 12341 study groups";10.1186/s12955-021-01844-3;['Journal Article'];True;2021-08-23
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;32228542;DERIVED;Caries experience and oral health related quality of life in a cohort of Ugandan HIV-1 exposed uninfected children compared with a matched cohort of HIV unexposed uninfected children.;"Birungi N; Fadnes LT; Engebretsen IMS; Lie SA; Tumwine JK; Åstrøm AN; ANRS 12174 and 12341 study groups";10.1186/s12889-020-08564-1;['Journal Article'];True;2020-03-30
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;30814028;DERIVED;Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial.;"Blanche S; Tylleskär T; Peries M; Kankasa C; Engebretsen I; Meda N; Tumwine JK; Singata-Madliki M; Mwiya M; Van de Perre P; Nagot N; ANRS 12174 Trial Group";10.1016/S2352-3018(18)30361-8;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2019-05-01
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;32991450;DERIVED;Antiretroviral treatment and its impact on oral health outcomes in 5 to 7 year old Ugandan children: A 6 year follow-up visit from the ANRS 12174 randomized trial.;"Birungi N; Fadnes LT; Engebretsen IMS; Tumwine JK; Åstrøm AN; for ANRS 12174 AND 12341 study groups";10.1097/MD.0000000000022352;['Clinical Trial', 'Journal Article', 'Randomized Controlled Trial'];True;2020-09-25
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;28469697;DERIVED;Breastfeeding patterns and its determinants among mothers living with Human Immuno-deficiency Virus -1 in four African countries participating in the ANRS 12174 trial.;"Somé EN; Engebretsen IMS; Nagot N; Meda N; Lombard C; Vallo R; Peries M; Kankasa C; Tumwine JK; Hofmeyr GJ; Singata M; Harper K; Van De Perre P; Tylleskar T; ANRS 12174 Trial Group";10.1186/s13006-017-0112-2;['Journal Article'];True;2016-12-01
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;23039034;DERIVED;Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174.;"Nagot N; Kankasa C; Meda N; Hofmeyr J; Nikodem C; Tumwine JK; Karamagi C; Sommerfelt H; Neveu D; Tylleskär T; Van de Perre P; PROMISE-PEP group";10.1186/1471-2334-12-246;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2012-10-06
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;27895016;DERIVED;Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding.;"Foissac F; Blume J; Tréluyer JM; Tylleskär T; Kankasa C; Meda N; Tumwine JK; Singata-Madliki M; Harper K; Illamola SM; Bouazza N; Nagot N; Van de Perre P; Blanche S; Hirt D";10.1128/AAC.01869-16;['Journal Article'];True;2017-02-01
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;17825642;BACKGROUND;Prevention of human immunodeficiency virus-1 transmission to the infant through breastfeeding: new developments.;"Kourtis AP; Jamieson DJ; de Vincenzi I; Taylor A; Thigpen MC; Dao H; Farley T; Fowler MG";10.1016/j.ajog.2007.03.003;['Journal Article', 'Review'];True;2007-09-01
NCT00640263;Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding;French National Agency for Research on AIDS and Viral Hepatitis;European and Developing Countries Clinical Trials Partnership (EDCTP) | The Research Council of Norway | Swedish International Development Cooperation Agency (SIDA) | Université Montpellier | University of Bergen;COMPLETED;INTERVENTIONAL;False;2008-03-21;2009-12;2014-02;31633158;DERIVED;Lopinavir-Ritonavir Impairs Adrenal Function in Infants.;"Kariyawasam D; Peries M; Foissac F; Eymard-Duvernay S; Tylleskär T; Singata-Madliki M; Kankasa C; Meda N; Tumwine J; Mwiya M; Engebretsen I; Flück CE; Hartmann MF; Wudy SA; Hirt D; Treluyer JM; Molès JP; Blanche S; Van De Perre P; Polak M; Nagot N; ANRS 12174 Trial Group";10.1093/cid/ciz888;['Journal Article'];True;2019-10-21
NCT02987530;National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;INTERVENTIONAL;False;2016-12-09;2017-04-11;2020-01-31;;;;;;;;
NCT04808986;Seroprevalence of IgG Antibodies to SARS-CoV-2 (COVID-19) in Primary Health Care Workers and Their Household Contacts;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2021-03-22;2021-05-10;2021-10-12;;;;;;;;
NCT02626286;Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa;ANRS, Emerging Infectious Diseases;Expertise France | Université Montpellier | IRD Unité SESSTIM (IRD, Inserm, Université Aix-Marseille) | Coalition Internationale Sida | ARCAD-SIDA MALI | Espace Confiance, Côte d'Ivoire | Programme PAC-CI, Abidjan, Côte d'Ivoire | Association African Solidarité | Centre de Recherche Internationale pour la Santé, Ouagadougou, Burkina Faso | Espoir Vie-Togo - ONG;COMPLETED;INTERVENTIONAL;False;2015-12-10;2015-06;2021-01-05;33753460;DERIVED;Decrease in incidence of sexually transmitted infections symptoms in men who have sex with men enrolled in a quarterly HIV prevention and care programme in West Africa (CohMSM ANRS 12324-Expertise France).;"Yaya I; Diallo F; Kouamé MJ; Agboyibor MK; Traoré I; Coulibaly A; Maiga K; Mora M; Palvadeau P; Dah ETT; Mensah E; Anoma C; Dembélé Keita B; Spire B; Laurent C; CohMSM Study Group";10.1136/sextrans-2020-054755;['Journal Article'];True;2021-03-22
NCT02626286;Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa;ANRS, Emerging Infectious Diseases;Expertise France | Université Montpellier | IRD Unité SESSTIM (IRD, Inserm, Université Aix-Marseille) | Coalition Internationale Sida | ARCAD-SIDA MALI | Espace Confiance, Côte d'Ivoire | Programme PAC-CI, Abidjan, Côte d'Ivoire | Association African Solidarité | Centre de Recherche Internationale pour la Santé, Ouagadougou, Burkina Faso | Espoir Vie-Togo - ONG;COMPLETED;INTERVENTIONAL;False;2015-12-10;2015-06;2021-01-05;34022820;DERIVED;Adherence to quarterly HIV prevention services and its impact on HIV incidence in men who have sex with men in West Africa (CohMSM ANRS 12324 - Expertise France).;"Dah TTE; Yaya I; Sagaon-Teyssier L; Coulibaly A; Kouamé MJ; Agboyibor MK; Maiga K; Traoré I; Mora M; Palvadeau P; Rojas-Castro D; Diallo F; Mensah E; Anoma C; Keita BD; Spire B; Laurent C; CohMSM Study Group";10.1186/s12889-021-10994-4;['Journal Article'];True;2021-05-22
NCT02626286;Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa;ANRS, Emerging Infectious Diseases;Expertise France | Université Montpellier | IRD Unité SESSTIM (IRD, Inserm, Université Aix-Marseille) | Coalition Internationale Sida | ARCAD-SIDA MALI | Espace Confiance, Côte d'Ivoire | Programme PAC-CI, Abidjan, Côte d'Ivoire | Association African Solidarité | Centre de Recherche Internationale pour la Santé, Ouagadougou, Burkina Faso | Espoir Vie-Togo - ONG;COMPLETED;INTERVENTIONAL;False;2015-12-10;2015-06;2021-01-05;34352834;DERIVED;Rapid antiretroviral therapy initiation and its effect on treatment response in MSM in West Africa.;"Dah TTE; Yaya I; Mensah E; Coulibaly A; Kouamé JM; Traoré I; Mora M; Palvadeau P; Anoma C; Keita BD; Spire B; Laurent C; CohMSM Study Group";10.1097/QAD.0000000000003046;['Journal Article'];True;2021-08-04
NCT00670839;Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST);ANRS, Emerging Infectious Diseases;MCM Vaccines B.V.;COMPLETED;INTERVENTIONAL;False;2008-05-02;2008-05;2013-02;26257021;DERIVED;Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial.;"Rey D; Piroth L; Wendling MJ; Miailhes P; Michel ML; Dufour C; Haour G; Sogni P; Rohel A; Ajana F; Billaud E; Molina JM; Launay O; Carrat F; ANRS HB04 B-BOOST study group";10.1016/S1473-3099(15)00220-0;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];False;2015-11-01
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;26075647;BACKGROUND;Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs?;"Perlman DC; Des Jarlais DC; Feelemyer J";10.1080/10550887.2015.1059111;['Journal Article'];True;2015-06-15
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;26080690;BACKGROUND;HIV, Hepatitis C, and Abstinence from Alcohol Among Injection and Non-injection Drug Users.;"Elliott JC; Hasin DS; Stohl M; Des Jarlais DC";10.1007/s10461-015-1113-z;['Journal Article'];True;2015-06-17
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;27178119;RESULT;Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.;"Des Jarlais D; Duong HT; Pham Minh K; Khuat OH; Nham TT; Arasteh K; Feelemyer J; Heckathorn DD; Peries M; Moles JP; Laureillard D; Nagot N; (The Drive Study Team)";10.1080/09540121.2016.1178698;['Journal Article'];True;2016-05-13
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;28612212;RESULT;Risk Behaviors for HIV and HCV Infection Among People Who Inject Drugs in Hai Phong, Viet Nam, 2014.;"Duong HT; Jarlais DD; Khuat OHT; Arasteh K; Feelemyer J; Khue PM; Giang HT; Laureillard D; Hai VV; Vallo R; Michel L; Moles JP; Nagot N; Drive Study Group";10.1007/s10461-017-1814-6;['Journal Article'];True;2017-06-13
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;26050614;BACKGROUND;An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential.;"Perlman DC; Jordan AE; Uuskula A; Huong DT; Masson CL; Schackman BR; Des Jarlais DC";10.1016/j.drugpo.2015.04.015;['Journal Article'];True;2015-11-01
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;26032121;BACKGROUND;Design and baseline findings of a large-scale rapid response to an HIV outbreak in people who inject drugs in Athens, Greece: the ARISTOTLE programme.;"Hatzakis A; Sypsa V; Paraskevis D; Nikolopoulos G; Tsiara C; Micha K; Panopoulos A; Malliori M; Psichogiou M; Pharris A; Wiessing L; van de Laar M; Donoghoe M; Heckathorn DD; Friedman SR; Des Jarlais DC";10.1111/add.12999;['Journal Article'];True;2015-07-14
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;27006257;RESULT;Prospects for ending the HIV epidemic among persons who inject drugs in Haiphong, Vietnam.;"Des Jarlais DC; Thi Huong D; Thi Hai Oanh K; Khuê Pham M; Thi Giang H; Thi Tuyet Thanh N; Arasteh K; Feelemyer J; Hammett T; Peries M; Michel L; Vu Hai V; Roustide MJ; Moles JP; Laureillard D; Nagot N; DRIVE Study Team";10.1016/j.drugpo.2016.02.021;['Journal Article'];True;2016-06-01
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;25540950;BACKGROUND;AIDS, people who use drugs, and altruism: reflection on a personal image.;Des Jarlais DC;10.3109/10826084.2015.978185;['Journal Article'];False;2014-12-26
NCT02573948;Feasibility of Interventions on People Who Inject Drugs in Vietnam;ANRS, Emerging Infectious Diseases;National Institute on Drug Abuse (NIDA);COMPLETED;OBSERVATIONAL;True;2015-10-12;2014-09;2016-06;28800503;RESULT;Intravenous heroin use in Haiphong, Vietnam: Need for comprehensive care including methamphetamine use-related interventions.;"Michel L; Des Jarlais DC; Duong Thi H; Khuat Thi Hai O; Pham Minh K; Peries M; Vallo R; Nham Thi Tuyet T; Hoang Thi G; Le Sao M; Feelemyer J; Vu Hai V; Moles JP; Laureillard D; Nagot N; DRIVE Study Team";10.1016/j.drugalcdep.2017.07.004;['Journal Article'];True;2017-10-01
NCT02014727;Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults;Institut National de la Santé Et de la Recherche Médicale, France;EVI Industries, Inc. | BPRC | Recherche Clinique Paris Descartes Necker Cochin Sainte Anne | Centre national de recherche et de formation sur le paludisme;COMPLETED;INTERVENTIONAL;False;2013-12-18;2014-01;2015-07;28947345;DERIVED;Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.;"Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O; AMA1-DiCo Study Group";10.1016/j.vaccine.2017.09.027;['Journal Article', 'Randomized Controlled Trial'];False;2017-10-01
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;22310560;BACKGROUND;Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact.;"Curran GM; Bauer M; Mittman B; Pyne JM; Stetler C";10.1097/MLR.0b013e3182408812;['Journal Article'];True;2012-03-01
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;27178119;BACKGROUND;Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.;"Des Jarlais D; Duong HT; Pham Minh K; Khuat OH; Nham TT; Arasteh K; Feelemyer J; Heckathorn DD; Peries M; Moles JP; Laureillard D; Nagot N; (The Drive Study Team)";10.1080/09540121.2016.1178698;['Journal Article'];True;2016-05-13
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;27537841;BACKGROUND;Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.;"Dore GJ; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Grebely J; Howe AY; Gendrano IN; Chen E; Huang HC; Dutko FJ; Nickle DC; Nguyen BY; Wahl J; Barr E; Robertson MN; Platt HL; C-EDGE CO-STAR Study Group";10.7326/M16-0816;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];False;2016-08-09
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;29432973;BACKGROUND;Using dual capture/recapture studies to estimate the population size of persons who inject drugs (PWID) in the city of Hai Phong, Vietnam.;"Des Jarlais D; Khue PM; Feelemyer J; Arasteh K; Thi Huong D; Thi Hai Oanh K; Thi Giang H; Thi Tuyet Thanh N; Vinh VH; Heckathorn DD; Moles JP; Vallo R; Quillet C; Rapoud D; Michel L; Laureillard D; Hammett T; Nagot N";10.1016/j.drugalcdep.2017.11.033;['Journal Article'];True;2018-04-01
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;26806260;BACKGROUND;Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care.;"Chevaliez S; Poiteau L; Rosa I; Soulier A; Roudot-Thoraval F; Laperche S; Hézode C; Pawlotsky JM";10.1016/j.cmi.2016.01.009;['Journal Article'];True;2016-05-01
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;27168667;BACKGROUND;Improving Screening Methods for Hepatitis C Among People Who Inject Drugs: Findings from the HepTLC Initiative, 2012-2014.;"Blackburn NA; Patel RC; Zibbell JE";10.1177/00333549161310S214;['Journal Article'];True;2016-05-01
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;35774932;DERIVED;Reaching Hard-to-Reach People Who Use Drugs: A Community-Based Strategy for the Elimination of Hepatitis C.;"Nagot N; D'Ottavi M; Quillet C; Debellefontaine A; Castellani J; Langendorfer N; Hanslik B; Guichard S; Baglioni R; Faucherre V; Tuaillon E; Pageaux GP; Laureillard D; Donnadieu-Rigole H";10.1093/ofid/ofac181;['Journal Article'];True;2022-04-14
NCT04008927;A Community-based Intervention Among Active Drug Users in Montpellier;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2019-07-05;2020-09-18;2021-09-10;28004616;BACKGROUND;Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys.;"Leon L; Kasereka S; Barin F; Larsen C; Weill-Barillet L; Pascal X; Chevaliez S; Pillonel J; Jauffret-Roustide M; LE Strat Y";10.1017/S0950268816002934;['Journal Article'];True;2016-12-22
NCT03546127;Molecular Profiling to Improve Outcome of Patients in Cancer. A Pilot Study;Institut National de la Santé Et de la Recherche Médicale, France;Institut Bergonié | Plateforme labellisée Inca - Institut Bergonié, Bordeaux | Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris | CNRGH, Evry | EUCLID Clinical Trial Platform;COMPLETED;OBSERVATIONAL;False;2018-06-06;2017-05-23;2017-09-21;;;;;;;;
NCT02650427;A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-01-08;2016-02;2018-09;;;;;;;;
NCT02497274;Obesity and Lipids: a Matter of Taste?;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-07-14;2016-01-11;2019-01;;;;;;;;
NCT05311865;Transmission of Covid-19 During Clubbing Events in Closed Places;ANRS, Emerging Infectious Diseases;Cerballiance | Kappa Santé;COMPLETED;INTERVENTIONAL;False;2022-04-05;2021-09-04;2022-02-26;37795682;PUBMED;A randomised controlled trial to study the transmission of SARS-CoV-2 and other respiratory viruses during indoor clubbing events (ANRS0066s ITOC study).;"Luong Nguyen LB; Goupil de Bouillé J; Menant L; Noret M; Dumas A; Salmona M; Le Goff J; Delaugerre C; Crépey P; Zeggagh J; ITOC Study Group";10.1093/cid/ciad603;['Journal Article'];True;2023-10-05
NCT05311865;Transmission of Covid-19 During Clubbing Events in Closed Places;ANRS, Emerging Infectious Diseases;Cerballiance | Kappa Santé;COMPLETED;INTERVENTIONAL;False;2022-04-05;2021-09-04;2022-02-26;36438274;PUBMED;Transmission of SARS-CoV-2 during indoor clubbing events: A clustered randomized, controlled, multicentre trial protocol.;"Goupil de Bouillé J; Luong Nguyen LB; Crépey P; Garlantezec R; Doré V; Dumas A; Ben Mechlia M; Tattevin P; Gaudart J; Spire B; Lert F; Yazdanpanah Y; Delaugerre C; Noret M; Zeggagh J";10.3389/fpubh.2022.981213;['Journal Article'];True;2022-11-04
NCT02592174;Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2015-10-30;2016-01-26;2017-10-27;31755936;DERIVED;Increased Prevalence of Neurocognitive Impairment in Aging People Living With Human Immunodeficiency Virus: The ANRS EP58 HAND 55-70 Study.;"Makinson A; Dubois J; Eymard-Duvernay S; Leclercq P; Zaegel-Faucher O; Bernard L; Vassallo M; Barbuat C; Gény C; Thouvenot E; Costagliola D; Ozguler A; Zins M; Simony M; Reynes J; Berr C";10.1093/cid/ciz670;['Journal Article'];True;2019-07-25
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement;COMPLETED;OBSERVATIONAL;False;2014-04-01;2009-01;2013-12;24808487;DERIVED;Interindividual variability of lutein bioavailability in healthy men: characterization, genetic variants involved, and relation with fasting plasma lutein concentration.;"Borel P; Desmarchelier C; Nowicki M; Bott R; Morange S; Lesavre N";10.3945/ajcn.114.085720;['Journal Article', 'Randomized Controlled Trial'];True;2014-07-01
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement;COMPLETED;OBSERVATIONAL;False;2014-04-01;2009-01;2013-12;26063065;DERIVED;A Combination of Single-Nucleotide Polymorphisms Is Associated with Interindividual Variability in Dietary β-Carotene Bioavailability in Healthy Men.;"Borel P; Desmarchelier C; Nowicki M; Bott R";10.3945/jn.115.212837;['Journal Article'];True;2015-08-01
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement;COMPLETED;OBSERVATIONAL;False;2014-04-01;2009-01;2013-12;21957063;BACKGROUND;Genetic variations involved in interindividual variability in carotenoid status.;Borel P;10.1002/mnfr.201100322;['Journal Article', 'Review'];True;2012-02-01
NCT02100774;Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability;Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement;COMPLETED;OBSERVATIONAL;False;2014-04-01;2009-01;2013-12;27798339;DERIVED;A Combination of Single-Nucleotide Polymorphisms Is Associated with Interindividual Variability in Cholecalciferol Bioavailability in Healthy Men.;"Desmarchelier C; Borel P; Goncalves A; Kopec R; Nowicki M; Morange S; Lesavre N; Portugal H; Reboul E";10.3945/jn.116.237115;['Journal Article'];True;2016-10-26
NCT02273765;Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC | Ministry of Health, Brazil;COMPLETED;INTERVENTIONAL;False;2014-10-24;2015-09-11;2018-11-28;33667406;DERIVED;Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.;"De Castro N; Marcy O; Chazallon C; Messou E; Eholié S; N'takpe JB; Bhatt N; Khosa C; Timana Massango I; Laureillard D; Chau GD; Domergue A; Veloso V; Escada R; Wagner Cardoso S; Delaugerre C; Anglaret X; Molina JM; Grinsztejn B; ANRS 12300 Reflate TB2 study group";10.1016/S1473-3099(20)30869-0;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2021-06-01
NCT01022476;Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients;ANRS, Emerging Infectious Diseases;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2009-12-01;2010-05;2013-05;;;;;;;;
NCT02078076;IRM Cardiaque en Respiration Libre Pour Des Patients Atteints de Dystrophinopathie sévère;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-03-05;2013-06;2015-11;;;;;;;;
NCT02099474;Evaluation of Raltegravir During the Third Trimester of Pregnancy;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-03-31;2014-06-30;2017-04;32661003;DERIVED;Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial.;"Zheng Y; Hirt D; Delmas S; Lui G; Benaboud S; Lechedanec J; Tréluyer JM; Chenevier-Gobeaux C; Arezes E; Gelley A; Amri I; Urien S; Bouazza N; Foissac F; Warszawski J; Ghosn J";10.1128/AAC.00759-20;['Journal Article', 'Multicenter Study'];True;2020-09-21
NCT03078439;EPIPAGE2 Cohort Study Follow up at Five and a Half Years;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2017-03-13;2016-09-02;2018-01-08;38408861;PUBMED;Birth weight and head circumference discordance and outcome in preterms: results from the EPIPAGE-2 cohort.;"Guellec I; Brunet A; Lapillonne A; Taine M; Torchin H; Favrais G; Gascoin G; Simon L; Heude B; Scherdel P; Kayem G; Delorme P; Jarreau PH; Ancel PY";10.1136/archdischild-2023-326336;['Journal Article'];False;2024-02-26
NCT02081066;Identification of CETP as a Marker of Atherosclerosis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-03-07;2014-09-25;2020-09;;;;;;;;
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32338732;RESULT;Prevalence of SARS-CoV-2 Infection in Residents of a Large Homeless Shelter in Boston.;"Baggett TP; Keyes H; Sporn N; Gaeta JM";10.1001/jama.2020.6887;['Journal Article'];True;2020-06-02
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32109013;RESULT;Clinical Characteristics of Coronavirus Disease 2019 in China.;"Guan WJ; Ni ZY; Hu Y; Liang WH; Ou CQ; He JX; Liu L; Shan H; Lei CL; Hui DSC; Du B; Li LJ; Zeng G; Yuen KY; Chen RC; Tang CL; Wang T; Chen PY; Xiang J; Li SY; Wang JL; Liang ZJ; Peng YX; Wei L; Liu Y; Hu YH; Peng P; Wang JM; Liu JY; Chen Z; Li G; Zheng ZJ; Qiu SQ; Luo J; Ye CJ; Zhu SY; Zhong NS; China Medical Treatment Expert Group for Covid-19";10.1056/NEJMoa2002032;['Journal Article'];True;2020-04-30
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;31978945;RESULT;A Novel Coronavirus from Patients with Pneumonia in China, 2019.;"Zhu N; Zhang D; Wang W; Li X; Yang B; Song J; Zhao X; Huang B; Shi W; Lu R; Niu P; Zhan F; Ma X; Wang D; Xu W; Wu G; Gao GF; Tan W; China Novel Coronavirus Investigating and Research Team";10.1056/NEJMoa2001017;['Journal Article'];True;2020-02-20
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32224310;RESULT;Clinical and virological data of the first cases of COVID-19 in Europe: a case series.;"Lescure FX; Bouadma L; Nguyen D; Parisey M; Wicky PH; Behillil S; Gaymard A; Bouscambert-Duchamp M; Donati F; Le Hingrat Q; Enouf V; Houhou-Fidouh N; Valette M; Mailles A; Lucet JC; Mentre F; Duval X; Descamps D; Malvy D; Timsit JF; Lina B; van-der-Werf S; Yazdanpanah Y";10.1016/S1473-3099(20)30200-0;['Journal Article'];True;2020-06-01
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32070465;RESULT;First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020.;"Bernard Stoecklin S; Rolland P; Silue Y; Mailles A; Campese C; Simondon A; Mechain M; Meurice L; Nguyen M; Bassi C; Yamani E; Behillil S; Ismael S; Nguyen D; Malvy D; Lescure FX; Georges S; Lazarus C; Tabaï A; Stempfelet M; Enouf V; Coignard B; Levy-Bruhl D; Investigation team";10.2807/1560-7917.ES.2020.25.6.2000094;['Journal Article'];True;2020-02-13
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32046819;RESULT;Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020.;"Backer JA; Klinkenberg D; Wallinga J";10.2807/1560-7917.ES.2020.25.5.2000062;['Journal Article'];True;2020-02-06
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;32371096;RESULT;SARS-CoV-2 was already spreading in France in late December 2019.;"Deslandes A; Berti V; Tandjaoui-Lambotte Y; Alloui C; Carbonnelle E; Zahar JR; Brichler S; Cohen Y";10.1016/j.ijantimicag.2020.106006;['Journal Article'];True;2020-06-01
NCT04470648;COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey;Institut National de la Santé Et de la Recherche Médicale, France;Samusocial de Paris | Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2020-07-14;2020-07-22;2021-08-22;31995857;RESULT;Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.;"Li Q; Guan X; Wu P; Wang X; Zhou L; Tong Y; Ren R; Leung KSM; Lau EHY; Wong JY; Xing X; Xiang N; Wu Y; Li C; Chen Q; Li D; Liu T; Zhao J; Liu M; Tu W; Chen C; Jin L; Yang R; Wang Q; Zhou S; Wang R; Liu H; Luo Y; Liu Y; Shao G; Li H; Tao Z; Yang Y; Deng Z; Liu B; Ma Z; Zhang Y; Shi G; Lam TTY; Wu JT; Gao GF; Cowling BJ; Yang B; Leung GM; Feng Z";10.1056/NEJMoa2001316;['Journal Article'];True;2020-03-26
NCT02566148;Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France;ANRS, Emerging Infectious Diseases;Ministry of Health, France | Institut de Recherche pour le Developpement | Institut National de la Santé Et de la Recherche Médicale, France | Institut national de prevention et d'education pour la sante;COMPLETED;OBSERVATIONAL;False;2015-10-02;2012-02;2013-05;29982518;DERIVED;Refusal to provide healthcare to sub-Saharan migrants in France: a comparison according to their HIV and HBV status.;"Vignier N; Dray Spira R; Pannetier J; Ravalihasy A; Gosselin A; Lert F; Lydie N; Bouchaud O; Desgrees Du Lou A; Chauvin P; PARCOURS Study Group";10.1093/eurpub/cky118;['Journal Article'];True;2018-07-02
NCT02566148;Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France;ANRS, Emerging Infectious Diseases;Ministry of Health, France | Institut de Recherche pour le Developpement | Institut National de la Santé Et de la Recherche Médicale, France | Institut national de prevention et d'education pour la sante;COMPLETED;OBSERVATIONAL;False;2015-10-02;2012-02;2013-05;29437866;DERIVED;How to use sequence analysis for life course epidemiology? An example on HIV-positive Sub-Saharan migrants in France.;"Gosselin A; Desgrées du Loû A; Lelièvre E; PARCOURS Study Group";10.1136/jech-2017-209739;['Journal Article'];False;2018-02-02
NCT02566148;Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France;ANRS, Emerging Infectious Diseases;Ministry of Health, France | Institut de Recherche pour le Developpement | Institut National de la Santé Et de la Recherche Médicale, France | Institut national de prevention et d'education pour la sante;COMPLETED;OBSERVATIONAL;False;2015-10-02;2012-02;2013-05;29307383;DERIVED;Prevalence and circumstances of forced sex and post-migration HIV acquisition in sub-Saharan African migrant women in France: an analysis of the ANRS-PARCOURS retrospective population-based study.;"Pannetier J; Ravalihasy A; Lydié N; Lert F; Desgrées du Loû A; Parcours study group";10.1016/S2468-2667(17)30211-6;['Journal Article'];True;2018-01-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;33264556;RESULT;Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.;"WHO Solidarity Trial Consortium; Pan H; Peto R; Henao-Restrepo AM; Preziosi MP; Sathiyamoorthy V; Abdool Karim Q; Alejandria MM; Hernández García C; Kieny MP; Malekzadeh R; Murthy S; Reddy KS; Roses Periago M; Abi Hanna P; Ader F; Al-Bader AM; Alhasawi A; Allum E; Alotaibi A; Alvarez-Moreno CA; Appadoo S; Asiri A; Aukrust P; Barratt-Due A; Bellani S; Branca M; Cappel-Porter HBC; Cerrato N; Chow TS; Como N; Eustace J; García PJ; Godbole S; Gotuzzo E; Griskevicius L; Hamra R; Hassan M; Hassany M; Hutton D; Irmansyah I; Jancoriene L; Kirwan J; Kumar S; Lennon P; Lopardo G; Lydon P; Magrini N; Maguire T; Manevska S; Manuel O; McGinty S; Medina MT; Mesa Rubio ML; Miranda-Montoya MC; Nel J; Nunes EP; Perola M; Portolés A; Rasmin MR; Raza A; Rees H; Reges PPS; Rogers CA; Salami K; Salvadori MI; Sinani N; Sterne JAC; Stevanovikj M; Tacconelli E; Tikkinen KAO; Trelle S; Zaid H; Røttingen JA; Swaminathan S";10.1056/NEJMoa2023184;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2021-02-11
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34350582;DERIVED;Remdesivir for the treatment of COVID-19.;"Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F";10.1002/14651858.CD014962;['Journal Article'];True;2021-08-05
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34473343;DERIVED;SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.;"Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N";10.1002/14651858.CD013825.pub2;['Journal Article', 'Review'];True;2021-09-02
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35533972;RESULT;An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results.;"Ader F; DisCoVeRy Study Group";10.1016/j.cmi.2022.04.016;['Letter', 'Randomized Controlled Trial'];True;2022-09-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;37728045;RESULT;Association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients.;"Néant N; Lingas G; Gaymard A; Belhadi D; Hites M; Staub T; Greil R; Paiva JA; Poissy J; Peiffer-Smadja N; Costagliola D; Yazdanpanah Y; Bouscambert-Duchamp M; Gagneux-Brunon A; Ader F; Mentré F; Wallet F; Burdet C; Guedj J; DisCoVeRy study group";10.1002/psp4.13051;['Journal Article', 'Randomized Controlled Trial'];True;2023-10-11
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;36680782;BACKGROUND;Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortia.;"Terzić V; Levoyer L; Figarella M; Bigagli E; Mercier N; De Gastines L; Gibowski S; Trøseid M; Demotes J; Olsen IC; Hites M; Ader F; Lopez JRA; Mentré F; Espérou H; Costagliola D; Røttingen JA; Poissy J; Rozé JC; Warris A; O'Leary J; Fernandes RM; Assoumou L; Hankard R; Turner MA; Yazdanpanah Y; Diallo A; EU-Response safety group; c4c safety group";10.1111/bcp.15669;['Journal Article', 'Review'];True;2023-02-08
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;38552208;PUBMED;Cardiac Adverse Events and Remdesivir in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19): A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.;"Terzić V; Miantezila Basilua J; Billard N; de Gastines L; Belhadi D; Fougerou-Leurent C; Peiffer-Smadja N; Mercier N; Delmas C; Ferrane A; Dechanet A; Poissy J; Espérou H; Ader F; Hites M; Andrejak C; Greil R; Paiva JA; Staub T; Tacconelli E; Burdet C; Costagliola D; Mentré F; Yazdanpanah Y; Diallo A; DisCoVeRy study group";10.1093/cid/ciae170;['Journal Article'];True;2024-03-29
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;37269068;BACKGROUND;Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial.;"Mercier N; Belhadi D; DeChanet A; Delmas C; Saillard J; Dumousseaux M; Le Mestre S; Fougerou-Leurent C; Ferrane A; Burdet C; Espérou H; Ader F; Hites M; Peiffer-Smadja N; Poissy J; Andrejak C; Paiva JA; Tacconelli E; Staub T; Greil R; Costagliola D; Mentre F; Yazdanpanah Y; Diallo A; DisCoVeRy Safety Working group";10.1002/prp2.1072;['Journal Article', 'Review'];True;2023-06-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;32958495;BACKGROUND;Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.;"Ader F; Discovery French Trial Management Team";10.1136/bmjopen-2020-041437;['Journal Article'];True;2020-09-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;36828006;BACKGROUND;Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials.;"Amstutz A; Speich B; Mentré F; Rueegg CS; Belhadi D; Assoumou L; Burdet C; Murthy S; Dodd LE; Wang Y; Tikkinen KAO; Ader F; Hites M; Bouscambert M; Trabaud MA; Fralick M; Lee TC; Pinto R; Barratt-Due A; Lund-Johansen F; Müller F; Nevalainen OPO; Cao B; Bonnett T; Griessbach A; Taji Heravi A; Schönenberger C; Janiaud P; Werlen L; Aghlmandi S; Schandelmaier S; Yazdanpanah Y; Costagliola D; Olsen IC; Briel M";10.1016/S2213-2600(22)00528-8;['Meta-Analysis', 'Journal Article'];True;2023-05-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;36695483;PUBMED;Remdesivir for the treatment of COVID-19.;"Grundeis F; Ansems K; Dahms K; Thieme V; Metzendorf MI; Skoetz N; Benstoem C; Mikolajewska A; Griesel M; Fichtner F; Stegemann M";10.1002/14651858.CD014962.pub2;['Journal Article', 'Review'];True;2023-01-25
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;32473020;BACKGROUND;Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.;"Lê MP; Peiffer-Smadja N; Guedj J; Néant N; Mentré F; Ader F; Yazdanpanah Y; Peytavin G";10.1093/jac/dkaa191;['Journal Article', 'Review'];True;2020-05-30
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34763056;BACKGROUND;Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group.;"EU-Response investigators group; Diallo A; Trøseid M; Simensen VC; Boston A; Demotes J; Olsen IC; Chung F; Paiva JA; Hites M; Ader F; Arribas JR; Baratt-Due A; Melien Ø; Tacconelli E; Staub T; Greil R; Tsiodras S; Briel M; Esperou H; Mentré F; Eustace J; Saillard J; Delmas C; LeMestre S; Dumousseaux M; Costagliola D; Røttingen JA; Yazdanpanah Y";10.1016/j.cmi.2021.10.011;['Journal Article'];True;2022-01-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34534511;RESULT;Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.;"Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F; DisCoVeRy Study Group";10.1016/S1473-3099(21)00485-0;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2022-02-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;34048876;RESULT;An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.;"Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F; DisCoVeRy study group";10.1016/j.cmi.2021.05.020;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2021-12-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;32304640;DERIVED;Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base.;"Taccone FS; Gorham J; Vincent JL";10.1016/S2213-2600(20)30172-7;['Journal Article'];True;2020-06-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35512728;DERIVED;Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.;WHO Solidarity Trial Consortium;10.1016/S0140-6736(22)00519-0;['Journal Article', 'Meta-Analysis'];True;2022-05-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35643099;RESULT;Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19.;"Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Mentré F; Burdet C; DisCoVeRy Study Group";10.1016/S1473-3099(22)00295-X;['Letter'];True;2022-06-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35623577;BACKGROUND;Immunocompromised patients have been neglected in COVID-19 trials: a call for action.;"Trøseid M; Hentzien M; Ader F; Cardoso SW; Arribas JR; Molina JM; Mueller N; Hites M; Bonnet F; Manuel O; Costagliola D; Grinsztejn B; Olsen IC; Yazdapanah Y; Calmy A; EU RESPONSE; COMBINE";10.1016/j.cmi.2022.05.005;['Journal Article'];True;2022-09-01
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;35233617;RESULT;Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.;"Lingas G; Néant N; Gaymard A; Belhadi D; Peytavin G; Hites M; Staub T; Greil R; Paiva JA; Poissy J; Peiffer-Smadja N; Costagliola D; Yazdanpanah Y; Wallet F; Gagneux-Brunon A; Mentré F; Ader F; Burdet C; Guedj J; Bouscambert-Duchamp M";10.1093/jac/dkac048;['Journal Article', 'Randomized Controlled Trial'];True;2022-03-02
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;33089306;BACKGROUND;Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response.;"Lê MP; Peiffer-Smadja N; Guedj J; Neant N; Mentré F; Ader F; Yazdanpanah Y; Peytavin G; C-20-15 DisCoVeRy French Steering Committee";10.1093/jac/dkaa415;['Journal Article', 'Comment'];True;2020-10-22
NCT04315948;Trial of Treatments for COVID-19 in Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-03-20;2020-03-22;2023-09-25;37302469;BACKGROUND;Ensuring quality control in a COVID-19 clinical trial during the pandemic: The experience of the Inserm C20-15 DisCoVeRy study.;"Fougerou-Leurent C; Delmas C; Saillard J; Dumousseaux M; Ferrane A; Mercier N; Terzic V; Le Mestre S; Dechanet A; Belhadi D; Metois A; Burdet C; Mentré F; Noret M; Diallo A; Petrov-Sanchez V; Couffin-Cadiergues S; Hites M; Ader F; Esperou H";10.1016/j.cct.2023.107267;['Journal Article'];True;2023-08-01
NCT01713335;Proteasis Evaluation in COPD;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-10-24;2012-10-18;2017-04;;;;;;;;
NCT01874808;From Movement Preparation to Gait Execution in ALS;Institut National de la Santé Et de la Recherche Médicale, France;Université Paris Ouest-EA 2931-CEntre de Recherches sur le Sport et le Mouvement;COMPLETED;OBSERVATIONAL;False;2013-06-11;2013-06-21;2015-12-21;;;;;;;;
NCT01895920;Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread?;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2013-07-11;2013-01;2018-02;;;;;;;;
NCT02978924;Trans-spinal Direct Current Stimulation in Primary Orthostatic Tremor;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-01;2017-01-17;2017-11-28;;;;;;;;
NCT02160119;Emotional and Change-related Attention in Autism;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2014-06-10;2014-05-27;2018-05-27;;;;;;;;
NCT04631224;Longitudinal Analysis of Oral Communication in Friedreich's Ataxia;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2020-11-17;2015-02;2017-02;;;;;;;;
NCT01693835;"""Cancersensor"": Circadian Rhythms";Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-09-26;2012-08;2014-06;;;;;;;;
NCT01917175;Early Identification and Treatment of Early HIV Infection in Côte d'Ivoire;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2013-08-06;1997-06;2018-09;;;;;;;;
NCT01952587;X-linked Biological Response to HIV Sensing: the ANRS EP 53 Study;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2013-09-30;2013-11;2015-06;;;;;;;;
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-31;2014-12;2015-09;26930627;DERIVED;Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.;"Sissoko D; Laouenan C; Folkesson E; M'Lebing AB; Beavogui AH; Baize S; Camara AM; Maes P; Shepherd S; Danel C; Carazo S; Conde MN; Gala JL; Colin G; Savini H; Bore JA; Le Marcis F; Koundouno FR; Petitjean F; Lamah MC; Diederich S; Tounkara A; Poelart G; Berbain E; Dindart JM; Duraffour S; Lefevre A; Leno T; Peyrouset O; Irenge L; Bangoura N; Palich R; Hinzmann J; Kraus A; Barry TS; Berette S; Bongono A; Camara MS; Chanfreau Munoz V; Doumbouya L; Souley Harouna; Kighoma PM; Koundouno FR; Réné Lolamou; Loua CM; Massala V; Moumouni K; Provost C; Samake N; Sekou C; Soumah A; Arnould I; Komano MS; Gustin L; Berutto C; Camara D; Camara FS; Colpaert J; Delamou L; Jansson L; Kourouma E; Loua M; Malme K; Manfrin E; Maomou A; Milinouno A; Ombelet S; Sidiboun AY; Verreckt I; Yombouno P; Bocquin A; Carbonnelle C; Carmoi T; Frange P; Mely S; Nguyen VK; Pannetier D; Taburet AM; Treluyer JM; Kolie J; Moh R; Gonzalez MC; Kuisma E; Liedigk B; Ngabo D; Rudolf M; Thom R; Kerber R; Gabriel M; Di Caro A; Wölfel R; Badir J; Bentahir M; Deccache Y; Dumont C; Durant JF; El Bakkouri K; Gasasira Uwamahoro M; Smits B; Toufik N; Van Cauwenberghe S; Ezzedine K; D'Ortenzio E; Pizarro L; Etienne A; Guedj J; Fizet A; Barte de Sainte Fare E; Murgue B; Tran-Minh T; Rapp C; Piguet P; Poncin M; Draguez B; Allaford Duverger T; Barbe S; Baret G; Defourny I; Carroll M; Raoul H; Augier A; Eholie SP; Yazdanpanah Y; Levy-Marchal C; Antierrens A; Van Herp M; Günther S; de Lamballerie X; Keïta S; Mentre F; Anglaret X; Malvy D; JIKI Study Group";10.1371/journal.pmed.1001967;['Clinical Trial', 'Journal Article'];True;2016-03-01
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-31;2014-12;2015-09;25435054;BACKGROUND;Dose regimen of favipiravir for Ebola virus disease.;"Mentré F; Taburet AM; Guedj J; Anglaret X; Keïta S; de Lamballerie X; Malvy D";10.1016/S1473-3099(14)71047-3;['Letter'];True;2015-02-01
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-31;2014-12;2015-09;28231247;DERIVED;Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.;"Nguyen TH; Guedj J; Anglaret X; Laouénan C; Madelain V; Taburet AM; Baize S; Sissoko D; Pastorino B; Rodallec A; Piorkowski G; Carazo S; Conde MN; Gala JL; Bore JA; Carbonnelle C; Jacquot F; Raoul H; Malvy D; de Lamballerie X; Mentré F; JIKI study group";10.1371/journal.pntd.0005389;['Clinical Trial', 'Journal Article'];True;2017-02-23
NCT02329054;Efficacy of Favipiravir Against Ebola (JIKI);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-12-31;2014-12;2015-09;27046271;RESULT;Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.;"Sissoko D; Laouenan C; Folkesson E; M'Lebing AB; Beavogui AH; Baize S; Camara AM; Maes P; Shepherd S; Danel C; Carazo S; Conde MN; Gala JL; Colin G; Savini H; Bore JA; Le Marcis F; Koundouno FR; Petitjean F; Lamah MC; Diederich S; Tounkara A; Poelart G; Berbain E; Dindart JM; Duraffour S; Lefevre A; Leno T; Peyrouset O; Irenge L; Bangoura N; Palich R; Hinzmann J; Kraus A; Barry TS; Berette S; Bongono A; Camara MS; Munoz VC; Doumbouya L; Harouna S; Kighoma PM; Koundouno FR; Lolamou R; Loua CM; Massala V; Moumouni K; Provost C; Samake N; Sekou C; Soumah A; Arnould I; Komano MS; Gustin L; Berutto C; Camara D; Camara FS; Colpaert J; Delamou L; Jansson L; Kourouma E; Loua M; Malme K; Manfrin E; Maomou A; Milinouno A; Ombelet S; Sidiboun AY; Verreckt I; Yombouno P; Bocquin A; Carbonnelle C; Carmoi T; Frange P; Mely S; Nguyen VK; Pannetier D; Taburet AM; Treluyer JM; Kolie J; Moh R; Gonzalez MC; Kuisma E; Liedigk B; Ngabo D; Rudolf M; Thom R; Kerber R; Gabriel M; Di Caro A; Wölfel R; Badir J; Bentahir M; Deccache Y; Dumont C; Durant JF; El Bakkouri K; Uwamahoro MG; Smits B; Toufik N; Van Cauwenberghe S; Ezzedine K; D'Ortenzio E; Pizarro L; Etienne A; Guedj J; Fizet A; de Sainte Fare EB; Murgue B; Tran-Minh T; Rapp C; Piguet P; Poncin M; Draguez B; Duverger TA; Barbe S; Baret G; Defourny I; Carroll M; Raoul H; Augier A; Eholie SP; Yazdanpanah Y; Levy-Marchal C; Antierrens A; Van Herp M; Günther S; de Lamballerie X; Keïta S; Mentre F; Anglaret X; Malvy D; JIKI Study Group";10.1371/journal.pmed.1002009;['Published Erratum'];True;2016-04-05
NCT04842851;Cardiac Resynchronization Therapy in Congenital Heart Diseases With Systemic Right Ventricle;Paris Cardiovascular Research Center (Inserm U970);Marie Lannelongue Hospital, Le Plessis Robinson, France | Clinique Pasteur Toulouse | Groupe Hospitalier Pitie-Salpetriere | Hopital Louis Pradel | University Hospital, Montpellier | European Georges Pompidou Hospital;COMPLETED;OBSERVATIONAL;False;2021-04-13;2004-01-01;2020-12-31;;;;;;;;
NCT02093754;Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-03-21;2014-05;2016-03;;;;;;;;
NCT02916732;Zika Virus Infection's Pregnancy Consequences in French Department of America;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2016-09-27;2016-04;2019-02;33657112;RESULT;Reassessment of the risk of birth defects due to Zika virus in Guadeloupe, 2016.;"Funk AL; Hoen B; Vingdassalom I; Ryan C; Kadhel P; Schepers K; Gaete S; Tressières B; Fontanet A";10.1371/journal.pntd.0009048;['Journal Article'];True;2021-03-03
NCT02916732;Zika Virus Infection's Pregnancy Consequences in French Department of America;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2016-09-27;2016-04;2019-02;29539287;RESULT;Pregnancy Outcomes after ZIKV Infection in French Territories in the Americas.;"Hoen B; Schaub B; Funk AL; Ardillon V; Boullard M; Cabié A; Callier C; Carles G; Cassadou S; Césaire R; Douine M; Herrmann-Storck C; Kadhel P; Laouénan C; Madec Y; Monthieux A; Nacher M; Najioullah F; Rousset D; Ryan C; Schepers K; Stegmann-Planchard S; Tressières B; Voluménie JL; Yassinguezo S; Janky E; Fontanet A";10.1056/NEJMoa1709481;['Journal Article'];True;2018-03-15
NCT03215732;Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, Senegal;ANRS, Emerging Infectious Diseases;Institute of Research for Development, France;COMPLETED;OBSERVATIONAL;False;2017-07-12;2017-10-19;2019-07-31;31320358;DERIVED;Burden and impacts of chronic hepatitis B infection in rural Senegal: study protocol of a cross-sectional survey in the area of Niakhar (AmBASS ANRS 12356).;"Coste M; De Sèze M; Diallo A; Carrieri MP; Marcellin F; Boyer S; ANRS 12356 AmBASS Study Group";10.1136/bmjopen-2019-030211;['Journal Article'];True;2019-07-01
NCT03215732;Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, Senegal;ANRS, Emerging Infectious Diseases;Institute of Research for Development, France;COMPLETED;OBSERVATIONAL;False;2017-07-12;2017-10-19;2019-07-31;37143029;PUBMED;Hepatitis B prevention and treatment needs in women in Senegal (ANRS 12356 AmBASS survey).;"Djaogol T; Périères L; Marcellin F; Diouf A; Carrieri MP; Diallo A; Boyer S; ANRS 12356 AmBASS Study Group";10.1186/s12889-023-15710-y;['Journal Article'];True;2023-05-05
NCT01089387;Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2010-03-18;2010-05;2015-03;25974235;DERIVED;Mesenchymal stem cell therapy for the treatment of erectile dysfunction.;"Khera M; Albersen M; Mulhall JP";10.1111/jsm.12871;['Journal Article'];False;2015-05-01
NCT01089387;Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2010-03-18;2010-05;2015-03;26439886;PUBMED;Safety of Intracavernous Bone Marrow-Mononuclear Cells for Postradical Prostatectomy Erectile Dysfunction: An Open Dose-Escalation Pilot Study.;"Yiou R; Hamidou L; Birebent B; Bitari D; Lecorvoisier P; Contremoulins I; Khodari M; Rodriguez AM; Augustin D; Roudot-Thoraval F; de la Taille A; Rouard H";10.1016/j.eururo.2015.09.026;['Journal Article'];False;2016-06-01
NCT01089387;Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2010-03-18;2010-05;2015-03;28753830;DERIVED;Intracavernous Injections of Bone Marrow Mononucleated Cells for Postradical Prostatectomy Erectile Dysfunction: Final Results of the INSTIN Clinical Trial.;"Yiou R; Hamidou L; Birebent B; Bitari D; Le Corvoisier P; Contremoulins I; Rodriguez AM; Augustin D; Roudot-Thoraval F; de la Taille A; Rouard H";10.1016/j.euf.2017.06.009;['Letter'];False;2017-12-01
NCT01269632;Cohort of Young Adults Infected With HIV Since Birth or During Childhood;French National Agency for Research on AIDS and Viral Hepatitis;;COMPLETED;INTERVENTIONAL;False;2011-01-04;2010-06;2018-12-27;;;;;;;;
NCT04120415;A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02);ANRS, Emerging Infectious Diseases;EuroVacc Foundation | European AIDS Treatment Group (EATG) | Medical Research Council | University College London Hospitals | University of Liverpool | Erasmus Medical Center | Henri Mondor University Hospital | European Georges Pompidou Hospital | Saint-Louis Hospital, Paris, France | Centre Hospitalier Universitaire Vaudois | Chelsea and Westminster Hospital, UK | Universitätsklinikum Hamburg-Eppendorf | Hospital Clinic of Barcelona | Istituto Nazionale Malattie Infettive Lazaro Spallanzani | Imperial College London | Institut d'Investigacions Biomèdiques August Pi i Sunyer | European Commission | Swiss Government;COMPLETED;INTERVENTIONAL;False;2019-10-09;2022-06-21;2023-07-12;;;;;;;;
NCT02236832;Study of the Neural Basis of Analogical Reasoning;Institut National de la Santé Et de la Recherche Médicale, France;Fondation pour la Recherche Médicale;COMPLETED;INTERVENTIONAL;False;2014-09-11;2015-02;2021-02;;;;;;;;
NCT00604149;Cardiac AResT And GENEtic;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2008-01-30;2008-01;2014-01;;;;;;;;
NCT01779752;Vestibular Cortex and TMS;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2013-01-30;2013-01-20;2016-01;;;;;;;;
NCT02647632;Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2016-01-06;2016-01;2017-04;29077864;DERIVED;Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.;"de Lédinghen V; Laforest C; Hézode C; Pol S; Renault A; Alric L; Larrey D; Métivier S; Tran A; Jézéquel C; Samuel D; Zoulim F; Tual C; Pailhé A; Gibowski S; Bourlière M; Bellissant E; Pawlotsky JM";10.1093/cid/cix916;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2017-10-25
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;20802298;BACKGROUND;Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir.;"Gutmann C; Cusini A; Günthard HF; Fux C; Hirschel B; Decosterd LA; Cavassini M; Yerly S; Vernazza PL; Swiss HIV Cohort Study (SHCS)";10.1097/QAD.0b013e32833db9a1;['Journal Article', 'Randomized Controlled Trial'];False;2010-09-24
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;18097218;BACKGROUND;Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.;"Pulido F; Arribas JR; Delgado R; Cabrero E; González-García J; Pérez-Elias MJ; Arranz A; Portilla J; Pasquau J; Iribarren JA; Rubio R; Norton M; OK04 Study Group";10.1097/QAD.0b013e3282f4243b;['Classical Article', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];False;2008-01-11
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;16249701;BACKGROUND;Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).;"Arribas JR; Pulido F; Delgado R; Lorenzo A; Miralles P; Arranz A; González-García JJ; Cepeda C; Hervás R; Paño JR; Gaya F; Carcas A; Montes ML; Costa JR; Peña JM";10.1097/01.qai.0000180077.59159.f4;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2005-11-01
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;21811554;BACKGROUND;Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis.;"Mathis S; Khanlari B; Pulido F; Schechter M; Negredo E; Nelson M; Vernazza P; Cahn P; Meynard JL; Arribas J; Bucher HC";10.1371/journal.pone.0022003;['Journal Article', 'Meta-Analysis', 'Review'];True;2011-07-19
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;22441252;BACKGROUND;Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.;"Bartlett JA; Ribaudo HJ; Wallis CL; Aga E; Katzenstein DA; Stevens WS; Norton MR; Klingman KL; Hosseinipour MC; Crump JA; Supparatpinyo K; Badal-Faesen S; Kallungal BA; Kumarasamy N";10.1097/QAD.0b013e328353b066;['Journal Article', 'Multicenter Study'];True;2012-07-17
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;22814125;BACKGROUND;Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).;"Gilks CF; Walker AS; Dunn DT; Gibb DM; Kikaire B; Reid A; Musana H; Mambule I; Kasirye R; Robertson V; Ssali F; Spyer M; Pillay D; Yirrell D; Kaleebu P; DART Virology Group and Trial Team";10.3851/IMP2253;['Journal Article', 'Randomized Controlled Trial'];False;2012-10-01
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;20010070;BACKGROUND;The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.;"Arribas JR; Horban A; Gerstoft J; Fätkenheuer G; Nelson M; Clumeck N; Pulido F; Hill A; van Delft Y; Stark T; Moecklinghoff C";10.1097/QAD.0b013e3283348944;['Journal Article', 'Randomized Controlled Trial'];False;2010-01-01
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;18540803;BACKGROUND;A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.;"Cameron DW; da Silva BA; Arribas JR; Myers RA; Bellos NC; Gilmore N; King MS; Bernstein BM; Brun SC; Hanna GJ";10.1086/589622;['Journal Article'];True;2008-07-15
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;20802297;BACKGROUND;Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.;"Katlama C; Valantin MA; Algarte-Genin M; Duvivier C; Lambert-Niclot S; Girard PM; Molina JM; Hoen B; Pakianather S; Peytavin G; Marcelin AG; Flandre P";10.1097/QAD.0b013e32833dec20;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];False;2010-09-24
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;28566227;DERIVED;Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.;"Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E; MOBIDIP study group";10.1016/S2352-3018(17)30069-3;['Clinical Trial', 'Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];False;2017-09-01
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;23075703;BACKGROUND;A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.;"Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K; HIV STAR Study Group";10.3851/IMP2443;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2012-10-01
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;16549962;BACKGROUND;Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).;"Castagna A; Danise A; Menzo S; Galli L; Gianotti N; Carini E; Boeri E; Galli A; Cernuschi M; Hasson H; Clementi M; Lazzarin A";10.1097/01.aids.0000218542.08845.b2;['Journal Article', 'Randomized Controlled Trial'];False;2006-04-04
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;17545707;BACKGROUND;The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial.;"Vernazza P; Daneel S; Schiffer V; Decosterd L; Fierz W; Klimkait T; Hoffmann M; Hirschel B";10.1097/QAD.0b013e32814e6b1c;['Journal Article'];False;2007-06-01
NCT01905059;Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa;ANRS, Emerging Infectious Diseases;Janssen Pharmaceuticals;COMPLETED;INTERVENTIONAL;False;2013-07-23;2014-02;2017-02;21886816;BACKGROUND;Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen.;"Cahn P; Montaner J; Junod P; Patterson P; Krolewiecki A; Andrade-Villanueva J; Cassetti I; Sierra-Madero J; Casiró AD; Bortolozzi R; Lupo SH; Longo N; Rampakakis E; Ackad N; Sampalis JS";10.1371/journal.pone.0023726;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2011-08-19
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-29;2017-04-21;2018-09-18;36068621;DERIVED;Effects of a mindfulness-based versus a health self-management intervention on objective cognitive performance in older adults with subjective cognitive decline (SCD): a secondary analysis of the SCD-Well randomized controlled trial.;"Whitfield T; Demnitz-King H; Schlosser M; Barnhofer T; Frison E; Coll-Padros N; Dautricourt S; Requier F; Delarue M; Gonneaud J; Klimecki OM; Lutz A; Paly L; Salmon E; Schild AK; Walker Z; Jessen F; Chételat G; Collette F; Wirth M; Marchant NL; Medit-Ageing Research Group";10.1186/s13195-022-01057-w;['Journal Article', 'Randomized Controlled Trial'];True;2022-09-06
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-29;2017-04-21;2018-09-18;38100477;PUBMED;Effects of a mindfulness-based intervention and a health self-management programme on psychological well-being in older adults with subjective cognitive decline: Secondary analyses from the SCD-Well randomised clinical trial.;"Schlosser M; Demnitz-King H; Barnhofer T; Collette F; Gonneaud J; Chételat G; Jessen F; Kliegel M; Klimecki OM; Lutz A; Marchant NL; Medit-Ageing Research Group";10.1371/journal.pone.0295175;['Randomized Controlled Trial', 'Journal Article'];True;2023-12-15
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-29;2017-04-21;2018-09-18;35853750;DERIVED;Association of Self-reflection With Cognition and Brain Health in Cognitively Unimpaired Older Adults.;"Demnitz-King H; Gonneaud J; Klimecki OM; Chocat A; Collette F; Dautricourt S; Jessen F; Krolak-Salmon P; Lutz A; Morse RM; Molinuevo JL; Poisnel G; Touron E; Wirth M; Walker Z; Chételat G; Marchant NL; Medit-Ageing Research Group";10.1212/WNL.0000000000200951;['Clinical Trial', 'Journal Article'];False;2022-09-27
NCT03005652;Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-12-29;2017-04-21;2018-09-18;33873195;DERIVED;Effects of a Mindfulness-Based Intervention versus Health Self-Management on Subclinical Anxiety in Older Adults with Subjective Cognitive Decline: The SCD-Well Randomized Superiority Trial.;"Marchant NL; Barnhofer T; Coueron R; Wirth M; Lutz A; Arenaza-Urquijo EM; Collette F; Poisnel G; Demnitz-King H; Schild AK; Coll-Padros N; Delphin-Combe F; Whitfield T; Schlosser M; Gonneaud J; Asselineau J; Walker Z; Krolak-Salmon P; Molinuevo JL; Frison E; Chételat G; Jessen F; Klimecki OM; The Medit-Ageing Research Group";10.1159/000515669;['Journal Article', 'Randomized Controlled Trial'];True;2021-01-01
NCT02542800;The Influence of Collective Schemas on Individual Memory;Institut National de la Santé Et de la Recherche Médicale, France;La Région Basse-Normandie | Université de Caen Normandie | University Hospital, Caen | Ecole Pratique des Hautes Etudes | Equipement d'Excellence Matrice;COMPLETED;INTERVENTIONAL;False;2015-09-07;2015-09;2017-06-02;;;;;;;;
NCT01779713;Transcriptomic Signature of Vasospasm Consecutive to Sub-arachnoid Aneurismal Hemorrhage;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2013-01-30;2013-02-04;2016-07-04;30354977;DERIVED;Whole-Blood miRNA Sequencing Profiling for Vasospasm in Patients With Aneurysmal Subarachnoid Hemorrhage.;"Pulcrano-Nicolas AS; Proust C; Clarençon F; Jacquens A; Perret C; Roux M; Shotar E; Thibord F; Puybasset L; Garnier S; Degos V; Trégouët DA";10.1161/STROKEAHA.118.021101;['Journal Article'];True;2018-09-01
NCT01842919;Dance and Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2013-04-30;2013-04;2016-07-08;;;;;;;;
NCT02405013;Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2015-04-01;2015-10;2017-11;36686592;PUBMED;Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial).;"Marcellin F; Mourad A; Lemoine M; Kouanfack C; Seydi M; Carrieri P; Attia A; Protopopescu C; Lacombe K; Boyer S";10.1016/j.jhepr.2022.100665;['Journal Article'];True;2023-03-01
NCT01801618;National Evaluation of PI-based 2nd Line Efficacy in Cambodia;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2013-03-01;2013-02;2014-12;29662875;PUBMED;Positive Virological Outcomes of HIV-Infected Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276 2PICAM Study.;"Ségéral O; Nerrienet E; Neth S; Spire B; Khol V; Ferradini L; Sarun S; Mom C; Ngin S; Charpentier C; Men P; Mora M; Mean Chhi V; Ly P; Saphonn V";10.3389/fpubh.2018.00063;['Journal Article'];True;2018-03-19
NCT06260319;Decoding Developmental Disorders in Humams;Institut National de la Santé Et de la Recherche Médicale, France;Imagine Institute | Commissariat A L'energie Atomique;COMPLETED;OBSERVATIONAL;False;2024-02-15;2019-01-01;2024-01-01;;;;;;;;
NCT02125500;Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-04-29;2014-08;2015-12;;;;;;;;
NCT00445575;Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone;Institut National de la Santé Et de la Recherche Médicale, France;ZonMw: The Netherlands Organisation for Health Research and Development | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Charite University, Berlin, Germany;COMPLETED;INTERVENTIONAL;False;2007-03-09;2007-07-22;2017-12-07;;;;;;;;
NCT02051413;Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN);Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-01-31;2014-02-18;2018-05;;;;;;;;
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;16193476;RESULT;New mutations in protein kinase Cgamma associated with spinocerebellar ataxia type 14.;"Klebe S; Durr A; Rentschler A; Hahn-Barma V; Abele M; Bouslam N; Schöls L; Jedynak P; Forlani S; Denis E; Dussert C; Agid Y; Bauer P; Globas C; Wüllner U; Brice A; Riess O; Stevanin G";10.1002/ana.20628;['Journal Article'];False;2005-09-28
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;18853458;RESULT;Complicated forms of autosomal dominant hereditary spastic paraplegia are frequent in SPG10.;"Goizet C; Boukhris A; Mundwiller E; Tallaksen C; Forlani S; Toutain A; Carriere N; Paquis V; Depienne C; Durr A; Stevanin G; Brice A";10.1002/humu.20920;['Journal Article'];True;2009-02-01
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;16501573;RESULT;Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes.;"Waters MF; Minassian NA; Stevanin G; Figueroa KP; Bannister JP; Nolte D; Mock AF; Evidente VG; Fee DB; Müller U; Dürr A; Brice A; Papazian DM; Pulst SM";10.1038/ng1758;['Journal Article'];False;2006-02-26
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;17098887;RESULT;Exon deletions of SPG4 are a frequent cause of hereditary spastic paraplegia.;"Depienne C; Fedirko E; Forlani S; Cazeneuve C; Ribaï P; Feki I; Tallaksen C; Nguyen K; Stankoff B; Ruberg M; Stevanin G; Durr A; Brice A";10.1136/jmg.2006.046425;['Letter'];True;2007-04-01
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;15313841;RESULT;Mutation in the catalytic domain of protein kinase C gamma and extension of the phenotype associated with spinocerebellar ataxia type 14.;"Stevanin G; Hahn V; Lohmann E; Bouslam N; Gouttard M; Soumphonphakdy C; Welter ML; Ollagnon-Roman E; Lemainque A; Ruberg M; Brice A; Durr A";10.1001/archneur.61.8.1242;['Journal Article'];False;2004-08-01
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;24780882;DERIVED;Prediction of the age at onset in spinocerebellar ataxia type 1, 2, 3 and 6.;"Tezenas du Montcel S; Durr A; Rakowicz M; Nanetti L; Charles P; Sulek A; Mariotti C; Rola R; Schols L; Bauer P; Dufaure-Garé I; Jacobi H; Forlani S; Schmitz-Hübsch T; Filla A; Timmann D; van de Warrenburg BP; Marelli C; Kang JS; Giunti P; Cook A; Baliko L; Melegh B; Boesch S; Szymanski S; Berciano J; Infante J; Buerk K; Masciullo M; Di Fabio R; Depondt C; Ratka S; Stevanin G; Klockgether T; Brice A; Golmard JL";10.1136/jmedgenet-2013-102200;['Journal Article'];True;2014-04-29
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;16055926;RESULT;Spastin mutations are frequent in sporadic spastic paraparesis and their spectrum is different from that observed in familial cases.;"Depienne C; Tallaksen C; Lephay JY; Bricka B; Poea-Guyon S; Fontaine B; Labauge P; Brice A; Durr A";10.1136/jmg.2005.035311;['Letter'];True;2005-08-23
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;17597328;RESULT;A de novo SPAST mutation leading to somatic mosaicism is associated with a later age at onset in HSP.;"Depienne C; Fedirko E; Faucheux JM; Forlani S; Bricka B; Goizet C; Lesourd S; Stevanin G; Ruberg M; Durr A; Brice A";10.1007/s10048-007-0090-4;['Letter'];False;2007-06-28
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;22491195;DERIVED;Factors influencing disease progression in autosomal dominant cerebellar ataxia and spastic paraplegia.;"Tezenas du Montcel S; Charles P; Goizet C; Marelli C; Ribai P; Vincitorio C; Anheim M; Guyant-Maréchal L; Le Bayon A; Vandenberghe N; Tchikviladzé M; Devos D; Le Ber I; N'Guyen K; Cazeneuve C; Tallaksen C; Brice A; Durr A";10.1001/archneurol.2011.2713;['Journal Article', 'Multicenter Study'];True;2012-04-01
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;15365159;RESULT;Mutations in the FGF14 gene are not a major cause of spinocerebellar ataxia in Caucasians.;"Stevanin G; Durr A; Dussert C; Penet C; Brice A";10.1212/01.wnl.0000137020.30604.1e;['Journal Article'];False;2004-09-14
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;17605047;RESULT;"A novel locus for autosomal dominant ""uncomplicated"" hereditary spastic paraplegia maps to chromosome 8p21.1-q13.3.";"Hanein S; Dürr A; Ribai P; Forlani S; Leutenegger AL; Nelson I; Babron MC; Elleuch N; Depienne C; Charon C; Brice A; Stevanin G";10.1007/s00439-007-0396-1;['Journal Article'];False;2007-06-28
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;17957230;RESULT;Mental deficiency in three families with SPG4 spastic paraplegia.;"Ribaï P; Depienne C; Fedirko E; Jothy AC; Viveweger C; Hahn-Barma V; Brice A; Durr A";10.1038/sj.ejhg.5201922;['Journal Article'];True;2007-10-24
NCT00136630;Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations;Institut National de la Santé Et de la Recherche Médicale, France;Assistance Publique - Hôpitaux de Paris;COMPLETED;OBSERVATIONAL;False;2005-08-29;2005-05;2020-05;18378516;RESULT;Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment.;"du Montcel ST; Charles P; Ribai P; Goizet C; Le Bayon A; Labauge P; Guyant-Maréchal L; Forlani S; Jauffret C; Vandenberghe N; N'guyen K; Le Ber I; Devos D; Vincitorio CM; Manto MU; Tison F; Hannequin D; Ruberg M; Brice A; Durr A";10.1093/brain/awn059;['Journal Article', 'Multicenter Study'];True;2008-03-31
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;18614870;RESULT;Response to combination antiretroviral therapy: variation by age.;"Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group; Sabin CA; Smith CJ; d'Arminio Monforte A; Battegay M; Gabiano C; Galli L; Geelen S; Gibb D; Guiguet M; Judd A; Leport C; Dabis F; Pantazis N; Porter K; Raffi F; Thorne C; Torti C; Walker S; Warszawski J; Wintergerst U; Chene G; Lundgren J";10.1097/QAD.0b013e3282f88d02;['Journal Article', 'Multicenter Study'];False;2008-07-31
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;21971357;RESULT;Early antiretroviral therapy in HIV-1-infected infants, 1996-2008: treatment response and duration of first-line regimens.;"Judd A; European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord";10.1097/QAD.0b013e32834d614c;['Journal Article'];True;2011-11-28
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;24253249;RESULT;Naive T lymphocytes and recent thymic emigrants are associated with HIV-1 disease history in french adolescents and young adults infected in the perinatal period: the ANRS-EP38-IMMIP study.;"Blanche S; Scott-Algara D; Le Chenadec J; Didier C; Montange T; Avettand-Fenoel V; Rouzioux C; Mélard A; Viard JP; Dollfus C; Bouallag N; Warszawski J; Buseyne F";10.1093/cid/cit729;['Journal Article'];True;2013-11-18
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;17712765;RESULT;Long-term nonprogression of HIV infection in children: evaluation of the ANRS prospective French Pediatric Cohort.;"Warszawski J; Lechenadec J; Faye A; Dollfus C; Firtion G; Meyer L; Douard D; Monpoux F; Tricoire J; Benmebarek Y; Rouzioux C; Blanche S";10.1086/521165;['Journal Article'];True;2007-09-15
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;22427678;RESULT;Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study.;"Avettand-Fenoel V; Blanche S; Le Chenadec J; Scott-Algara D; Dollfus C; Viard JP; Bouallag N; Benmebarek Y; Rivière Y; Warszawski J; Rouzioux C; Buseyne F";10.1093/infdis/jis233;['Journal Article'];True;2012-03-15
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;21511330;RESULT;Risk of triple-class virological failure in children with HIV: a retrospective cohort study.;"Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE); Castro H; Judd A; Gibb DM; Butler K; Lodwick RK; van Sighem A; Ramos JT; Warsawski J; Thorne C; Noguera-Julian A; Obel N; Costagliola D; Tookey PA; Colin C; Kjaer J; Grarup J; Chene G; Phillips A";10.1016/S0140-6736(11)60208-0;['Journal Article'];True;2011-05-01
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;19194272;RESULT;Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants.;"Goetghebuer T; Haelterman E; Le Chenadec J; Dollfus C; Gibb D; Judd A; Green H; Galli L; Ramos JT; Giaquinto C; Warszawski J; Levy J; European Infant Collaboration group";10.1097/QAD.0b013e328326ca37;['Journal Article', 'Multicenter Study'];False;2009-03-13
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;24705410;RESULT;Low birth weight in perinatally HIV-exposed uninfected infants: observations in urban settings in Cameroon.;"Sofeu CL; Warszawski J; Ateba Ndongo F; Penda IC; Tetang Ndiang S; Guemkam G; Makwet N; Owona F; Kfutwah A; Tchendjou P; Texier G; Tchuente M; Faye A; Tejiokem MC; ANRS-PEDIACAM Study Group";10.1371/journal.pone.0093554;['Journal Article'];True;2014-04-03
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;20536367;RESULT;Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10).;"Dollfus C; Le Chenadec J; Faye A; Blanche S; Briand N; Rouzioux C; Warszawski J";10.1086/653674;['Journal Article'];True;2010-07-15
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;26762993;RESULT;HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.;"Frange P; Faye A; Avettand-Fenoël V; Bellaton E; Descamps D; Angin M; David A; Caillat-Zucman S; Peytavin G; Dollfus C; Le Chenadec J; Warszawski J; Rouzioux C; Sáez-Cirión A; ANRS EPF-CO10 Pediatric Cohort and the ANRS EP47 VISCONTI study group";10.1016/S2352-3018(15)00232-5;['Journal Article'];True;2016-01-01
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;22198788;RESULT;Short- and long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation.;"Goetghebuer T; Le Chenadec J; Haelterman E; Galli L; Dollfus C; Thorne C; Judd A; Keiser O; Ramos JT; Levy J; Warszawski J; European Infant Collaboration Group";10.1093/cid/cir950;['Journal Article'];True;2011-12-23
NCT03235258;Cohort of HIV-infected Children;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-08-01;2004-07;2020-06;24945880;RESULT;Interruption of cART in clinical practice is associated with an increase in the long-term risk of subsequent immunosuppression in HIV-1-infected children.;"Aupiais C; Faye A; Le Chenadec J; Rouzioux C; Bouallag N; Laurent C; Blanche S; Dollfus C; Warszawski J; ANRS EPF-CO10 French Pediatric Cohort";10.1097/INF.0000000000000450;['Journal Article', 'Multicenter Study'];False;2014-12-01
NCT02428816;Evaluation of a Multimodal Neuroimaging Method for Diagnosis in Parkinsonian Syndromes;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-04-29;2013-01-24;2016-07-28;;;;;;;;
NCT02886416;Co-adaptation Between Human Immunodeficiency Virus (HIV) and Cluster of Differentiation 8 (CD8) Cellular Immunity;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2016-09-01;2016-08;2017-04;;;;;;;;
NCT01899196;Epicardial Adipose Tissue And Coronary Risk In HIV-Infected Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2013-07-15;2013-07;2016-03;;;;;;;;
NCT04684758;HIV Acquisition and Life Course of Born-abroad Men Who Have Sex With Men Living in Ile-de-France: the GANYMEDE Study;ANRS, Emerging Infectious Diseases;Institut National de la Santé Et de la Recherche Médicale, France;COMPLETED;OBSERVATIONAL;False;2020-12-28;2021-04-14;2022-06-30;;;;;;;;
NCT02116374;Physiopathology Study of the Microbiota Biodiversity of HIV Seropositive Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2014-04-16;2014-12;2016-06;;;;;;;;
NCT03459157;Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP);ANRS, Emerging Infectious Diseases;Expertise France | Université Montpellier | SESSTIM (IRD, Inserm, Université Aix-Marseille) | Coalition Internationale Sida | Institut de Médecine Tropicale, Anvers, Belgique | ARCAD-SIDA MALI | Association African Solidarité | Centre de Recherche Internationale pour la Santé, Université de Ouagadougou | Espace Confiance, Côte d'Ivoire | Espoir Vie-Togo - ONG | Laboratoire BIOLIM, Université de Lomé;COMPLETED;INTERVENTIONAL;False;2018-03-08;2017-11-20;2021-06-30;34048794;DERIVED;HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study.;"Laurent C; Dembélé Keita B; Yaya I; Le Guicher G; Sagaon-Teyssier L; Agboyibor MK; Coulibaly A; Traoré I; Malan JB; De Baetselier I; Eubanks A; Riegel L; Rojas Castro D; Fayé-Ketté H; Koné A; Diandé S; Dagnra CA; Serrano L; Diallo F; Mensah E; Dah TTE; Anoma C; Vuylsteke B; Spire B; CohMSM-PrEP Study Group";10.1016/S2352-3018(21)00005-9;['Journal Article'];False;2021-07-01
NCT01579435;Experimental Therapeutics in Essential Tremor Using Transcranial Direct Current Stimulation;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-04-18;2012-04;2013-04;;;;;;;;
NCT01493934;Development of a Fast Measurement Technique of Insulin Resistance in Human;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-16;2010-04;2013-03;;;;;;;;
NCT02192658;Disability and HIV: Vulnerability of People With Disabilities to HIV Infection in Sub-Saharan Africa;ANRS, Emerging Infectious Diseases;Handicap International | Institut de Recherche pour le Developpement | Institut de Formation et de Recherche Démographique | Forum Camerounais de Psychologie | Centre de Recherche Internationale pour la Santé de l'Université de Ouagadougou;COMPLETED;OBSERVATIONAL;False;2014-07-17;2014-11;2016-07;26846895;DERIVED;HandiVIH--A population-based survey to understand the vulnerability of people with disabilities to HIV and other sexual and reproductive health problems in Cameroon: protocol and methodological considerations.;"De Beaudrap P; Pasquier E; Tchoumkeu A; Touko A; Essomba F; Brus A; Desgrées du Loû A; Aderemi TJ; Hanass-Hancock J; Eide AH; Mont D; Mac-Seing M; Beninguisse G";10.1136/bmjopen-2015-008934;['Journal Article'];True;2016-02-01
NCT03071458;Mutational Landscape in Hepatocellular Carcinoma;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2017-03-07;2008-01;2015-05;;;;;;;;
NCT02527096;A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol);ANRS, Emerging Infectious Diseases;ViiV Healthcare;COMPLETED;INTERVENTIONAL;False;2015-08-18;2015-09-17;2017-03;;;;;;;;
NCT02057796;Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-02-07;2014-09;2018-04;32558469;DERIVED;Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults.;"Blanc FX; Badje AD; Bonnet M; Gabillard D; Messou E; Muzoora C; Samreth S; Nguyen BD; Borand L; Domergue A; Rapoud D; Natukunda N; Thai S; Juchet S; Eholié SP; Lawn SD; Domoua SK; Anglaret X; Laureillard D; STATIS ANRS 12290 Trial Team";10.1056/NEJMoa1910708;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2020-06-18
NCT02057796;Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-02-07;2014-09;2018-04;36883573;PUBMED;High performance of systematic combined urine LAM test and sputum Xpert MTB/RIF® for tuberculosis screening in severely immunosuppressed ambulatory adults with HIV.;"Bonnet M; Gabillard D; Domoua S; Muzoora C; Messou E; Sovannarith S; Nguyen DB; Badje A; Juchet S; Bunnet D; Borand L; Natukunda N; Tran TH; Anglaret X; Laureillard D; Blanc FX; STATIS ANRS 12290 Trial Team";10.1093/cid/ciad125;['Journal Article'];False;2023-03-08
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;25245939;BACKGROUND;Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.;"Bruggmann P; Grebely J";10.1016/j.drugpo.2014.08.014;['Journal Article'];True;2015-02-01
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;26298331;BACKGROUND;Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.;"Smith DJ; Combellick J; Jordan AE; Hagan H";10.1016/j.drugpo.2015.07.004;['Journal Article', 'Meta-Analysis', 'Review'];True;2015-10-01
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;33208326;DERIVED;Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam-hepatitis C).;"Rapoud D; Quillet C; Pham Minh K; Vu Hai V; Nguyen Thanh B; Nham Thi Tuyet T; Tran Thi H; Molès JP; Vallo R; Michel L; Feelemyer J; Weiss L; Lemoine M; Vickerman P; Fraser H; Duong Thi H; Khuat Thi Hai O; Des Jarlais D; Nagot N; Laureillard D; DRIVE-C Study Group";10.1136/bmjopen-2020-039234;['Journal Article'];True;2020-11-01
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23675659;BACKGROUND;Current and future therapies for hepatitis C virus infection.;"Liang TJ; Ghany MG";10.1056/NEJMra1213651;['Journal Article', 'Review'];True;2013-05-16
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;22098550;BACKGROUND;Liver disease in Viet Nam: screening, surveillance, management and education: a 5-year plan and call to action.;"Gish RG; Bui TD; Nguyen CT; Nguyen DT; Tran HV; Tran DM; Trinh HN; International Group for Liver Health in Viet Nam";10.1111/j.1440-1746.2011.06974.x;['Journal Article', 'Review'];False;2012-01-20
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23884064;BACKGROUND;Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.;"Martin NK; Hickman M; Hutchinson SJ; Goldberg DJ; Vickerman P";10.1093/cid/cit296;['Journal Article'];True;2013-08-15
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27427455;BACKGROUND;The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia.;"Altice FL; Azbel L; Stone J; Brooks-Pollock E; Smyrnov P; Dvoriak S; Taxman FS; El-Bassel N; Martin NK; Booth R; Stöver H; Dolan K; Vickerman P";10.1016/S0140-6736(16)30856-X;['Journal Article', 'Review'];True;2016-09-01
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27148964;BACKGROUND;High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262).;"Nguyen Truong T; Laureillard D; Lacombe K; Duong Thi H; Pham Thi Hanh P; Truong Thi Xuan L; Chu Thi N; Luong Que A; Vu Hai V; Nagot N; Tuaillon E; Dominguez S; Lemoine M";10.1371/journal.pone.0153744;['Journal Article'];True;2016-05-05
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;25920094;BACKGROUND;From non-A, non-B hepatitis to hepatitis C virus cure.;"Pawlotsky JM; Feld JJ; Zeuzem S; Hoofnagle JH";10.1016/j.jhep.2015.02.006;['Journal Article', 'Review'];True;2015-04-01
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23172780;BACKGROUND;Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.;"Mohd Hanafiah K; Groeger J; Flaxman AD; Wiersma ST";10.1002/hep.26141;['Journal Article', 'Meta-Analysis', 'Review'];True;2013-02-04
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;25086286;BACKGROUND;Global epidemiology and genotype distribution of the hepatitis C virus infection.;"Gower E; Estes C; Blach S; Razavi-Shearer K; Razavi H";10.1016/j.jhep.2014.07.027;['Journal Article', 'Review'];True;2014-11-01
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23553643;BACKGROUND;Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals.;"Martin NK; Vickerman P; Grebely J; Hellard M; Hutchinson SJ; Lima VD; Foster GR; Dillon JF; Goldberg DJ; Dore GJ; Hickman M";10.1002/hep.26431;['Journal Article'];True;2013-08-26
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27667367;BACKGROUND;EASL Recommendations on Treatment of Hepatitis C 2016.;European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu;10.1016/j.jhep.2016.09.001;['Journal Article', 'Practice Guideline'];True;2017-01-01
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;22564041;BACKGROUND;Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings.;"Vickerman P; Martin N; Turner K; Hickman M";10.1111/j.1360-0443.2012.03932.x;['Journal Article'];False;2012-07-12
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;20041309;BACKGROUND;Prevalence and incidence of HCV infection among Vietnam heroin users with recent onset of injection.;"Clatts MC; Colón-López V; Giang LM; Goldsamt LA";10.1007/s11524-009-9417-9;['Journal Article'];True;2009-12-30
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27178119;BACKGROUND;Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.;"Des Jarlais D; Duong HT; Pham Minh K; Khuat OH; Nham TT; Arasteh K; Feelemyer J; Heckathorn DD; Peries M; Moles JP; Laureillard D; Nagot N; (The Drive Study Team)";10.1080/09540121.2016.1178698;['Journal Article'];True;2016-05-13
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;20196807;BACKGROUND;Vietnamese community screening for hepatitis B virus and hepatitis C virus.;"Kallman JB; Tran S; Arsalla A; Haddad D; Stepanova M; Fang Y; Wrobel VJ; Srishord M; Younossi ZM";10.1111/j.1365-2893.2010.01278.x;['Journal Article'];False;2010-12-10
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;20572071;BACKGROUND;Multiple routes of hepatitis C virus transmission among injection drug users in Hai Phong, Northern Vietnam.;"Tanimoto T; Nguyen HC; Ishizaki A; Chung PT; Hoang TT; Nguyen VT; Kageyama S; Oka S; Pham VT; Ichimura H";10.1002/jmv.21787;['Journal Article'];True;2010-06-22
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;22828983;BACKGROUND;Epidemiology, responses, and way forward: the silent epidemic of viral hepatitis and HIV coinfection in Vietnam.;"Sereno L; Mesquita F; Kato M; Jacka D; Nguyen TT; Nguyen TN";10.1177/1545109712453939;['Journal Article', 'Review'];True;2012-07-24
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;19839502;BACKGROUND;High prevalence of Hepatitis C virus genotype 6 in Vietnam.;"Pham DA; Leuangwutiwong P; Jittmittraphap A; Luplertlop N; Bach HK; Akkarathamrongsin S; Theamboonlers A; Poovorawan Y";;['Journal Article'];;
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;27349488;BACKGROUND;Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.;"Conti F; Buonfiglioli F; Scuteri A; Crespi C; Bolondi L; Caraceni P; Foschi FG; Lenzi M; Mazzella G; Verucchi G; Andreone P; Brillanti S";10.1016/j.jhep.2016.06.015;['Journal Article'];True;2016-10-01
NCT03537196;DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C);ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2018-05-25;2018-11-13;2022-12-30;23728143;BACKGROUND;Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.;"Grebely J; Matthews GV; Lloyd AR; Dore GJ";10.1093/cid/cit377;['Journal Article'];True;2013-05-31
NCT00265642;Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C;ANRS, Emerging Infectious Diseases;Sanofi;COMPLETED;INTERVENTIONAL;False;2005-12-15;2006-10;2013-11;;;;;;;;
NCT01592175;Magnetoencephalography (MEG), Attention and Conscience;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-05-07;2012-03-08;2013-07-02;;;;;;;;
NCT03193099;Decoding Presymptomatic White Matter Changes in Huntington Disease;Institut National de la Santé Et de la Recherche Médicale, France;University College, London;COMPLETED;INTERVENTIONAL;False;2017-06-20;2017-07-11;2019-12-30;;;;;;;;
NCT01725542;Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb;COMPLETED;INTERVENTIONAL;False;2012-11-14;2012-12;2014-06;25977266;DERIVED;High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.;"Piroth L; Paniez H; Taburet AM; Vincent C; Rosenthal E; Lacombe K; Billaud E; Rey D; Zucman D; Bailly F; Bronowicki JP; Simony M; Diallo A; Izopet J; Aboulker JP; Meyer L; Molina JM; ANRS HC30 QUADRIH Study Group";10.1093/cid/civ381;['Journal Article', 'Multicenter Study'];True;2015-05-14
NCT02038842;Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-01-17;2014-03;2016-03;;;;;;;;
NCT01094899;Abnormal Structure and Bone Density in Diabetes;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2010-03-29;2010-03-10;2014-07-10;;;;;;;;
NCT04265742;Microbiota and Bone Fragility:Study of the Relation Between Gut Microbiota and Bone Microarchitecture;Institut National de la Santé Et de la Recherche Médicale, France;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2020-02-12;2019-02-08;2022-02-04;;;;;;;;
NCT01569399;Efficacity of rTMS in Alcohol Dependance;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-04-03;2011-02-11;2016-08;;;;;;;;
NCT00918307;Efficacy and Safety of Varenicline Among HIV-infected Patients;ANRS, Emerging Infectious Diseases;Pfizer;COMPLETED;INTERVENTIONAL;False;2009-06-11;2009-10;2014-07;34611902;DERIVED;Interventions for preventing weight gain after smoking cessation.;"Hartmann-Boyce J; Theodoulou A; Farley A; Hajek P; Lycett D; Jones LL; Kudlek L; Heath L; Hajizadeh A; Schenkels M; Aveyard P";10.1002/14651858.CD006219.pub4;['Journal Article', 'Meta-Analysis', 'Review'];True;2021-10-06
NCT00918307;Efficacy and Safety of Varenicline Among HIV-infected Patients;ANRS, Emerging Infectious Diseases;Pfizer;COMPLETED;INTERVENTIONAL;False;2009-06-11;2009-10;2014-07;29329763;DERIVED;Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial.;"Mercié P; Arsandaux J; Katlama C; Ferret S; Beuscart A; Spadone C; Duvivier C; Reynes J; Wirth N; Moinot L; Bénard A; Zucman D; Duval X; Molina JM; Spire B; Fagard C; Chêne G; ANRS 144 Inter-ACTIV study group";10.1016/S2352-3018(18)30002-X;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];False;2018-03-01
NCT02082171;Multidomain Intervention to Prevent Disability in Elders;Institut National de la Santé Et de la Recherche Médicale, France;National Research Agency, France;COMPLETED;INTERVENTIONAL;False;2014-03-10;2013-10-16;2016-01-27;;;;;;;;
NCT02150993;First-Line Treatment for HIV-2;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-05-30;2016-01-26;2019-05-15;38740027;PUBMED;Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial.;"Eholie SP; Ekouevi DK; Chazallon C; Charpentier C; Messou E; Diallo Z; Zoungrana J; Minga A; Ngom Gueye NF; Hawerlander D; Dembele F; Colin G; Tchounga B; Karcher S; Le Carrou J; Tchabert-Guié A; Toni TD; Ouédraogo AS; Bado G; Toure Kane C; Seydi M; Poda A; Mensah E; Diallo I; Drabo YJ; Anglaret X; Brun-Vezinet F; FIT-2 study group";10.1016/S2352-3018(24)00085-7;['Journal Article'];False;2024-05-01
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);ANRS, Emerging Infectious Diseases;Institut Pasteur, Cambodia | National Pediatric Hospital, Cambodia | Angkor Hospital for Children | Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam | Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam | Number 2 Children's Hospital, Ho Chi Minh City | Hôpital Necker-Enfants Malades, Paris, France | Groupe Hospitalier Pitie-Salpetriere | CHRU Arnaud de Villeveuve, Montpellier, France | IRD, Yaounde, Cameroon | Fondation Chantal Biya,Yaounde, Cameroon | CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso | Centre Muraz | Centre Pasteur du Cameroun | Centre Hospitalier D'essos;COMPLETED;INTERVENTIONAL;False;2011-04-08;2011-04;2014-05;31455612;DERIVED;A Treatment-Decision Score for HIV-Infected Children With Suspected Tuberculosis.;"Marcy O; Borand L; Ung V; Msellati P; Tejiokem M; Huu KT; Do Chau V; Ngoc Tran D; Ateba-Ndongo F; Tetang-Ndiang S; Nacro B; Sanogo B; Neou L; Goyet S; Dim B; Pean P; Quillet C; Fournier I; Berteloot L; Carcelain G; Godreuil S; Blanche S; Delacourt C; ANRS 12229 PAANTHER 01 STUDY GROUP";10.1542/peds.2018-2065;['Journal Article'];True;2019-09-01
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);ANRS, Emerging Infectious Diseases;Institut Pasteur, Cambodia | National Pediatric Hospital, Cambodia | Angkor Hospital for Children | Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam | Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam | Number 2 Children's Hospital, Ho Chi Minh City | Hôpital Necker-Enfants Malades, Paris, France | Groupe Hospitalier Pitie-Salpetriere | CHRU Arnaud de Villeveuve, Montpellier, France | IRD, Yaounde, Cameroon | Fondation Chantal Biya,Yaounde, Cameroon | CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso | Centre Muraz | Centre Pasteur du Cameroun | Centre Hospitalier D'essos;COMPLETED;INTERVENTIONAL;False;2011-04-08;2011-04;2014-05;30689814;DERIVED;Isolation of Nontuberculous Mycobacteria in Southeast Asian and African Human Immunodeficiency Virus-infected Children With Suspected Tuberculosis.;"Borand L; de Lauzanne A; Nguyen NL; Cheng S; Pham TH; Eyangoh S; Ouedraogo AS; Ung V; Msellati P; Tejiokem M; Nacro B; Inghammar M; Dim B; Delacourt C; Godreuil S; Blanche S; Marcy O; Pediatric Asian African Network for Tuberculosis and HIV Research (PAANTHER) Study Group";10.1093/cid/ciy897;['Clinical Trial', 'Journal Article', 'Multicenter Study'];True;2019-01-28
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);ANRS, Emerging Infectious Diseases;Institut Pasteur, Cambodia | National Pediatric Hospital, Cambodia | Angkor Hospital for Children | Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam | Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam | Number 2 Children's Hospital, Ho Chi Minh City | Hôpital Necker-Enfants Malades, Paris, France | Groupe Hospitalier Pitie-Salpetriere | CHRU Arnaud de Villeveuve, Montpellier, France | IRD, Yaounde, Cameroon | Fondation Chantal Biya,Yaounde, Cameroon | CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso | Centre Muraz | Centre Pasteur du Cameroun | Centre Hospitalier D'essos;COMPLETED;INTERVENTIONAL;False;2011-04-08;2011-04;2014-05;26908804;DERIVED;Performance of Xpert MTB/RIF and Alternative Specimen Collection Methods for the Diagnosis of Tuberculosis in HIV-Infected Children.;"Marcy O; Ung V; Goyet S; Borand L; Msellati P; Tejiokem M; Nguyen Thi NL; Nacro B; Cheng S; Eyangoh S; Pham TH; Ouedraogo AS; Tarantola A; Godreuil S; Blanche S; Delacourt C";10.1093/cid/ciw036;['Clinical Trial', 'Journal Article'];True;2016-02-07
NCT01331811;Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon);ANRS, Emerging Infectious Diseases;Institut Pasteur, Cambodia | National Pediatric Hospital, Cambodia | Angkor Hospital for Children | Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam | Pediatric Hospital Nhi Dong 1, Ho Chi Minh City, Vietnam | Number 2 Children's Hospital, Ho Chi Minh City | Hôpital Necker-Enfants Malades, Paris, France | Groupe Hospitalier Pitie-Salpetriere | CHRU Arnaud de Villeveuve, Montpellier, France | IRD, Yaounde, Cameroon | Fondation Chantal Biya,Yaounde, Cameroon | CHU Sourô Sanou, Bobo Dioulasso, Burkina Faso | Centre Muraz | Centre Pasteur du Cameroun | Centre Hospitalier D'essos;COMPLETED;INTERVENTIONAL;False;2011-04-08;2011-04;2014-05;29174612;DERIVED;Mortality and its determinants in antiretroviral treatment-naive HIV-infected children with suspected tuberculosis: an observational cohort study.;"Marcy O; Tejiokem M; Msellati P; Truong Huu K; Do Chau V; Tran Ngoc D; Nacro B; Ateba-Ndongo F; Tetang-Ndiang S; Ung V; Dim B; Neou L; Berteloot L; Borand L; Delacourt C; Blanche S; ANRS 12229 PAANTHER 01 Study Group";10.1016/S2352-3018(17)30206-0;['Clinical Trial', 'Journal Article', 'Multicenter Study'];False;2018-02-01
NCT02567071;Natural Microbiota Restoration After C-section Birth;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-10-02;2016-04-06;2019-04;;;;;;;;
NCT04392388;Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2020-05-18;2020-05-01;2023-04-11;34293141;PUBMED;Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study.;"Carrat F; de Lamballerie X; Rahib D; Blanché H; Lapidus N; Artaud F; Kab S; Renuy A; Szabo de Edelenyi F; Meyer L; Lydié N; Charles MA; Ancel PY; Jusot F; Rouquette A; Priet S; Saba Villarroel PM; Fourié T; Lusivika-Nzinga C; Nicol J; Legot S; Druesne-Pecollo N; Esseddik Y; Lai C; Gagliolo JM; Deleuze JF; Bajos N; Severi G; Touvier M; Zins M; for the SAPRIS and SAPRIS-SERO study groups";10.1093/ije/dyab110;['Journal Article'];True;2021-07-19
NCT01534728;Identification of Hepatitis C Virus (HCV) Specific T Cells;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-02-17;2012-02;2014-03;;;;;;;;
NCT02453061;A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease;Institut National de la Santé Et de la Recherche Médicale, France;Ultragenyx Pharmaceutical Inc;COMPLETED;INTERVENTIONAL;False;2015-05-25;2015-06-29;2019-12-03;31381524;DERIVED;Huntington's Disease Clinical Trials Corner: June 2019.;"Rodrigues FB; Ferreira JJ; Wild EJ";10.3233/JHD-199003;['Journal Article'];True;2019-08-27
NCT02833961;Diffusion Spectroscopy in Stroke;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-07-14;2016-07-28;2019-10-25;36318030;PUBMED;Longitudinal Monitoring of Microstructural Alterations in Cerebral Ischemia with in Vivo Diffusion-weighted MR Spectroscopy.;"Genovese G; Diaz-Fernandez B; Lejeune FX; Ronen I; Marjańska M; Yahia-Cherif L; Lehéricy S; Branzoli F; Rosso C";10.1148/radiol.220430;['Journal Article'];True;2023-03-01
NCT04288128;Integrated Functional Evaluation of the Cerebellum;Institut National de la Santé Et de la Recherche Médicale, France;Biogen | Ionis Pharmaceuticals, Inc.;COMPLETED;OBSERVATIONAL;False;2020-02-28;2020-05-28;2022-06-01;38421662;PUBMED;ATXN7-Related Cone-Rod Dystrophy: The Integrated Functional Evaluation of the Cerebellum (CERMOI) Study.;"Nassisi M; Coarelli G; Blanchard B; Dubec-Fleury C; Drine K; Kitic N; Sancho S; Hilab R; Tezenas du Montcel S; Junge C; Lane R; Arnold HM; Durr A; Audo I";10.1001/jamaophthalmol.2024.0001;['Journal Article', 'Comment'];False;2024-04-01
NCT04288128;Integrated Functional Evaluation of the Cerebellum;Institut National de la Santé Et de la Recherche Médicale, France;Biogen | Ionis Pharmaceuticals, Inc.;COMPLETED;OBSERVATIONAL;False;2020-02-28;2020-05-28;2022-06-01;38419144;PUBMED;Digital Gait Measures Capture 1-Year Progression in Early-Stage Spinocerebellar Ataxia Type 2.;"Seemann J; Daghsen L; Cazier M; Lamy JC; Welter ML; Giese MA; Synofzik M; Durr A; Ilg W; Coarelli G";10.1002/mds.29757;['Journal Article'];True;2024-02-28
NCT02214511;Biomarkers of Social Sensitivity in Major Depression;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2014-08-12;2014-10-23;2017-03-01;;;;;;;;
NCT00928187;Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé);ANRS, Emerging Infectious Diseases;Gilead Sciences | Janssen Pharmaceutica;COMPLETED;INTERVENTIONAL;True;2009-06-25;2009-11;2015-12;31273686;DERIVED;Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa.;"Boyer S; Nishimwe ML; Sagaon-Teyssier L; March L; Koulla-Shiro S; Bousmah MQ; Toby R; Mpoudi-Etame MP; Ngom Gueye NF; Sawadogo A; Kouanfack C; Ciaffi L; Spire B; Delaporte E; 2-Lady Group";10.1007/s41669-019-0157-9;['Journal Article'];True;2019-07-04
NCT00116454;Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2005-06-30;2005-07;2013-08;;;;;;;;
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;26372388;RESULT;Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients.;ANRS CO13 HEPAVIH Cohort;10.1097/QAD.0000000000000787;['Journal Article'];False;2015-09-10
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22173166;RESULT;Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH.;"Salmon D; Bani-Sadr F; Loko MA; Stitou H; Gervais A; Durant J; Rosenthal E; Quertainmont Y; Barange K; Vittecoq D; Shoai-Tehrani M; Alvarez M; Winnock M; Trinchet JC; Dabis F; Sogni P";10.1016/j.jhep.2011.11.009;['Journal Article'];False;2012-04-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28942916;RESULT;Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.;"Carrieri MP; Protopopescu C; Marcellin F; Rosellini S; Wittkop L; Esterle L; Zucman D; Raffi F; Rosenthal E; Poizot-Martin I; Salmon-Ceron D; Dabis F; Spire B; ANRS CO13 HEPAVIH Study Group";10.1016/j.jhep.2017.08.005;['Journal Article', 'Multicenter Study'];False;2017-12-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;30570526;DERIVED;Nadir CD4 Is Negatively Associated With Antinuclear Antibody Detection in HCV/HIV-Coinfected Patients.;"Poizot-Martin I; Rosenthal E; Gilbert C; Cano CE; Simon A; Lascoux-Combe C; Alric L; Gervais A; Neau D; Esterle L; Salmon D; Sogni P; Wittkop L; ANRS CO13 HEPAVIH Study Group";10.1097/QAI.0000000000001940;['Journal Article'];False;2019-04-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23226258;RESULT;HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients.;"Abravanel F; Raymond S; Pambrun E; Winnock M; Bonnard P; Sogni P; Trimoulet P; Dabis F; Salmon-Ceron D; Izopet J; ANRS CO13 HEPAVIH Study Group";10.1371/journal.pone.0050289;['Journal Article'];True;2012-11-30
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;20876416;RESULT;Chocolate intake, depression, and clinical progression in HIV-HCV coinfected patients: still more questions than answers.;"Carrieri MP; Cohen J; Winnock M; Salmon D";10.1001/archinternmed.2010.330;['Comment', 'Letter'];False;2010-09-27
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;25015913;RESULT;High levels of alcohol consumption increase the risk of advanced hepatic fibrosis in HIV/hepatitis C virus-coinfected patients: a sex-based analysis using transient elastography at enrollment in the HEPAVIH ANRS CO13 cohort.;"Marcellin F; Roux P; Loko MA; Lions C; Caumont-Prim A; Dabis F; Salmon-Ceron D; Spire B; Carrieri MP; HEPAVIH (ANRS CO13) Study Group";10.1093/cid/ciu525;['Letter', 'Comment'];True;2014-07-11
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28418984;RESULT;Short article: Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH).;"Marcellin F; Protopopescu C; Esterle L; Wittkop L; Piroth L; Aumaitre H; Bouchaud O; Goujard C; Vittecoq D; Dabis F; Salmon-Ceron D; Spire B; Roux P; Carrieri MP; ANRS CO13-HEPAVIH Study Group";10.1097/MEG.0000000000000883;['Journal Article'];False;2017-07-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;26528903;RESULT;HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.;"Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F; ANRS CO13HEPAVIH study group";10.1016/j.jcv.2015.10.010;['Journal Article', 'Multicenter Study'];False;2015-12-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21920402;RESULT;Prevalence of immunity to hepatitis viruses A and B in a large cohort of HIV/HCV-coinfected patients, and factors associated with HAV and HBV vaccination.;"Winnock M; Bani-Sadr F; Pambrun E; Loko MA; Lascoux-Combe C; Garipuy D; Rosenthal E; Carrieri P; Dabis F; Salmon D";10.1016/j.vaccine.2011.08.125;['Journal Article'];False;2011-11-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;20969743;RESULT;The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010.;"Loko MA; Salmon D; Carrieri P; Winnock M; Mora M; Merchadou L; Gillet S; Pambrun E; Delaune J; Valantin MA; Poizot-Martin I; Neau D; Bonnard P; Rosenthal E; Barange K; Morlat P; Lacombe K; Gervais A; Rouges F; See AB; Lascoux-Combe C; Vittecoq D; Goujard C; Duvivier C; Spire B; Izopet J; Sogni P; Serfaty L; Benhamou Y; Bani-Sadr F; Dabis F; ANRS CO 13 HEPAVIH Study Group";10.1186/1471-2334-10-303;['Journal Article'];True;2010-10-22
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28235612;RESULT;Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.;"Piroth L; Wittkop L; Lacombe K; Rosenthal E; Gilbert C; Miailhes P; Carrieri P; Chas J; Poizot-Martin I; Gervais A; Dominguez S; Neau D; Zucman D; Billaud E; Morlat P; Aumaitre H; Lascoux-Combe C; Simon A; Bouchaud O; Teicher E; Bani-Sadr F; Alric L; Vittecoq D; Boué F; Duvivier C; Valantin MA; Esterle L; Dabis F; Sogni P; Salmon D; ANRS CO13 HEPAVIH study group";10.1016/j.jhep.2017.02.012;['Journal Article'];False;2017-07-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22285372;RESULT;Hepatitis C virus RNA quantitation in a nationwide French cohort of patients co-infected with HIV and HCV: should the same test be applied to all samples?;"Trimoulet P; Merchadou L; Winnock M; Loko MA; Fleury H; Salmon D; Dabis F; Neau D; ANRS CO 13 HEPAVIH Study Group";10.1016/j.jviromet.2012.01.006;['Journal Article'];False;2012-04-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21239121;RESULT;Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: the role of the physician.;"Roux P; Cohen J; Lascoux-Combe C; Sogni P; Winnock M; Salmon-Ceron D; Spire B; Dabis F; Carrieri MP; ANRS-CO13-HEPAVIH study group";10.1016/j.drugalcdep.2010.09.025;['Journal Article'];False;2011-07-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22409788;RESULT;Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France).;"Salmon-Ceron D; Cohen J; Winnock M; Roux P; Sadr FB; Rosenthal E; Martin IP; Loko MA; Mora M; Sogni P; Spire B; Dabis F; Carrieri MP; HEPAVIH group";10.1186/1472-6963-12-59;['Journal Article'];True;2012-03-12
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21692942;RESULT;Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.;"Loko MA; Bani-Sadr F; Winnock M; Lacombe K; Carrieri P; Neau D; Morlat P; Serfaty L; Dabis F; Salmon D; ANRS CO 13 HEPAVIH Study Group";10.1111/j.1365-2893.2010.01417.x;['Journal Article'];False;2011-01-11
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22535683;RESULT;Elevated coffee consumption and reduced risk of insulin resistance in HIV-HCV coinfected patients (HEPAVIH ANRS CO-13).;"Carrieri MP; Sogni P; Cohen J; Loko MA; Winnock M; Spire B; HEPAVIH Study Group";10.1002/hep.25813;['Letter', 'Comment'];True;2012-10-31
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;32798585;DERIVED;Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.;"Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L; ANRS CO13 HEPAVIH and ANRS CO22 HEPATHER cohort study groups";10.1016/j.jhep.2020.08.008;['Journal Article', 'Multicenter Study'];True;2021-01-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21888878;RESULT;Coffee consumption and reduced self-reported side effects in HIV-HCV co-infected patients during PEG-IFN and ribavirin treatment: results from ANRS CO13 HEPAVIH.;"Carrieri MP; Cohen J; Salmon-Ceron D; Winnock M";10.1016/j.jhep.2011.08.005;['Letter'];True;2012-03-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23978720;RESULT;Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort study.;"Carrieri MP; Lions C; Sogni P; Winnock M; Roux P; Mora M; Bonnard P; Salmon D; Dabis F; Spire B; ANRS CO13 HEPAVIH Study Group";10.1016/j.jhep.2013.08.014;['Journal Article'];False;2014-01-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;25778750;RESULT;Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH).;"Carrieri MP; Serfaty L; Vilotitch A; Winnock M; Poizot-Martin I; Loko MA; Lions C; Lascoux-Combe C; Roux P; Salmon-Ceron D; Spire B; Dabis F; ANRS CO13 HEPAVIH Study Group";10.1093/cid/civ217;['Journal Article'];True;2015-03-16
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;22781224;RESULT;Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction?;"Solas C; Pambrun E; Winnock M; Salmon D; Poizot-Martin I; Dominguez S; Bani-Sadr F; Izopet J; Garraffo R; Peytavin G; ANRS CO-13 HEPAVIH Study Group";10.1097/QAD.0b013e32835763a4;['Journal Article', 'Multicenter Study'];False;2012-11-13
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;21819472;RESULT;Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.;"Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP; ANRS-CO-13-HEPAVIH Study Group";10.1111/j.1360-0443.2011.03608.x;['Journal Article'];False;2011-10-12
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;27317796;RESULT;All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.;"Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L";10.1093/cid/ciw379;['Journal Article'];True;2016-06-17
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;27339598;RESULT;A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients.;"Ulveling D; Le Clerc S; Cobat A; Labib T; Noirel J; Laville V; Coulonges C; Carpentier W; Nalpas B; Heim MH; Poynard T; Cerny A; Pol S; Bochud PY; Dabis F; Theodorou I; Lévy Y; Salmon D; Abel L; Dominguez S; Zagury JF; HEPAVIH ANRS CO13 Cohort Study Group; Swiss Hepatitis C Cohort Study Group; French ANRS HC EP 26 Genoscan Study Group";10.1002/hep.28695;['Journal Article'];True;2016-07-29
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;34212476;DERIVED;Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants.;"Chalouni M; Wittkop L; Bani-Sadr F; Lacombe K; Esterle L; Gilbert C; Miailhes P; Zucman D; Valantin MA; Brégigeon-Ronot S; Morlat P; Billaud E; Piroth L; Naqvi A; Sogni P; Salmon D; ANRS CO13 HEPAVIH Cohort Study Group";10.1111/hiv.13127;['Journal Article'];True;2021-07-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;24499953;RESULT;Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients: possible role of the hepatitis C virus sustained viral response.;"Bani-Sadr F; Loko MA; Pambrun E; Winnock M; Carrieri P; Gilbert C; Duvivier C; Bouchaud O; Gervais A; Dabis F; Salmon D; ANRS CO 13 HEPAVIH Study Group";10.1097/QAD.0000000000000218;['Journal Article'];False;2014-05-15
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;20493576;RESULT;Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection.;"Calès P; Halfon P; Batisse D; Carrat F; Perré P; Penaranda G; Guyader D; d'Alteroche L; Fouchard-Hubert I; Michelet C; Veillon P; Lambert J; Weiss L; Salmon D; Cacoub P";10.1016/j.jhep.2010.03.007;['Journal Article', 'Multicenter Study'];False;2010-08-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28430385;RESULT;Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort.;"Knight R; Roux P; Vilotitch A; Marcellin F; Rosenthal E; Esterle L; Boué F; Rey D; Piroth L; Dominguez S; Sogni P; Salmon-Ceron D; Spire B; Carrieri MP; ANRS CO13-HEPAVIH Study Group";10.1111/add.13851;['Journal Article'];False;2017-06-06
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23461846;RESULT;Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions.;"Winnock M; Bani-Sadr F; Pambrun E; Loko MA; Carrieri P; Neau D; Morlat P; Marchou B; Dabis F; Salmon D; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) CO13 HEPAVIH Study Group";10.1111/hiv.12023;['Journal Article'];True;2013-03-05
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;28780609;RESULT;Unstable Housing Still a Barrier to Receiving HCV Treatment in France (ANRS CO13 HEPAVIH Cohort).;"Yaya I; Roux P; Marcellin F; Salmon-Ceron D; Carrieri MP";10.1007/s10620-017-4703-y;['Letter', 'Comment'];False;2017-08-05
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;27073179;RESULT;No significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVIH French cohort).;"Marcellin F; Lions C; Rosenthal E; Roux P; Sogni P; Wittkop L; Protopopescu C; Spire B; Salmon-Ceron D; Dabis F; Carrieri MP; HEPAVIH ANRS CO13 Study Group*";10.1111/dar.12398;['Journal Article'];False;2016-04-13
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23421419;RESULT;Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVIH ARNS CO13 cohort).;"Marcellin F; Lions C; Winnock M; Salmon D; Durant J; Spire B; Mora M; Loko MA; Dabis F; Dominguez S; Roux P; Carrieri MP; ANRS CO13 HEPAVIH Study Group";10.1111/add.12149;['Journal Article', 'Multicenter Study'];False;2013-03-21
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;23052829;RESULT;Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.;"Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D; ANRS CO 13 HEPAVIH Study Group";10.3851/IMP2419;['Journal Article'];True;2012-10-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;27177169;RESULT;Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort).;"Marcellin F; Protopopescu C; Poizot-Martin I; Miailhes P; Esterle L; Wittkop L; Spire B; Bocquier A; Salmon-Ceron D; Dabis F; Carrieri MP; HEPAVIH ANRS CO13 Study Group";10.1097/MEG.0000000000000664;['Journal Article', 'Multicenter Study'];False;2016-09-01
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;24580042;RESULT;Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort.;"Marcellin F; Roux P; Winnock M; Lions C; Dabis F; Salmon-Ceron D; Loko MA; Spire B; Carrieri MP";10.1586/17474124.2014.888949;['Journal Article', 'Review'];False;2014-03-03
NCT03324633;Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV;ANRS, Emerging Infectious Diseases;Bristol-Myers Squibb | GlaxoSmithKline | Merck Serono International SA | Roche Pharma AG | Schering-Plough;COMPLETED;OBSERVATIONAL;False;2017-10-30;2005-06;2022-12;24166726;RESULT;Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV-HCV-coinfected patients: results from the ANRS-CO13-HEPAVIH cohort.;"Roux P; Lions C; Cohen J; Winnock M; Salmon-Céron D; Bani-Sadr F; Sogni P; Spire B; Dabis F; Carrieri MP; ANRS-CO13-HEPAVIH Study Group";10.3851/IMP2699;['Journal Article'];True;2013-02-01
NCT02027233;Clinical Trial to Assess the Influenza Vaccination of the Hospitalized Adults;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-01-06;2014-01;2022-12-31;;;;;;;;
NCT02931097;DBS of the MLR for Gait and Balance Disorders in PD Patients;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-10-12;2016-10;2020-10;;;;;;;;
NCT02408354;Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-04-03;2015-04-15;2017-04-05;28969699;DERIVED;A randomized, controlled, double-blind, crossover trial of triheptanoin in alternating hemiplegia of childhood.;"Hainque E; Caillet S; Leroy S; Flamand-Roze C; Adanyeguh I; Charbonnier-Beaupel F; Retail M; Le Toullec B; Atencio M; Rivaud-Péchoux S; Brochard V; Habarou F; Ottolenghi C; Cormier F; Méneret A; Ruiz M; Doulazmi M; Roubergue A; Corvol JC; Vidailhet M; Mochel F; Roze E";10.1186/s13023-017-0713-2;['Journal Article', 'Randomized Controlled Trial'];True;2017-10-02
NCT03954054;Therapeutic Education for Harm Reduction in People With Alcohol Use Disorder;Institut National de la Santé Et de la Recherche Médicale, France;Regional Agency for Health PACA | SESSTIM UMR1252 (Aix-Marseille Univ, INSERM, IRD);COMPLETED;OBSERVATIONAL;False;2019-05-17;2019-10-28;2021-07-31;35012570;DERIVED;Evaluation of a novel therapeutic education programme for people with alcohol use disorder in France: a mixed-methods intervention study protocol (ETHER).;"Antwerpes S; Costa M; Coste M; Bureau M; Maradan G; Cutarella C; Leloutre J; Riccobono-Soulier O; Hedoire S; Frot E; Vernier F; Vassas-Goyard S; Barré T; Casanova D; Carrieri P";10.1186/s12954-021-00587-0;['Journal Article'];True;2022-01-10
NCT02027051;Etude génétique Des Arméniens;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2014-01-03;2014-01;2017-01;;;;;;;;
NCT02157311;4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2014-06-06;2014-07;2016-01;29186458;DERIVED;Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial.;"de Truchis P; Assoumou L; Landman R; Mathez D; Le Dû D; Bellet J; Amat K; Katlama C; Gras G; Bouchaud O; Duracinsky M; Abe E; Alvarez JC; Izopet J; Saillard J; Melchior JC; Leibowitch J; Costagliola D; Girard PM; Perronne C; ANRS 162-4D Study Group";10.1093/jac/dkx434;['Clinical Trial', 'Journal Article', 'Multicenter Study'];True;2017-11-25
NCT01495897;Abnormal Movements, Cerebellum and Sensorimotor : Oculomotor Study;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2011-12-20;2011-03;2014-03;;;;;;;;
NCT04409405;Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola);Institut National de la Santé Et de la Recherche Médicale, France;Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo | Institut de Recherche pour le Developpement;COMPLETED;OBSERVATIONAL;False;2020-06-01;2020-04-16;2021-10-18;38043556;PUBMED;Effect of anti-Ebola virus monoclonal antibodies on endogenous antibody production in survivors of Ebola virus disease in the Democratic Republic of the Congo: an observational cohort study.;"Nkuba-Ndaye A; Dilu-Keti A; Tovar-Sanchez T; Diallo MSK; Mukadi-Bamuleka D; Kitenge R; Formenty P; Legand A; Edidi-Atani F; Thaurignac G; Pelloquin R; Mbala-Kingebeni P; Toure A; Ayouba A; Muyembe-Tamfum JJ; Delaporte E; Peeters M; Ahuka-Mundeke S; Les Vainqueurs d’Ebola Study Group";10.1016/S1473-3099(23)00552-2;['Journal Article'];False;2024-03-01
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;22008658;BACKGROUND;Burden of HIV disease and comorbidities on the chances of maintaining employment in the era of sustained combined antiretoviral therapies use.;"Dray-Spira R; Legeai C; Le Den M; Boué F; Lascoux-Combe C; Simon A; May T; Goujard C; Meyer L; ANRS-COPANA Cohort Study Group";10.1097/QAD.0b013e32834dcf61;['Journal Article', 'Multicenter Study'];True;2012-01-14
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;23936509;BACKGROUND;Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.;"Krastinova E; Seng R; Yeni P; Viard JP; Vittecoq D; Lascoux-Combe C; Fourn E; Pahlavan G; Delfraissy JF; Goujard C; Meyer L; ANRS PRIMO and COPANA Cohorts";10.1371/journal.pone.0071473;['Journal Article'];True;2013-08-01
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;25573889;BACKGROUND;Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART.;"El Khoury P; Ghislain M; Villard EF; Le Goff W; Lascoux-Combe C; Yeni P; Meyer L; Vigouroux C; Goujard C; Guerin M";10.1194/jlr.M054510;['Clinical Trial', 'Journal Article', 'Multicenter Study'];True;2015-03-01
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;23079802;BACKGROUND;Does pregnancy affect the early response to cART?;"Rachas A; Warszawski J; Le Chenadec J; Legeai C; Teglas JP; Goujard C; Rouzioux C; Mandelbrot L; Tubiana R; Meyer L";10.1097/QAD.0b013e32835ac8bc;['Journal Article', 'Multicenter Study'];True;2013-01-28
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;22267473;BACKGROUND;Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort.;"Boufassa F; Goujard C; Viard JP; Carlier R; Lefebvre B; Yeni P; Bouchaud O; Capeau J; Meyer L; Vigouroux C; ANRS COPANA Cohort Study Group";10.3851/IMP1916;['Journal Article', 'Multicenter Study'];True;2012-01-01
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;24465584;BACKGROUND;Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration.;"Boufassa F; Lechenadec J; Meyer L; Costagliola D; Hunt PW; Pereyra F; Deeks S; Pancino G; Taulera O; Lichterfeld M; Delobel P; Saez-Cirion A; Lambotte O; ANRS CO18 HIV Controllers Cohort; Cascade Collaboration in Eurocoord; SCOPE Cohort; International HIV Controllers Study";10.1371/journal.pone.0085516;['Journal Article'];True;2014-01-17
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;24058636;BACKGROUND;Associations between 25-hydroxyvitamin D and immunologic, metabolic, inflammatory markers in treatment-naive HIV-infected persons: the ANRS CO9 «COPANA» cohort study.;"Legeai C; Vigouroux C; Souberbielle JC; Bouchaud O; Boufassa F; Bastard JP; Carlier R; Capeau J; Goujard C; Meyer L; Viard JP; ANRS-COPANA Cohort Study Group";10.1371/journal.pone.0074868;['Journal Article'];True;2013-09-18
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;26636578;BACKGROUND;Late Antiretroviral Therapy (ART) Initiation Is Associated with Long-Term Persistence of Systemic Inflammation and Metabolic Abnormalities.;"Ghislain M; Bastard JP; Meyer L; Capeau J; Fellahi S; Gérard L; May T; Simon A; Vigouroux C; Goujard C; ANRS-COPANA Cohort Study Group";10.1371/journal.pone.0144317;['Clinical Trial', 'Journal Article', 'Multicenter Study'];True;2015-12-04
NCT03137797;Cohort of Patients Naive of Antiretroviral Treatment at Enrollment;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2017-05-03;2004-02;2016-06;27509048;BACKGROUND;Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset.;"Ploquin MJ; Madec Y; Casrouge A; Huot N; Passaes C; Lécuroux C; Essat A; Boufassa F; Jacquelin B; Jochems SP; Petitjean G; Angin M; Gärtner K; Garcia-Tellez T; Noël N; Booiman T; Boeser-Nunnink BD; Roques P; Saez-Cirion A; Vaslin B; Dereudre-Bosquet N; Barré-Sinoussi F; Ghislain M; Rouzioux C; Lambotte O; Albert ML; Goujard C; Kootstra N; Meyer L; Müller-Trutwin MC";10.1371/journal.ppat.1005774;['Journal Article'];True;2016-08-10
NCT02052271;Experimental Therapeutics in Essential Tremor Using Cerebellar Transcranial Direct Current Stimulation;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-02-03;2014-06-03;2018-03-27;;;;;;;;
NCT03831906;Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia);Institut National de la Santé Et de la Recherche Médicale, France;UNITAID;COMPLETED;INTERVENTIONAL;False;2019-02-06;2019-03-20;2021-06-30;33743621;BACKGROUND;Impact of systematic early tuberculosis detection using Xpert MTB/RIF Ultra in children with severe pneumonia in high tuberculosis burden countries (TB-Speed pneumonia): a stepped wedge cluster randomized trial.;"Vessière A; Font H; Gabillard D; Adonis-Koffi L; Borand L; Chabala C; Khosa C; Mavale S; Moh R; Mulenga V; Mwanga-Amumpere J; Taguebue JV; Eang MT; Delacourt C; Seddon JA; Lounnas M; Godreuil S; Wobudeya E; Bonnet M; Marcy O";10.1186/s12887-021-02576-5;['Journal Article', 'Randomized Controlled Trial'];True;2021-03-20
NCT03831906;Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia);Institut National de la Santé Et de la Recherche Médicale, France;UNITAID;COMPLETED;INTERVENTIONAL;False;2019-02-06;2019-03-20;2021-06-30;32853411;DERIVED;Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children.;"Kay AW; González Fernández L; Takwoingi Y; Eisenhut M; Detjen AK; Steingart KR; Mandalakas AM";10.1002/14651858.CD013359.pub2;['Journal Article', 'Meta-Analysis'];True;2020-08-27
NCT03831906;Impact of Systematic Early Tuberculosis Detection Using Xpert MTB/RIF Ultra in Children With Severe Pneumonia in High Tuberculosis Burden Countries (TB-Speed Pneumonia);Institut National de la Santé Et de la Recherche Médicale, France;UNITAID;COMPLETED;INTERVENTIONAL;False;2019-02-06;2019-03-20;2021-06-30;36395782;DERIVED;Effect of systematic tuberculosis detection on mortality in young children with severe pneumonia in countries with high incidence of tuberculosis: a stepped-wedge cluster-randomised trial.;"Marcy O; Wobudeya E; Font H; Vessière A; Chabala C; Khosa C; Taguebue JV; Moh R; Mwanga-Amumpaire J; Lounnas M; Mulenga V; Mavale S; Chilundo J; Rego D; Nduna B; Shankalala P; Chirwa U; De Lauzanne A; Dim B; Tiogouo Ngouana E; Folquet Amorrissani M; Cisse L; Amon Tanoh Dick F; Komena EA; Kwedi Nolna S; Businge G; Natukunda N; Cumbe S; Mbekeka P; Kim A; Kheang C; Pol S; Maleche-Obimbo E; Seddon JA; Mao TE; Graham SM; Delacourt C; Borand L; Bonnet M; TB-Speed Pneumonia Study Group";10.1016/S1473-3099(22)00668-5;['Randomized Controlled Trial', 'Journal Article'];False;2023-03-01
NCT01164436;Cohort of HIV Associated Lymphomas;ANRS, Emerging Infectious Diseases;Dr Yassine Taoufik Dr Houria Chavez Hôpital Bicêtre CIB Paris Sud France | Dr Guislaine Garcelain Hôpital Pitié Slapétrière Paris France | University Hospital, Grenoble | Dr Irène Joab Hôpital Paul Brousse Villejuif France | Dr Alex Duval Fondation Jean Dausset CEPH | Hopital Antoine Beclere;COMPLETED;OBSERVATIONAL;False;2010-07-16;2008-06;2017-06;;;;;;;;
NCT02656407;Intraoperative Functional Ultrasound;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-01-15;2016-02-11;2018-02;25955583;BACKGROUND;Spatiotemporal Clutter Filtering of Ultrafast Ultrasound Data Highly Increases Doppler and fUltrasound Sensitivity.;"Demené C; Deffieux T; Pernot M; Osmanski BF; Biran V; Gennisson JL; Sieu LA; Bergel A; Franqui S; Correas JM; Cohen I; Baud O; Tanter M";10.1109/TMI.2015.2428634;['Journal Article'];False;2015-11-01
NCT02906137;Gut-Associated Lymphocyte Trafficking;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2016-09-19;2017-02-06;2020-02-25;;;;;;;;
NCT02102737;Comparison of A New Technique of Measure of the Insulin Resistance By Scintigraphy With the Reference Technique;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-04-03;2014-05-13;2018-03;;;;;;;;
NCT01492985;Lipopeptide Immunisation With GTU-multiHIV Trial;ANRS, Emerging Infectious Diseases;;COMPLETED;INTERVENTIONAL;False;2011-12-15;2013-07;2017-04-08;33568510;DERIVED;A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.;"Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R";10.1128/JVI.02165-20;['Journal Article', 'Randomized Controlled Trial'];True;2021-04-12
NCT02346409;Cerebello-thalamo-cortical Coupling in Essential Tremor;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-01-27;2015-02-04;2018-02-16;;;;;;;;
NCT02014883;Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS;Institut National de la Santé Et de la Recherche Médicale, France;Ultragenyx Pharmaceutical Inc;COMPLETED;INTERVENTIONAL;False;2013-12-18;2013-12-04;2019-07-04;26536893;DERIVED;Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency.;"Mochel F; Hainque E; Gras D; Adanyeguh IM; Caillet S; Héron B; Roubertie A; Kaphan E; Valabregue R; Rinaldi D; Vuillaumier S; Schiffmann R; Ottolenghi C; Hogrel JY; Servais L; Roze E";10.1136/jnnp-2015-311475;['Clinical Trial', 'Journal Article'];True;2015-11-03
NCT01693861;"""Cancersensor"" Chemotherapy";Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-09-26;2012-10;2015-02;;;;;;;;
NCT01463956;Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation;French National Agency for Research on AIDS and Viral Hepatitis;Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2011-11-02;2012-01-06;2015-01-22;;;;;;;;
NCT05090956;Developpement of 3T MRI Protocol;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2021-10-25;2012-06-08;2020-01-29;;;;;;;;
NCT01698411;Study of the Influence of Sleep on Hemodynamic Parameters in Patients With Sleep Disorders;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2012-10-03;2012-10;2015-02;;;;;;;;
NCT04396288;Ultrasound Imaging-based Measurement of Intra-osseous Vascular Response;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2020-05-20;2021-09-14;2024-01-30;;;;;;;;
NCT05472051;Health and Migration Trajectories of Housekeepers in Bamako;ANRS, Emerging Infectious Diseases;;COMPLETED;OBSERVATIONAL;False;2022-07-25;2022-02-28;2023-06-22;;;;;;;;
NCT01880151;Neuroelectrical Biomarkers for Alzheimer's Disease Stages;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2013-06-18;2013-07-12;2019-01;;;;;;;;
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;23639243;DERIVED;Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.;"Ouattara E; Danel C; Moh R; Gabillard D; Peytavin G; Konan R; Carrou JL; Bohoussou F; Eholie SP; Anglaret X";10.7448/IAS.16.1.18059;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2013-01-01
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;26193126;DERIVED;A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.;"TEMPRANO ANRS 12136 Study Group; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X";10.1056/NEJMoa1507198;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2015-08-27
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;35093007;DERIVED;Association of cellular HIV-1 DNA and virological success of antiretroviral treatment in HIV-infected sub-Saharan African adults.;"Moh DR; Ntakpé JB; Gabillard D; Yayo-Emieme AA; Badjé A; Kouame GM; d'Aquin TT; Danel C; Anglaret X; Eholié SP";10.1186/s12879-022-07082-2;['Journal Article', 'Randomized Controlled Trial'];True;2022-01-29
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;29297443;DERIVED;Screening for active tuberculosis before isoniazid preventive therapy among HIV-infected West African adults.;"Moh R; Badjé A; N'takpé JB; Kouamé GM; Gabillard D; Ouassa T; Ouattara E; Le Carrou J; Bohoussou F; Messou E; Eholié S; Anglaret X; Danel C";10.5588/ijtld.17.0016;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];False;2017-12-01
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;29020361;DERIVED;Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication.;"Kouamé GM; Boyd A; Moh R; Badje A; Gabillard D; Ouattara E; Ntakpe JB; Emième A; Maylin S; Chekaraou MA; Eholié SP; Zoulim F; Lacombe K; Anglaret X; Danel C; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 12136 Temprano and ANRS 12240 VarBVA Study Groups";10.1093/cid/cix747;['Journal Article'];True;2017-08-19
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;24985779;DERIVED;Decrease in sexual risk behaviours after early initiation of antiretroviral therapy: a 24-month prospective study in Côte d'Ivoire.;"Jean K; Gabillard D; Moh R; Danel C; Desgrées-du-Loû A; N'takpe JB; Le Carrou J; Badjé A; Eholié S; Lert F; Anglaret X; Dray-Spira R";10.7448/IAS.17.1.18977;['Journal Article', 'Randomized Controlled Trial'];True;2014-01-01
NCT00495651;Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO);French National Agency for Research on AIDS and Viral Hepatitis;Gilead Sciences | Merck Sharp & Dohme LLC;COMPLETED;INTERVENTIONAL;False;2007-07-03;2008-03;2015-01;25330161;DERIVED;Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Côte d'Ivoire, West Africa.;"Danel C; Kabran M; Inwoley A; Badje A; Herrmann JL; Moh R; Lecarrou J; Gabillard D; Ntakpe JB; Deschamps N; Ouattara E; Perronne C; Eholie S; Anglaret X";10.1371/journal.pone.0107245;['Journal Article', 'Randomized Controlled Trial'];True;2014-10-16
NCT02721745;Cause and Consequence of Neural Fatigue;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-03-29;2016-05-23;2020-12;;;;;;;;
NCT02960698;Impulsivity in Tourette Syndrome : Behavioral and Neuroimaging Study;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-11-10;2016-10-14;2018-04-24;;;;;;;;
NCT02101398;Study of the Effect of Transcranial Stimulations in Aphasic Subject Within a Year of Their Stroke;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2014-04-02;2014-10-02;2016-07;;;;;;;;
NCT02481453;Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-06-25;2015-07-15;2018-01-22;38273639;PUBMED;Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial.;"Benveniste O; Hogrel JY; Belin L; Annoussamy M; Bachasson D; Rigolet A; Laforet P; Dzangué-Tchoupou G; Salem JE; Nguyen LS; Stojkovic T; Zahr N; Hervier B; Landon-Cardinal O; Behin A; Guilloux E; Reyngoudt H; Amelin D; Uruha A; Mariampillai K; Marty B; Eymard B; Hulot JS; Greenberg SA; Carlier PG; Allenbach Y";10.1016/S2665-9913(20)30280-0;['Journal Article'];True;2021-01-01
NCT02481453;Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-06-25;2015-07-15;2018-01-22;20413309;BACKGROUND;International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009.;"Benveniste O; Hilton-Jones D";10.1016/j.nmd.2010.03.014;[];True;2010-06-01
NCT02481453;Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2015-06-25;2015-07-15;2018-01-22;24975859;BACKGROUND;Evaluation and construction of diagnostic criteria for inclusion body myositis.;"Lloyd TE; Mammen AL; Amato AA; Weiss MD; Needham M; Greenberg SA";10.1212/WNL.0000000000000642;['Journal Article', 'Review'];True;2014-07-29
NCT02976298;Effects of Cerebellum or Supplementary Motor Area Functional Inactivation on Gait and Balance Control;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2016-11-29;2013-02;2015-01;;;;;;;;
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;32097754;DERIVED;Physical activity rather than sedentary behaviour is socially determined in French adolescents with overweight and obesity.;"Omorou AY; Manneville F; Langlois J; Legrand K; Böhme P; Muller L; Guillemin F; Briançon S; Lecomte E; PRALIMAP-INÈS Trial Group";10.1016/j.ypmed.2020.106043;['Journal Article', 'Multicenter Study'];True;2020-05-01
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;29696179;DERIVED;Reducing social inequalities in access to overweight and obesity care management for adolescents: The PRALIMAP-INÈS trial protocol and inclusion data analysis.;"Legrand K; Lecomte E; Langlois J; Muller L; Saez L; Quinet MH; Böhme P; Spitz E; Omorou AY; Briançon S; PRALIMAP-INÈS trial group";10.1016/j.conctc.2017.05.010;['Journal Article'];True;2017-09-01
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;29934380;DERIVED;Using facilitator-receiver peer dyads matched according to socioeconomic status to promote behaviour change in overweight adolescents: a feasibility study.;"Saez L; Legrand K; Alleyrat C; Ramisasoa S; Langlois J; Muller L; Omorou AY; De Lavenne R; Kivits J; Lecomte E; Briançon S; PRALIMAP-INÈS Trial Group";10.1136/bmjopen-2017-019731;['Journal Article', 'Multicenter Study', 'Randomized Controlled Trial'];True;2018-06-01
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;34087324;DERIVED;Sociodemographic and psychological characteristics associated with discrepancy between body satisfaction and weight change among adolescents.;"Manneville F; Omorou AY; Legrand K; Lecomte E; Rydberg JA; Briançon S; Guillemin F; PRALIMAP Trial Group";10.1016/j.ypmed.2021.106668;['Journal Article'];True;2021-09-01
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;35272723;PUBMED;Behavioural risk patterns in adolescents with excess weight participating in the PRALIMAP-INÈS trial.;"Julia C; Omorou A; Lecomte E; Langlois J; Touvier M; Hercberg S; Briançon S; Kesse-Guyot E; Guillemin F; PRALIMAP-INÈS Trial Group";10.1017/S136898002200057X;['Journal Article'];True;2022-03-11
NCT01688453;Overweight Management and Social Inequalities;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2012-09-19;2012-04;2015-11;29776897;DERIVED;Reach and Acceptability of a Mobile Reminder Strategy and Facebook Group Intervention for Weight Management in Less Advantaged Adolescents: Insights From the PRALIMAP-INÈS Trial.;"Saez L; Langlois J; Legrand K; Quinet MH; Lecomte E; Omorou AY; Briançon S; PRALIMAP-INÈS Trial Group";10.2196/mhealth.7657;['Journal Article'];True;2018-05-18
NCT02658253;Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults;Institut National de la Santé Et de la Recherche Médicale, France;EVI Industries, Inc. | Recherche Clinique Paris Descartes Necker Cochin Sainte Anne | Centre national de recherche et de formation sur le paludisme | EUCLID Clinical Trial Platform;COMPLETED;INTERVENTIONAL;False;2016-01-18;2016-01;2019-02-21;32032566;DERIVED;PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.;"Sirima SB; Richert L; Chêne A; Konate AT; Campion C; Dechavanne S; Semblat JP; Benhamouda N; Bahuaud M; Loulergue P; Ouédraogo A; Nébié I; Kabore M; Kargougou D; Barry A; Ouattara SM; Boilet V; Allais F; Roguet G; Havelange N; Lopez-Perez E; Kuppers A; Konaté E; Roussillon C; Kanté M; Belarbi L; Diarra A; Henry N; Soulama I; Ouédraogo A; Esperou H; Leroy O; Batteux F; Tartour E; Viebig NK; Thiebaut R; Launay O; Gamain B";10.1016/S1473-3099(19)30739-X;['Journal Article', 'Randomized Controlled Trial'];True;2020-05-01
NCT02658253;Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults;Institut National de la Santé Et de la Recherche Médicale, France;EVI Industries, Inc. | Recherche Clinique Paris Descartes Necker Cochin Sainte Anne | Centre national de recherche et de formation sur le paludisme | EUCLID Clinical Trial Platform;COMPLETED;INTERVENTIONAL;False;2016-01-18;2016-01;2019-02-21;33717176;DERIVED;Progress and Insights Toward an Effective Placental Malaria Vaccine.;"Gamain B; Chêne A; Viebig NK; Tuikue Ndam N; Nielsen MA";10.3389/fimmu.2021.634508;['Journal Article', 'Review'];True;2021-02-25
NCT01842477;Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;INTERVENTIONAL;False;2013-04-29;2013-05;2016-02-05;;;;;;;;
NCT02172677;The Influence of Collective Schemas on Individual Memory;Institut National de la Santé Et de la Recherche Médicale, France;La Région Basse-Normandie | Université de Caen Normandie | University Hospital, Caen | Ecole Pratique des Hautes Etudes | Equipement d'Excellence Matrice;COMPLETED;INTERVENTIONAL;False;2014-06-24;2014-10;2016-10-14;;;;;;;;
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2009-12-23;2009-05-07;2017-12-14;24780882;DERIVED;Prediction of the age at onset in spinocerebellar ataxia type 1, 2, 3 and 6.;"Tezenas du Montcel S; Durr A; Rakowicz M; Nanetti L; Charles P; Sulek A; Mariotti C; Rola R; Schols L; Bauer P; Dufaure-Garé I; Jacobi H; Forlani S; Schmitz-Hübsch T; Filla A; Timmann D; van de Warrenburg BP; Marelli C; Kang JS; Giunti P; Cook A; Baliko L; Melegh B; Boesch S; Szymanski S; Berciano J; Infante J; Buerk K; Masciullo M; Di Fabio R; Depondt C; Ratka S; Stevanin G; Klockgether T; Brice A; Golmard JL";10.1136/jmedgenet-2013-102200;['Journal Article'];True;2014-04-29
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2009-12-23;2009-05-07;2017-12-14;23707147;DERIVED;Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data.;"Jacobi H; Reetz K; du Montcel ST; Bauer P; Mariotti C; Nanetti L; Rakowicz M; Sulek A; Durr A; Charles P; Filla A; Antenora A; Schöls L; Schicks J; Infante J; Kang JS; Timmann D; Di Fabio R; Masciullo M; Baliko L; Melegh B; Boesch S; Bürk K; Peltz A; Schulz JB; Dufaure-Garé I; Klockgether T";10.1016/S1474-4422(13)70104-2;['Journal Article'];False;2013-07-01
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2009-12-23;2009-05-07;2017-12-14;35264424;DERIVED;Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1.;"Wilke C; Mengel D; Schöls L; Hengel H; Rakowicz M; Klockgether T; Durr A; Filla A; Melegh B; Schüle R; Reetz K; Jacobi H; Synofzik M";10.1212/WNL.0000000000200257;['Journal Article'];True;2022-05-17
NCT01037777;RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7;Institut National de la Santé Et de la Recherche Médicale, France;;COMPLETED;OBSERVATIONAL;False;2009-12-23;2009-05-07;2017-12-14;32822634;DERIVED;Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study.;"Jacobi H; du Montcel ST; Romanzetti S; Harmuth F; Mariotti C; Nanetti L; Rakowicz M; Makowicz G; Durr A; Monin ML; Filla A; Roca A; Schöls L; Hengel H; Infante J; Kang JS; Timmann D; Casali C; Masciullo M; Baliko L; Melegh B; Nachbauer W; Bürk-Gergs K; Schulz JB; Riess O; Reetz K; Klockgether T";10.1016/S1474-4422(20)30235-0;['Clinical Trial', 'Journal Article', 'Multicenter Study'];True;2020-09-01
